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ABSTRACT 
Cystic fibrosis (CF) is the most common life-limiting single-gene disease. It is caused by 
mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is 
expressed on immune cells such as dendritic cells, monocytes/macrophages and lymphocytes. 
Lack of CFTR expression on lymphocytes and monocytes/macrophages has been reported to 
result in abnormal immune responses. An unresolving hyperinflammatory and T helper 
(Th)2/Th17 skewed immune response has also been reported in CF. We therefore 
hypothesised that abnormalities in both the innate and adaptive immune responses may play a 
pivotal role in the pathogenesis of CF lung disease. 
Peripheral blood mononuclear cells (PBMC) isolated from people with CF, CF carriers and 
healthy age-matched controls were stained with antibodies for identification of CD4+ effector 
(Th1, Th2, Th17) and T regulatory (Treg) (FOXP3+ Treg, IL-10+ T regulatory 1 [Tr1], 
transforming growth factor (TGF)+ Th3) cells, naïve/memory CD4+ and Treg cells 
expressing the Th1-, Th2- and Th17-associated homing markers (CXCR3, CCR4, CCR6) and 
innate immune cell populations including natural killer (NK) cells, monocytes, dendritic cells 
(DC) and myeloid derived suppressor cells (MDSC) using multicolour flow cytometric
analysis. Gene expression of the main transcription regulators of CD4+ subsets and of 
inflammatory markers was also measured using reverse transcription–quantitative polymerase 
chain reaction (RT-qPCR). 
Subtle changes were observed in T cell subset proportions in CF peripheral blood, with a 
detectable Th2 bias and a link between poor lung function and high Th17 percent. All innate 
immune cell proportions were altered in CF compared with healthy controls, and percentages 
of NK and MDSC were also correlated with lung function. CF carriers, who have only one 
mutated CFTR copy, presented with an immune phenotype similar to CF patients or 
intermediate between those of controls and CF patients. Because the CF carriers did not have 
chronic infections, this suggested that the many of the abnormal immune responses seen in 
people with CF may be the consequence of defective CFTR rather than of chronic infection. 
These findings suggest that greater emphasis should be placed on treating aberrant immune 
responses in CF. 
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CHAPTER 1 
Literature Review 
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1.1.1 Introduction 
The work described in this thesis is related to the functioning of the immune system in people 
with cystic fibrosis (CF). Therefore, this literature review will first discuss the disease CF, 
then describe the functions of the important immune cells with a focus on the subsets that we 
studied, before relating these functions to the situation in CF. People with CF are known to 
have a hyperinflammatory and dysregulated immune response involving both innate and 
adaptive immune cells, but detailed research in this area is limited. The innate immune cells 
discussed in this review include monocytes, natural killer (NK) cells, dendritic cells (DCs) 
and myeloid derived suppressor cells (MDSC), macrophages and neutrophils while the 
adaptive immune cells discussed include the CD4+ effector (T helper (Th)1, Th2, Th17) and 
regulatory T cell (Treg) subsets (FOXP3+ Treg, IL-10+ T regulatory 1 [Tr1] and transforming 
growth factor (TGF)-+ Th3), CD8+ T cells and B cells. Chemokine-mediated homing of 
immune cells and its role in disease is also reviewed. Finally the current knowledge of the role 
of the innate and adaptive immune responses in CF pathogenesis is discussed. 
1.1.2 Cystic Fibrosis 
CF is the most common life-limiting single-gene disease in Caucasians, occurring at a rate of 
1 in every 2500 live births (1). In Tasmania there is a higher incidence of 1 in every 1600 live 
births (2), the second highest incidence in the world. CF was first recognized in the 1960s as a 
recessive genetic disease. At that time it presented with lung infections and deficiencies in 
pancreatic function and was fatal during childhood (3). The life expectancy of children with 
CF rose as more research was invested into understanding the pathophysiology of the disease 
and the full extent of the associated complications was revealed. CF is now understood to be a 
complex multisystem disease with additional complications often including diabetes, 
malnutrition, osteoporosis, arthritis, heart, kidney and liver disease and male infertility (3). 
The current average life expectancy of those with CF is 37 years, but it has been predicted 
that progressively advancing and aggressive therapeutic strategies will mean that those born 
in the 21st century will live to be in their 50s (4), and that there will soon be more adults than 
children with CF (1). 
1.1.3 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene 
CF results from mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene (5). The product of this gene acts as a cyclic AMP-regulated chloride channel but is also 
 P a g e  | 3 
 
involved in the regulation of sodium, calcium and potassium ion channels (6-8). The CFTR 
gene is located on chromosome 7 (9) and is classified as a member of the ATP-binding 
cassette (ABC) superfamily (10). Currently, over 1600 different mutations in CFTR have been 
identified (1), the most common of which is the deletion of phenylalanine at codon 508 
known as phe508del or DF508. This mutation occurs in around 70% of people with CF 
worldwide, although the frequency varies in specific ethnic groups and geographic regions 
(11). 
The different mutations of the CFTR gene result in diverse phenotypes (11) depending on 
whether the mutation affects synthesis, processing or transport of the protein or functionality 
of the resultant channel. CFTR mutations are classified into six groups (12), which include 
defective protein synthesis (class 1), abnormal or defective protein processing or transport 
(class 2), defective channel regulation (class 3), decreased channel conductance (class 4), 
reduced level of synthesis, maturation or transport of the protein (class 5) and decreased 
protein stability (class 6). The DF508 mutation of CFTR produces a protein that often retains 
a considerable amount of function as a chloride channel, but which is misfolded, resulting in 
ubiquitination that marks it for degradation before it can traffic to the epithelial cell surface 
(class 2) (13). Some mutant forms of the CFTR protein, such as A455E, reach the cell surface 
and retain moderate functionality as chloride channels (class 4), which may be a contributing 
factor to the occurrence of clinically milder forms of CF (14). Further investigation into the 
phenotype–genotype relationship has revealed that there is a strong correlation between 
genotype and pancreatic disease but minimal correlation with lung disease (11, 15, 16). This 
observation may suggest that environmental and additional genetic factors play a greater role 
in the development of lung disease (17). 
1.1.4 Effects of CFTR Gene Mutations 
The main cell type to express CFTR are epithelial cells, of which the most commonly affected 
in people with CF are those in the sweat glands, salivary glands, airways, nasal epithelium, 
bile ducts, pancreas, vas deferens (in males) and intestinal epithelium (18). The organ most 
affected by defective CFTR is the lungs, which are frequently chronically infected, leading to 
the main cause of morbidity and mortality (90%) in people with CF, respiratory failure (19). 
However, more recently it has also been shown that CFTR is expressed in other cell types 
including those of the immune system such as antigen presenting cells (APC) and T 
lymphocytes, although it is not yet known whether all or only some specific T cell subsets 
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express CFTR. Evidence suggests that expression of mutant CFTR on these immune cells 
could result in immunoregulatory defects (20-23). 
The means by which CFTR mutations cause lung disease have not yet been fully elucidated, 
but it has been postulated to result from a combination of different mechanisms. These 
mechanisms include impaired regulation of the fluid volume or composition on the surface of 
the airways (18, 24), increased binding of or decreased ability to clear pathogens such as 
Pseudomonas aeruginosa (25) and increased levels of proinflammatory cytokines in the 
airways (26, 27). The normal function of mucus in healthy lungs is to trap inhaled particles in 
order to keep the airways clean. Healthy mucus has low viscosity to allow ciliary beating, 
which promotes movement of the mucus and attached particles towards the mouth to be either 
swallowed or expelled. In people with CF, impaired fluid levels/composition in the airway 
result from a decreased level of chloride secretion and increased absorption of sodium by 
airway epithelial cells. This results in a lower water content in the mucus, causing its relative 
dehydration in the airways and mucus retention, resulting in a reduced ability to clear inhaled 
particles (28). This impaired ability to clear mucus and pathogens such as P. aeruginosa 
results in infection and inflammation then bronchiectasis, leading to progressive loss of lung 
function and eventually death. A vicious cycle of infection and inflammation occurs whereby 
harmful products such as proteases, elastases and oxidants, mainly produced by neutrophils, 
are released, causing inflammation that predisposes to further infection (29). 
It is not entirely clear whether it is inflammation or infection that occurs first in the lungs of 
CF patients. Muhlebach et al. (30) investigated bronchoalveolar lavage fluid (BALF) from 
paediatric CF patients with and without lower respiratory tract infection as well as healthy 
paediatric controls and revealed an increased level of neutrophils in both infected and non-
infected CF patients compared with healthy controls, indicating a proinflammatory state 
regardless of infection. Khan et al. (31) has also shown increased levels of neutrophils in 
BALF from CF infants without any detectable bacterial, viral or fungal infection. However, 
these studies did not exclude patients who had experienced infection prior to the study. In 
contrast, a study by Armstrong and colleagues comparing BALF from CF infants who were 
yet to experience any detectable infection with that of healthy controls showed normal levels 
of neutrophils in the CF patients. However, this study did not exclude the 30% of controls 
who tested positive for or developed symptoms of respiratory tract infection within 48 hours 
following bronchoscopy. A study by Hubeau et al. (32) that investigated lung samples from 
CF and non-CF foetuses that had therefore not experienced any infection showed that in CF 
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there was an increased level of macrophages, a source of neutrophil chemoattractants, 
indicating the existence of an inherently proinflammatory state even before exposure to 
pathogens. In summary, much of the evidence strongly supports the theory of a 
hyperinflammatory state in CF prior to any infection. 
1.1.5 Lung Infection in Cystic Fibrosis 
A significant clinical feature of CF is the development of chronic lung infection. 
Staphylococcus aureus and Haemophilus influenzae have traditionally been considered the 
most common initial infecting pathogens dominating in the lungs of CF children, with a 
dominance of P. aeruginosa and Burkholderia cepacia developing with increasing age (33, 34), 
as shown in Fig 1. However, with the advent of molecular identification techniques it has 
become apparent that CF lungs are colonised with a much more complex population of 
pathogens. While this was originally shown by Rogers and colleagues using 16s ribosomal 
DNA length heterogeneity PCR and 16s ribosomal DNA terminal restriction fragment length 
polymorphism (35), this has since been supported with other studies revealing an intricate 
community consisting of bacterial, viral and fungal infections (36-38). However, P. 
aeruginosa is still widely considered the most frequent, chronic and major pathogen, 
occurring in an estimated 80% of adults with CF (39). 
 
 
Fig. 1. Development of the microbial community within the CF lung. Figure illustrates the 
incidence of the primary respiratory pathogens in CF in relation to age. Figure taken from the 
Cystic Fibrosis Foundation’s annual data report (40). 
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While bacterial infection is a primary focus in regards to treatment of CF, viral infection also 
plays a significant role in deterioration of lung function. Respiratory syncytial virus (RSV) 
and influenza have been shown to have the most deleterious effects on the lungs (41), 
although other viruses such as parainfluenza, rhinovirus and adenovirus are also commonly 
detected in CF (42). Viral infections in CF have been associated with poorer lung function 
and increased frequency and duration of hospital admissions (43, 44). Of particular interest is 
the theory that viral infection, particularly RSV, facilitates bacterial infections such as with P. 
aeruginosa. In a 25 year retrospective study in Denmark, Johansen and Hoiby (45) found that 
the first detection of P. aeruginosa most commonly occurred during peak RSV season. 
However, this study needs to be considered cautiously given that the peak season for 
influenza is very similar to that of RSV. A study of six CF patients by Collinson and 
colleagues reported that five developed their first P. aeruginosa infection while experiencing 
symptoms of an upper respiratory tract infection. Armstrong et al. (41) also demonstrated that 
a viral infection was detected in BALF during 50% of exacerbations. The mechanism behind 
the link between viral and bacterial infection is yet to be elucidated, although it has been 
suggested that viral infection disrupts the epithelial cell membrane, thus facilitating greater 
bacterial adherence (43). This is supported by a study undertaken by Fainstern et al. (46) in 
which S. aureus, H. influenzae and S. pneumoniae all showed increased adherence to 
pharyngeal cells after participants received a live attenuated influenza vaccination. 
With the improvement of culture and molecular techniques it has become apparent that fungi 
are also dominant pathogens within the CF lung. Nagano et al. (47) have shown that although 
with traditional culture methods fungi could be detected in only 18% of CF sputum samples, 
the use of more specific culture techniques resulted in the detection of fungi in 78% of the 
samples. The use of next-generation sequencing analysis of the CF lung microbiome further 
supports this and has made it evident that fungi are indeed abundant within the CF lung (37, 
48). This could suggest that the impact of fungi within the CF lung has previously been 
underestimated. Aspergillus fumigatus is the most commonly isolated fungus, present in an 
estimated 50% of CF patients (49). Colonisation by this fungus can lead to allergic 
bronchopulmonary aspergillosis (ABPA), an allergic inflammatory condition which has been 
shown to be associated with worse lung function and a more rapid decline (50). ABPA has 
been associated with a predominantly Th2-type immune response in CF (51, 52) which has 
previously been shown to have negative impacts on the clearance of pathogens such as P. 
aeruginosa (53). Reports are also beginning to emerge that chronic A. fumigatus infection, 
even without ABPA, can result in worsened lung function (54, 55). In addition to this it has 
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also been shown that colonisation with A. fumigatus increases the risk of P. aeruginosa 
infection (56). Given the serious impact of P. aeruginosa in CF, this evidence suggests that 
fungal infections should be treated more seriously in management of CF. However, further 
research is required to determine the full extent of fungal infections and their interaction with 
bacterial infections in CF. 
1.1.5.1 Pseudomonas aeruginosa Infection 
P. aeruginosa is a Gram-negative aerobic bacillus. It is ubiquitous throughout the 
environment, mainly in environments such as soil and water, and is an opportunistic pathogen 
primarily affecting immune-compromised individuals such as those with burns, foreign 
bodies and those undergoing chemotherapy or invasive surgery, as well as those with CF. It is 
known to be the dominant pathogen in the CF airways and the most significant influence on 
progression, prognosis and ultimately mortality of those with the disease (57, 58). Eighty 
percent of adults with CF become chronically infected with P. aeruginosa (59), the most 
common source of which is the environment . 
P. aeruginosa has a high level of genetic diversity (60), which contributes to its ability to 
remain in the lungs of CF patients and to maintain its pathogenicity. It is able to metabolize 
many carbon and nitrogen sources to provide energy (60), and although it is aerobic it is able 
to adapt to an environment with limited or no oxygen (61). This characteristic facilitates lung 
colonization in those with CF because they have thick mucus in their airways that limits the 
diffusion of oxygen. P. aeruginosa also possesses many virulence factors that mediate 
infection and lung tissue damage, such as pili, flagella, lipopolysaccharide (LPS), elastases, 
proteases, phospholipase C, hydrogen cyanide, exotoxin A, exoenzyme S and pyocyanin (60, 
62). Once established in the lungs, P. aeruginosa undergoes many phenotypic changes 
associated with the selective pressures experienced within the CF lung, leading in many cases 
to the development of mucoid strains that are highly resistant to multiple antibiotics (63). 
1.2.1 Innate and Adaptive Immunity 
The innate immune response is the body’s first line of defence against infection, and acts 
immediately, recognising invasion by foreign microbes nonspecifically through detection of 
common microbial components. The adaptive immune response, which is delayed relative to 
the innate response, recognises foreign invaders through antigen-specific receptors on 
immune cell surfaces. After stimulation of these receptors, adaptive cell-mediated and 
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humoral immune responses are mounted, facilitated by T lymphocytes (CD8+ and CD4+ T 
cells) and B lymphocytes, respectively. 
1.2.2 Innate Immune Cells 
1.2.2.1 Monocytes 
Monocytes are a population of leukocytes that develop in bone marrow, circulate through 
blood and are the precursors of macrophages, DCs and osteoclasts. Monocytes have been 
implicated in many disease pathologies and, because recent research has indicated the 
presence of several distinct macrophage phenotypes, understanding the role of each individual 
subset in disease states has become even more important. Altered monocyte subsets have been 
implicated in an array of diseases including rheumatoid arthritis (64), systemic lupus 
erythematous (65), bacterial infections (66, 67), human immunodeficiency virus infection 
(68), asthma (69) and Crohn’s disease (70). Monocytes were traditionally categorised into two 
subsets, based on CD14 and CD16 expression, known as ‘classical’ and ‘non-classical’ 
monocytes, first identified by Passlick et al. (71). While distinct functions and phenotypes 
were identified for these two subsets (72, 73) it became apparent that there was greater 
heterogeneity amongst the non-classical monocytes. It is now widely accepted that monocytes 
consist of three distinct subsets that are still identified based on expression of CD14 and 
CD16. However, more defined flow cytometry gating parameters have allowed the isolation 
of an intermediate population (74). Because of inconsistent flow cytometry gating methods 
and isolation techniques used in different studies there are still some discrepancies in the 
reported functions of these monocyte subsets. 
The primary population, termed ‘classical’ monocytes and comprising approximately 80–90% 
of the monocyte population, are CD14hiCD16lo/neg. Classical monocytes are involved in injury 
and inflammation and are recruited to inflamed tissue. The homing of these cells to affected 
tissues occurs because of increased levels of the chemokine CCL2 at sites of inflammation 
and the high level of expression of the chemokine receptor CCR2 on classical monocytes. 
These cells are primarily involved in phagocytosis of pathogens and damaged cells, and are 
considered to be proinflammatory because they produce interleukin (IL)-6, IL-8, and the 
chemokines CCL2 and CCL3 (75). This population has not been shown to infiltrate tissues 
under homeostatic conditions but is able to infiltrate tissues and differentiate into DCs and 
macrophages under inflammatory conditions (76). 
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‘Intermediate’ monocytes are CD14intCD16int and comprise approximately 5% of the 
monocyte population. It is debated whether intermediate monocytes are a distinct population 
or a transitional population between classical and non-classical monocytes. Using hierarchical 
clustering, Cros et al. (77) demonstrated that classical and intermediate monocytes were 
closely related, while non-classical monocytes clustered separately and were more distantly 
related. However, there is stronger evidence to support a closer link between intermediate and 
non-classical monocytes (78, 79), and this relationship is present in rhesus monkeys, which 
possess homologous monocyte subsets (80). Intermediate monocytes are involved in antigen 
presentation and parasite recognition, as indicated by their high levels of expression of major 
histocompatibility complex (MHC) II-related processing and presentation genes (78, 79). It is 
recognised that this subset produces a moderate level of proinflammatory cytokines such as 
tumour necrosis factor (TNF), IL-1 and IL-6 (66, 81). While they express low levels of the 
chemokine receptor CCR2, they also express CCR5, which facilitates homing of these cells in 
response to the chemokines CCL3, CCL4 and CCL5 that are highly expressed in inflamed 
tissues (82). 
‘Non-classical’ monocytes are CD14loCD16hi and comprise approximately 10–15% of the 
monocyte population. They express low levels of the chemokine receptors CCR2 and CCR5 
but high levels of CX3CR1, which facilitates a prolonged patrolling behaviour along the 
endothelium that involves this population in local innate immune surveillance (78). Because 
of their lower expression of CD14, a coreceptor for detection of bacterial LPS, non-classical 
monocytes are less responsive to bacteria than the classical and intermediate subsets but are 
more responsive to viral pathogens (77). This population is primarily responsible for 
infiltrating tissues, including the lungs, under homeostatic conditions, and differentiating into 
tissue-resident macrophages (83). However, they have also been shown to be able to traffic to 
inflamed tissue (76). There is still disagreement about the cytokine profile of non-classical 
monocytes, with studies indicating this population is a poor producer of proinflammatory 
cytokines such as TNF (77). However, these studies have used isolated cells that have been 
manipulated extensively, while Belge et al. (84), who used a minimally invasive whole blood 
intracellular staining technique, showed that non-classical monocytes produce a high level of 
TNF. This finding was further supported by the results of Wong et al. (79). 
The effects of CFTR mutations in CF monocytes have been well documented (85-87) with 
reports describing defects in adhesion (85), IL-8, TNF, proteinase and elastase secretion (88-
91), and complement-mediated phagocytosis of pathogens such as P. aeruginosa (92). No 
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studies have yet investigated the three monocyte subpopulations and their role in CF 
pathogenesis. Considering the distinct functions of each subset, investigating this could 
provide a much more detailed understanding of monocyte dysfunction in CF. 
1.2.2.2 Neutrophils and Macrophages 
CF is characterised as a neutrophilic airway inflammatory condition (93, 94) in which there is 
an exaggerated influx of neutrophils to the lungs. As discussed in section 1.1.4, it has not been 
fully elucidated whether increased neutrophil levels are inherent to CF or are a result of 
infection. While neutrophils can be considered beneficial for combatting pathogens, in CF 
they can also become damaging to lung tissue through release of toxic granule contents 
accumulating over long periods of time (95). Studies have shown that CFTR affects 
microbicidal activity in neutrophils by reducing chloride anion concentration, which in turn 
reduces the ability of the phagosome to produce hypochlorous acid, a critical component in 
bacterial killing (96-98). Neutrophils have also been shown to have reduced phagocytic 
capacity in young CF patients (99). However, in contrast to this, another study by Kingma et 
al. (100) has shown no change in neutrophil phagocytic capacity in CF newborns, suggesting 
that this manifestation may be influenced by the development of infection. There are a 
significant number of studies, as reviewed by Hartl et al. (95), which have all demonstrated 
the link between neutrophils and/or detection of their products (proteases, oxidants and 
proteins) and reduced lung function. This evidence supports a significant role for neutrophils 
in CF lung disease and indicates the need for greater understanding of the molecular 
mechanisms driving their accumulation and modulating their function. 
While there are various populations of tissue macrophages, alveolar macrophages are of 
particular interest in CF as they are a key cell type involved in the initial defence against 
pathogens in the lung. Alveolar macrophages are phagocytes residing within the lungs that 
when activated in response to pathogens eliminate bacteria, dead cells and debris, and 
promote the influx of neutrophils and the activation of DCs and T cells, thereby connecting 
the innate and adaptive immune responses. However, alveolar macrophages are poorer 
presenters of antigen to T cells and have reduced expression of costimulatory molecules as an 
adaptation to reduce lung inflammation to innocuous microbes (101). Alveolar macrophages 
have been shown to be increased in infection-free CF children (102), suggesting that this 
elevation may be inherent to CF rather than infection mediated. This has been further 
supported by a study involving exposure of cftr knockout mice to P. aeruginosa, in which 
alveolar macrophages were shown to directly contribute to the exaggerated immune response 
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seen in CF. Alveolar macrophages, like that of monocytes, can be divided into two subsets 
known as ‘classically activated’ or ‘M1’ macrophages that produce proinflammatory 
cytokines and are polarised by bacterial infection and IFN, and the ‘alternatively activated’ 
or ‘M2’ macrophages that promote tissue remodelling and repair after inflammation. M2 
macrophages are polarised by Th2-associated cytokines such as IL-4 and IL-13 (95). An 
appropriate immune response requires the balanced coordination of both of these subsets. In 
CF, the polarisation of macrophages has been investigated but the results are inconclusive. 
Murphy et al. (103) have shown a polarisation towards an M2 phenotype in BALF of P. 
aeruginosa infected CF patients, while Tarique et al. (104) have shown an M1 phenotypic 
bias in CF peripheral blood. Meyer et al. (105) also shown using a CF mouse model that both 
the M1 and M2 phenotypes were upregulated in response to LPS from P. aeruginosa. These 
conflicting findings suggest that further research is required to understand the role and extent 
of macrophage polarisation in CF. 
Macrophages that circulate through blood and lymph are also important because they act not 
only as part of the innate immune system, through direct clearance of pathogens, but also as 
part of the adaptive immune system, through presentation of antigens to Th cells. Evidence 
now suggests that defective CFTR may inhibit macrophage activation and affect macrophage 
pathogen killing. This is supported by a study showing reduced numbers of activated 
macrophages in CF (as defined by F4/80 and MHC-II exppression) (106), although it is 
known that macrophage numbers are increased in CF lungs (107). It has been suggested that 
defective CFTR causes an accumulation of intracellular Ca2+ that is sufficient to alter gene 
expression (108) and hence alter processes involved in macrophage activation. This has been 
supported by a study showing that wild-type macrophages treated with CFTR inhibitors 
displayed increased intracellular Ca2+ levels (109). However, further investigation into 
alterations in macrophage gene expression in relation to function is required. Nevertheless, 
this suggests another immune cell that may be contributing to an ineffective immune response 
and clearance of pathogens in people with CF.  
1.2.2.3 Dendritic Cells 
DCs are professional antigen presenting cells that have the primary function of presenting 
antigen to T cells and aiding in the differentiation of B cells, thus creating a connection 
between the innate and adaptive immune systems. DCs develop in bone marrow and travel in 
blood throughout the body. Once they capture antigen for presentation they mature and travel 
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to the lymph nodes where they can encounter T cells for presentation (110). Mature tissue-
resident DCs can also be found in tissues, particularly at mucosal sites (111). 
There are two types of DCs present in human peripheral blood under normal conditions, 
known as ‘conventional/classical’ DCs and ‘plasmacytoid’ DCs (112). Conventional DCs can 
be further subdivided into two subsets based on CD1c and CD141 expression. However, in 
the presence of GM-CSF and IL-4 during inflammation, a third type of DC develops from 
CD14+ classical monocytes, termed ‘monocyte-derived’ DCs, a proinflammatory subset 
secreting TNF (113). 
Much of the research investigating DCs in CF has been undertaken using mouse models. 
These studies have shown a downregulation of expression of costimulatory molecules such as 
CD40, CD80 and CD86 (114), reduced maturation capacity and reduced expression of genes 
associated with membrane structure and lipid metabolism (23, 114-118), particularly in response 
to specific pathogens such as P. aeruginosa (23, 117) and B. cepacia complex (118). This 
suggests that dysfunction of DCs in CF may be influenced by a combination of both intrinsic 
and infection-mediated effects and, given that antigen presentation molecules are affected, 
this could have negative impacts on the generation of appropriate adaptive immune responses. 
1.2.2.4 Myeloid Derived Suppressor Cells  
MDSC are a heterogeneous population of immature innate myeloid cells with a potent 
suppressive capacity, which are thought to be precursors to monocytes, dendritic cells and 
granulocytes at various stages of differentiation (119). Because this population has been 
identified only recently and is heterogeneous, identification of distinct MDSC phenotypes is 
ongoing. However, two commonly accepted subsets have thus far been identified: monocytic 
MDSCs (lineagenegHLA-DRnegCD33+CD11b+CD14+) and granulocytic MDSCs 
(lineagenegHLA-DRnegCD33+CD11b+CD14negCD14negCD15+CD66b+) (120). MDSCs are 
believed to exert their suppressive capacity via cell contact dependent mechanisms such as 
interaction with cell surface receptors and the release of short lived soluble mediators (119).  
While expansion of MDSCs was originally described in cancer (121), it has become apparent 
that MDSCs play a role in many disease states including tumour formation (122), 
inflammatory diseases (123), and viral and parasitic infections (124, 125). Just one study, by 
Rieber and colleagues (126) has investigated MDSCs in CF and this focussed only on the 
granulocytic MDSC population in peripheral blood. Granulocytic MDSCs were shown to be 
increased in CF, particularly in response to P. aeruginosa infection, and their level positively 
correlated with lung function. This is supported by a study involving LPS-induced MDSCs in 
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non-CF lung bacterial infection that showed that these cells are able to both suppress T cell 
responses and efferocytose apoptotic neutrophils (127). This may indicate that MDSC are 
beneficial in CF, because a reduction in the damaging hyperinflammatory T cell and 
neutrophil responses may improve lung function. 
1.2.2.5 Natural Killer Cells 
NK cells were first identified by Keissling and colleagues in mice in 1975 (128). NK cells are 
now known to be a cytotoxic innate immune cell population that are primarily able to kill 
virus infected, stressed or non-self cells. In addition, they are able to influence the immune 
response through the production of cytokines such as interferon (IFN), TNF and 
granulocyte–macrophage colony stimulating factor (GMCSF) and chemokines such as CCL3 
and CCL4. Much of the literature describes two primary peripheral blood NK subsets based 
on CD16 and CD56 expression. CD56bright NKs are classified functionally as the cytokine-
producing population while CD56dim NKs are classified as the cytotoxic population (129), 
although recent in vitro studies have shown that under certain conditions each of these 
populations can be stimulated to perform the alternate function of either cytokine production 
or cytotoxicity (130, 131). More recently a third NK cell subset has been identified that is low 
in expression of both CD56 and CD16 and was shown to have moderate cytotoxic capacity 
and a moderate ability to produce cytokines such as IFN (132, 133). While CD56dim NKs 
dominate in the periphery, the CD56bright population tends to dominate in tissues, especially 
during inflammation (134). While there have been suggestions that NK cells can be further 
differentiated into five subsets based on further functional testing, this has yet to be confirmed 
(135). 
NK cells are essential in the lungs because this is a major site of entry for pathogens, where 
rapid responses are required to limit their spread. However, aberrant or reduced functioning of 
NK cells can contribute to immune pathologies in conditions such as autoimmunity, 
tuberculosis, influenza and asthma (136, 137). 
NK cells in CF have gained very little attention, with only a small number of studies 
investigating their frequency in peripheral blood (138-140). While all of these studies 
indicated a decrease of NK cells in CF peripheral blood, no further investigations of NK 
subpopulations or function were undertaken. NK cells have been implicated in not only viral 
infections of the lungs but also bacterial infections, where they are believed to play an early 
role in controlling bacterial dissemination (141). 
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1.2.3 Adaptive Immune Cells 
1.2.3.1 B Cells 
B cells form the humoral branch of the adaptive immune response and act through the 
production of antibodies/immunoglobulin, usually regulated by Th cells, which in turn can 
neutralise pathogens or tag them for destruction by other immune cells. There are three 
primary B cell subsets known as follicular (FO) B cells, marginal zone (MZ) B cells and B1 B 
cells. FO B cells are the most abundant and circulate through lymphoid follicles of lymph 
nodes and spleen and are specialised for antibody production in a T-cell dependent manner. 
MZ B cells are located in the marginal zones of the spleen where they are ideally situated to 
respond to blood borne antigens while B1 B cells are located at mucosal sites where they are 
positioned to combat invading environmental pathogens (142). However, B1 B cells are a less 
well characterised population in humans (143).   
There has been very little investigation of B cells in CF, with the few available studies 
indicating a dysregulation in the differentiation of B cells (144) as well as secretion of 
antibody (145), specifically in response to A. fumigatus antigens (146). While levels of B cells 
have not been specifically investigated in the CF lung, a study by Niell et al. (147) has shown 
an increase in BAFF, a B cell growth factor that promotes the maturation and antibody 
production of B cells, and an increase in the B cell chemoattractants CXCL13, CCL19 and 
CCL21 in P. aeruginosa-negative CF paediatric lungs. Consequently, this may suggest that B 
cells and their associated antibodies may be increased in CF lungs, which is supported by a 
study also indicating a dominance of B cells in CF nasal polyps (148). Dysregulation of 
immunoglobulins (Ig) secretion by B cells has also been shown in CF, with reports of 
increased IgG, IgM and IgA in the serum of adult CF patients compared with healthy controls 
(149) and increased IgM and IgA in paediatric CF patients compared with healthy controls 
(150). Of importance, IgG has been shown to be associated with poorer lung function and 
worsened disease severity in both adults and children with CF (149, 150) while IgM has been 
shown to be associated with worsened disease outcome in paediatrid CF patients (150). While 
the levels of IgE are not altered in the general CF population, elevated IgE has been recorded 
during the development of the allergic response to A. fumigatus known as ABPA, and has 
been associated with decreased lung function (151, 152). While the mechanisms behind 
immunoglobulin dysregulation are poorly understood, they are likely to be related to 
dysregulation of Th cell populations, while the evidence suggests that B cells and their 
associated antibodies may play a role in CF pathogenesis, particularly in people with ABPA. 
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1.2.3.2 CD8+ T Cells 
CD8+ T cells or cytotoxic T cells are T lymphocytes that are able to directly kill cells, 
particularly those infected with intracellular pathogens, which express foreign antigen in the 
context of MHC class I molecules. CD8+ T cells can eliminate these cells either through the 
release of cytotoxic granules, release of cytokines or via Fas/FasL interactions that result in 
apoptosis of the target cell (153). There has been limited investigation of CD8+ T cells in CF 
with Hauser et al. (140) demonstrating a decrease of these cells in CF peripheral blood and 
Xu et al. (115) demonstrating a dysregulation of cytokine secretion in these cells in response 
to RSV infection in a CF mouse model. Given that it is known that CFTR is normally 
expressed in CD3+ T cells (22) and that dysfunctional CFTR affects CD4+ T cells and antigen 
presenting cells, which heavily influence CD8+ T cell responses, a possible role for CD8 T 
cells in CF pathogenesis may exist. 
1.2.3.3 CD4+ T Cells 
The adaptive immune system is a highly specialised and specific system defending the host 
against invading pathogens. CD4+ T cells are a specialised cell type that coordinate and 
regulate various aspects of the immune response via the production of specific cytokines, and 
have varying effects including downregulation of the immune response and activation of 
cytotoxic T cells, B cells, innate immune cells and nonimmune cells (154). CD4+ T cells have 
been categorised into two distinct subsets known as T helper (Th) 1 and Th2 based on their 
cytokine profiles (cytokines required for their differentiation and the cytokines they produce), 
functional capabilities, and their transcriptional regulators (155). They exhibit an inverse 
relationship, with one or the other dominating in response to a particular pathogen. CD4+ T 
cells orchestrate the type of immune response elicited, depending on the type of invading 
pathogen. More recently, additional CD4+ T cell subsets have been described, including Th17 
and regulatory T cells (natural Treg [nTreg], induced Treg [iTreg], T regulatory 1 [Tr1] and 
Th3) (Fig. 2).  
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 Fig. 2. Differentiation pathways of CD4+ T cell subsets. Major transcriptional regulators 
(pink boxes), main cytokines required for differentiation (green boxes), signature cytokines 
produced (blue boxes) and associated chemokine receptors (orange boxes) are shown. 
Original figure. 
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Naïve T helper cells are functionally immature precursor cells that have migrated from the 
thymus to the peripheral lymphoid organs and are capable of producing only IL-2 (156). 
Antigenic stimulation is required for these naïve cells to differentiate into different CD4+ 
effector cells with distinct functions. Antigenic stimulation of a naïve T cell involves binding 
of the T cell receptor (TCR)-CD3 complex to the antigen–MHC II presented on APCs, with 
the additional interaction of costimulatory molecules. This in turn leads to the activation of 
downstream signalling pathways resulting in the proliferation of specific CD4+ subsets (157). 
Differentiation of CD4+ subsets is influenced by many factors including the structure, dose 
and route of entry of antigen (158, 159), the strength of TCR signalling (160), the presence of 
costimulatory molecules (158, 161), the type of APC (162, 163), the stimulation of pattern-
recognition receptors by pathogen-associated molecular patterns, and genetic factors. 
However, the most influential factor is the cytokine environment (164). Initially, cytokines in 
the microenvironment are produced by APCs and other cells of the innate immune system, 
but once T cells begin to differentiate they can initiate the production of cytokines, which 
results in a positive feedback loop to enhance their own survival and production. 
1.2.3.4 T Helper 1 and T Helper 2 Cells 
Th1 cells are involved in cell-mediated immunity and produce IL-2, IFN and lymphotoxin . 
These signature cytokines mediate the activation of macrophages and delayed-type 
hypersensitivity responses (156). This type of immune response is involved in defences 
against intracellular pathogens including viruses, bacteria and protozoa (158), and promotes 
antibody-isotype switching to IgG2a in mice (156) and IgG3 in humans (165). The cytokines 
IL-12 and IFN are required for the differentiation of Th1 cells (166, 167), and their master 
transcriptional regulator is the T-box transcription factor (T-BET). T-BET is known to be 
highly dependent on signal transducer and activator of transcription (STAT)1, which is 
activated by IFN (168) and must function in collaboration with STAT4, which requires IL-12 
for activation, for full differentiation of Th1 cells (169). The inverse relationship seen 
between Th1 and Th2 immune responses is mediated largely by T-BET through multiple 
mechanisms. Predominantly, T-BET upregulates the production of IFN which inhibits the 
development of the Th2 subset (170). It also inhibits Th2 development through suppression of 
IL-4 expression, which consequently impairs the functioning of GATA-binding protein 3 
(GATA3), the major transcriptional regulator of the Th2 subset (171). 
Th2 cells are involved in the humoral immunity that occurs in response to extracellular 
pathogens such as helminths, and are important in allergic responses (155). They produce IL-
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4, IL-5 and IL-13, which promote proliferation and differentiation of B cells and antibody-
isotype switching to IgG1 and IgE (156) in mice and IgG4 and IgE in humans (165). IL-2 and 
IL-4 are the major cytokines required for Th2 differentiation (172, 173) and GATA3 is their 
main transcriptional regulator. GATA3 is not able to regulate the differentiation of Th2 cells 
by itself but requires STAT6 (174), which is activated by IL-4 and which then upregulates 
expression of GATA3 (175). Both STAT3 and STAT5 have also been shown to be important 
in the differentiation of Th2 cells, with STAT3 assisting STAT6 (176) and STAT5 working in 
close collaboration with GATA3 (174). 
1.2.3.5 T Regulatory Cells 
Although the classification of Treg cells is still controversial, they can be divided into three 
separate types known as natural, induced and adaptive Tregs. Natural Treg cells (nTreg) are 
released from the thymus as a fully differentiated cell type expressing the transcription factor 
forkhead box P3 (FOXP3), while iTreg cells are induced in the periphery after specific 
antigen exposure to differentiate into FOXP3-expressing regulatory cells (157). However, the 
majority of FOXP3+ Treg cells are nTreg cells that develop soon after birth (177). The 
FOXP3 transcription factor regulates the suppressive capacity of Treg and iTreg cells and is 
essential for appropriate functioning and development of these cells (178). It has also been 
shown to be essential for maintaining immune homeostasis (179), with a deficiency in FOXP3 
resulting in a fatal autoimmune-like disease because of overactive T cells, and FOXP3 
overproduction resulting in reduced levels of T effector cells with impaired function (180). 
The expression of FOXP3 in non-regulatory cells has also been shown to result in the gain of 
suppressor function by peripheral activated T cells (178), indicating its importance in the 
function of these cells. Treg cells are vital in the regulation of the immune system and the 
induction of tolerance. They regulate many cell types including other T cells, B cells, NK 
cells and DCs. Regulation of T cells, both CD4+ and CD8+, occurs through inhibition of 
proliferation through contact dependent mechanisms and production of immunosuppressive 
soluble factors such as cytokines, although the specific mechanism are still under debate 
(181). nTregs regulate B cells by preventing immunoglobulin production, NK cells by 
preventing their cytotoxic activity, and DCs by preventing their maturation (182, 183). The 
major effector cytokines of nTreg cells include IL-10, transforming growth factor (TGF) and 
IL-35 (184-186), which are able to turn potentially self-reactive T cells into regulatory cells 
that in turn can then inhibit any remaining self-reactive cells (187). 
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The initial differentiation of nTreg cells begins from those cells that have a TCR with high 
affinity for self antigen. This differs from the process for other CD4+ subsets, which are 
eliminated by negative selection if they express high affinity for self antigens. The 
transcription factor c-REL is predominantly responsible for the differentiation of nTregs (188, 
189), however, it is the production of IL-2 and/or IL-15 that induces the FOXP3 expression 
that subsequently maintains the suppressive behaviour of the nTreg cells (190). In mouse 
models it has been shown that an absence of c-REL results in a reduction of the number of 
nTregs to just 15% of wild type (189). 
Induced Tregs are CD4 cells that have differentiated into FOXP3+ regulatory cells in the 
periphery in response to cytokines such as IL-12 and TGF (154). It has also been shown in 
mice that TGF is the main cytokine required for iTreg differentiation (157, 191). It activates 
Smad2 and Smad3, which then induce FoxP3 expression (192). Investigation of iTreg 
differentiation has revealed that c-REL is involved in expansion of these cells but is not 
critical for their differentiation (189). 
Adaptive Treg cells are believed to have an origin distinct from that of FOXP3+ Treg cells 
(193). They do not express FOXP3, but exert suppressive behaviour via IL-10- and TGF-
dependent mechanisms (194). Two types of adaptive Treg cells have been described: IL-10-
producing Tr1 cells and TGF-producing Th3 cells (195). While nTreg cells are mainly 
responsible for the maintenance of self-tolerance, Tr1 cells are responsible for the regulation 
of inflammation-dependent adaptive immunity and act to minimise immunopathology (196) 
while Th3 cells play a role in oral tolerance and providing help for IgA production, a 
noninflammatory antibody isotype, at mucosal sites (197). Because these subsets are 
relatively newly described, little is known about the factors involved in their differentiation. 
Using mouse models, Tr1 cells have been shown to require IL-27 for differentiation. This acts 
by inducing the major Tr1 transcriptional regulator c-MAF, IL-21 and the costimulatory 
receptor inducible T-cell costimulator (ICOS) (198). However, this pathway has yet to be 
fully investigated in humans. 
Conventionally, identification of Treg cells has involved the use of markers such as CD4, 
CD25 and FOXP3, but because FOXP3 is an intracellular marker, the detection of which 
requires permeabilisation of cells and therefore their destruction, a reliable surface marker to 
substitute for FOXP3 was required for more in-depth studies of this cell type. The CD127 
marker has since been identified as a reliable surface marker of FOXP3+ Treg cells, with the 
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level of CD4+CD25+CD127lo cells correlating with the level of CD4+ CD25+ FOXP3+ cells 
(199). 
1.2.3.6 T Helper 17 Cells 
The Th17 lineage was first described in 2005 (200) and is characterised by the production of 
its signature cytokines IL-17A, IL-17F, IL-22 and IL-26, which are involved in the 
recruitment of neutrophils (201, 202). Th17 cells are particularly important for host defence 
against fungi and extracellular bacteria (203, 204). 
The generation of Th17 cells from naïve T cells occurs in three stages. The initial 
differentiation step requires TGF, IL-6 and IL-1 (205-207); TGFβ is a cytokine critical for 
iTreg differentiation because it promotes expression of FOXP3 (157), and it only results in 
Th17 differentiation when in low concentrations and in the presence of IL-6 (206). If TGF is 
present in high concentrations it can cause a change from Th17 to iTreg phenotype (157). The 
combination of TGFβ and IL-6 results in the activation of RAR-related orphan receptor 
(ROR)γt, the main transcriptional regulator of Th17 cells (205). In addition to RORγt, STAT3 
has also been shown to be crucial for Th17 development because it induces the expression of 
RORγt (208). ROR was also found to be crucial in Th17 development because it works in 
close collaboration with RORγt. Absence of both RORγt and ROR results in complete loss 
of Th17 production (209). 
After this initial differentiation stage of Th17 cells, IL-21 is involved in a self-amplification 
process whereby, in collaboration with TGFβ, a positive feedback loop is created to generate 
further Th17 cells (210). The final stage of differentiation involves the production of IL-23, 
which is not involved at all in the differentiation of these cells but is required purely for their 
survival and expansion (205). 
1.2.3.7 Treg and Th17 Cells in Disease 
Treg and Th17 cells are known to have an inverse relationship, with Th17 cells having 
proinflammatory properties and Treg cells being anti-inflammatory. Their developmental 
pathways are interrelated and evidence suggests that there is plasticity between the subsets 
(211); Treg and Th17 subsets have shown to be more susceptible to transformation than other 
CD4+ subsets (212). For example, IL-6, a cytokine essential for Th17 differentiation, is able 
to convert a cell from Treg to Th17 phenotype (212), while Smad2 and Smad3, transcription 
factors essential for Treg differentiation, are able to hinder Th17 differentiation through 
inhibition of RORγt (213). This suggests that when considering the role of these subsets in 
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disease, analysing the balance between the two rather than each subset in isolation may be 
important. While there is little research on the balance between these two subsets in CF, other 
diseases may provide insight. In asthma a skewed balance between Treg and Th17 cells with 
dominance of the Th17 phenotype has been shown to contribute to disease pathology (214), 
and a similar effect of a predominance of the Th17 phenotype has been reported in 
inflammatory bowel disease (215). 
Research has also shown there to be a link between the severity of inflammatory diseases and 
the level of IL-17 found in serum and tissue fluids of patients (200, 207). In particular, a study 
by Tiringer and colleagues (216) has shown the levels of IL-17 in the lungs of people with CF 
to be predictive of P. aeruginosa infection. 
There is very little research investigating Tregs in CF and much of the research investigating 
Th17 cells in CF is focused on the lungs. The only study comparing levels of Treg cells in CF 
peripheral blood with those in healthy controls (217) showed that in CF, numbers of 
peripheral Tregs were decreased and their suppressive function was impaired. While it has 
been shown that Th17 cells predominate in CF lungs (216), a study by Tan and colleagues 
suggests that this could be a general feature of lung immunity (218). This group investigated 
the levels of IL-17 in the lungs of people with CF, non-CF bronchiectasis and healthy controls 
and showed that levels of Th17 cells were increased compared with controls in not only CF 
but also in non-CF bronchiectasis patients, although levels were higher in those with CF. Only 
two studies have compared peripheral blood Th17/IL-17 levels in CF with those in healthy 
controls (219, 220). One of these studies showed people with CF to have an increased 
percentage of Th17 cells and an increased propensity of naïve T cells to differentiate towards 
a Th17 phenotype (220). However, that study included only five CF participants, all of whom 
were female, and three healthy controls who were not age or sex matched, leading to 
considerable potential bias. The other study of Th17 cells in peripheral blood in fact found 
decreased IL-17 production by stimulated PBMC from people with CF (219). This study 
included a much larger, diverse participant group with an appropriately matched control 
population, providing much more reliable results. It did however show a link between high 
peripheral blood Th17 levels and reduced lung function. This may indicate that Th17 cells 
have homed to the lungs, where high levels have been reported and where their 
proinflammatory cytokines can be damaging, and that this is reflected in the periphery. 
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1.2.3.8 Relationship between CD4+ T Cell Subsets 
Several studies have recently shown that most CD4+ T cell subsets are not terminally 
differentiated (Fig. 3), meaning that regulation of the balance of T cell subsets is even more 
vital than originally thought because a change in one subset may affect others. After exposure 
to IL-6, Treg cells have shown to alter their phenotype to that of Th17 (212), while Th17 cells 
can switch to Th1 following exposure to IL-12 (221) and to Th2 after exposure to IL-4 (222). 
Therefore, the balance between CD4+ T cell subsets is tightly regulated, with Th1 and Th2 
cells dominating over Th17 cells because IL-12, IFNγ and IL-4 inhibit Th17 differentiation.  
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Fig. 3. The influence of various cytokines on the differentiation of CD4+ T cell subsets 
and expression of their major transcriptional regulators. Blue arrows represent the 
differentiation of naive T cells in the presence of specific cytokines. Green arrows represent 
the self-amplification loop directed by the circled cytokines. Red arrows represent the ability 
of subsets to alter their phenotype influenced by specific cytokines. Figure taken from 
Luckheerman et al. (154).  
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1.3.1 Homing of Immune Cells 
The ability of immune cells, particularly lymphocytes, to migrate around the body is essential 
to their efficient and effective functioning. Lymphocytes must be able to home to the lymph 
nodes where antigen presentation takes place and towards sites of infection and inflammation 
in order to elicit an appropriate response. The primary mechanism of homing of immune cells 
involves chemokines and their binding to corresponding chemokine receptors on the surface 
of immune cells. 
1.3.2 Chemokines 
Chemokines are a family of chemotactic cytokines, approximately 8–12 kDa in size, that 
influence the homing of immune cells during both homeostasis and inflammation (223). They 
are divided into four subfamilies (CC, CXC, CX3C and XC) based on the structure and 
arrangement of their conserved cysteine residues (224). Homeostatic chemokines are involved 
in the maintenance of maturation, trafficking and regeneration of leukocytes under normal 
physiological conditions while inflammatory chemokines are involved in recruitment of 
leukocytes to inflamed/damaged tissues with production of these chemokines by both local 
tissues as well as local and infiltrating immune cells (225). 
1.3.3 Chemokine Receptors and their Activation 
Chemokine receptors are a group of transmembrane G-protein-coupled receptors (GPCRs) 
that can be responsive to multiple chemokines, although only to those within the same 
subfamily (226, 227). Activation of chemokine receptors not only controls leukocyte 
trafficking but also plays a role in cell degranulation, gene transcription, mitogenesis and 
apoptosis (228). 
Binding of chemokines to these GPCRs results in the activation of phospholipase C which 
cleaves itself to produce diacylglycerol (DAG) and inositol-1,4,5 triphosphate (IP3). DAG 
remains at the plasma membrane while IP3 is released into the cytosol to bind to the IP3 
receptors on the endoplasmic reticulum (ER). This binding results in the release of Ca2+, 
increasing cytosolic calcium concentrations. The increase in intracellular calcium results in 
localization of the membrane proteins calcium release-activated calcium channel protein 1 
(ORAI1) and transient receptor potential cation channel, causing an influx of calcium through 
the plasma membrane. Calcium release-activated channels are also stimulated, further 
facilitating the influx of calcium. Further signalling events lead to actin polarisation and 
morphological changes in the responsive cell, leading to movement of that cell along the 
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chemokine concentration gradient towards an area of higher chemokine concentration 
(reviewed by Swaney et al. (229)). 
In CF, defective CFTR, particularly the forms that are retained in the ER such as DF508, is 
known to cause increases in IP3-mediated intracellular calcium flux (230). It has also been 
shown to affect the plasma membrane localisation of ORAI1, resulting in an increased influx 
of calcium (231). Because calcium signalling is heavily involved in chemokine receptor 
activation and therefore leukocyte migration, this is a potential contributing factor to the 
dysregulated immune response in CF. 
1.3.4 CXCR3, CCR4 and CCR6 
Currently over 20 chemokine receptors and over 40 related chemokines have been identified 
(226). CXCR3 is a chemokine receptor primarily expressed on Th1 CD4+ T cells, CD8+ T 
cells and NK cells (232). It permits entry of these cells into sites of Th1-mediated 
inflammation, is activated by the IFN-induced chemokines CXCL9, CXCL10, and CXCL11 
and has been implicated in many diseases states such as inflammatory bowel disease, 
leukaemia and diabetes (233). 
CCR4 is a chemokine receptor predominantly expressed by Th2 cells, platelets and basophils 
and is responsive to the CCL17 and CCL22 chemokines (234). CCR4 has been implicated in 
many allergic diseases such as asthma (235). 
CCR6 is a chemokine receptor, activated by CCL20, and is principally expressed by Th17 
CD4+ T cells but also CD8+ T cells and immature DCs (236, 237). This chemokine receptor is 
unique in that it is activated by only one chemokine. Cells expressing CCR6 are able to home 
towards sites of Th17-mediated inflammation. CCR6 is an important chemokine receptor in 
mucosal immunity, allowing cells to enter the lungs and gut (238), and has been implicated in 
many inflammatory diseases such as rheumatoid arthritis (239). 
1.3.5 Chemokines and Disease 
While chemokines are beneficial for maintaining homeostasis and directing immune cells 
toward sites of infection and inflammation to promote an efficient and effective immune 
response, dysregulation of chemokine secretion by immune cells and tissues can contribute to 
disease pathology. Because chemokine receptors can be responsive to multiple chemokines 
(226, 227), understanding their role in disease states can be quite complex. Chemokine 
dysfunction has been implicated in many disease states such as autoimmunity, cancers, 
tumours, asthma, atherosclerosis, multiple sclerosis, arthritis, and infection (240). 
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In CF, two chemokines in particular, CXCL8 and CCL2, have been implicated in the 
pathogenesis of the disease (241-244). Excessive and prolonged production of these 
chemokines has been shown to promote recruitment to the lungs of inflammatory cells such as 
neutrophils and macrophages, which over time can become just as harmful to the lung as the 
infection they were recruited to combat. 
1.4.1 The Immune System in Cystic Fibrosis 
The role of the innate and adaptive immune systems in CF disease pathophysiology is still 
unclear, with many inconsistencies observed in immune responses to particular pathogens. 
While a significant amount of research has been devoted to exploring the effect of CFTR 
mutations in epithelial cells, a great deal of the CF phenotype cannot be explained simply by 
defective transport of ions by these cells. More recently, the intrinsic effects of mutated CFTR 
on the immune system have become of interest, because alteration of immune responses could 
exacerbate CF disease pathology and impede the ability of people with CF to clear pathogens 
effectively. Current knowledge about the dysregulation of immune cells in CF is summarised 
in Table 1. 
1.4.2 Innate Immunity 
It is currently accepted that the innate immune system in CF functions inappropriately on 
multiple levels. Studies have shown that there is a hyperinflammatory immune response to 
pathogens in CF, with an excessive production of proinflammatory cytokines (27). There are 
known dysfunctions of the innate immune system involving epithelial cells, extracellular 
matrix, pattern recognition receptors, and chemokine and cytokine secretion, as well as 
phagocyte recruitment and function (reviewed in (245)). More recently, innate immune cells 
such as neutrophils, macrophages and monocytes have become of interest because, as 
discussed in section 1.2.2, new findings suggest that they may express defective CFTR and 
that this could play a significant role in their ability to function appropriately. Overall, this 
evidence suggests that there are intrinsic defects in CF innate immune cells, although more 
research is required to determine the full effects and contribution of this to CF disease 
pathology. In general, there appears to be an exaggerated and prolonged immune response to 
pathogens in CF cells but a decreased ability to clear them. 
1.4.3 Adaptive Immunity 
More recently the adaptive immune system has become a topic of great interest in CF 
research, particularly because CFTR has been shown to be expressed by cells such as APCs 
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and T cells (21, 246), and because of the increasing complexity of the classification of CD4+ 
T cell subsets. In addition to the characteristic hyperinflammatory immune response, people 
with CF also display a tendency to develop allergic reactions, asthma and dermatitis. In 
addition to this, they also display a characteristic Th2-biased immune response, particularly in 
response to infections with organisms such as P. aeruginosa (216, 247) and A. fumigatus 
(248), which has also been shown to become more dominant during pulmonary exacerbations 
(216). Th2-type immune responses favour allergies and are directed at clearing parasites 
rather than bacterial pathogens, which may partly explain why people with CF show 
ineffective clearance of pathogens such as P. aeruginosa. 
Mueller and colleagues (22) have demonstrated that mutated CFTR in T cells results directly 
in abnormal immune responses. They showed that Cftr-knockout mice mounted an 
exaggerated IgE response to A. fumigatus infection compared with that of wild-type controls, 
and produced increased levels of IL-13 and IL-4, typical of a Th2-type response. A study by 
Moss and colleagues (20) has shown that activated CF lymphocytes produce lower levels of 
IFNγ (Th1 cytokine) and increased levels of IL-10 (Th2 cytokine). This has been suggested to 
downregulate the expression of costimulatory molecules on macrophages, which could affect 
antigen presentation and hence impair appropriate immune responses (108). A study by Moser 
and colleagues (249) has shown the importance of a Th1-type immune response in the 
effective clearance of pathogens, particularly P. aeruginosa. They demonstrated that when 
mice were repeatedly infected with P. aeruginosa, resistance developed concomitant with a 
shift to a Th1-dominated immune response and increased IL-12 production. There was no 
increase in serum IgG compared with mice that were infected only once, which indicates that 
a Th1-dominated cell-mediated immune response is protective against chronic P. aeruginosa 
infection in CF regardless of antibody production. Mueller and colleagues (22) demonstrated 
that in Cftr-deficient mouse T cells there was an increased intracellular Ca2+ flux in response 
to TCR-mediated activation. With this increased Ca2+ flux there was also an increase in 
nuclear localization of the calcium-sensitive transcription factor nuclear factor of activated T 
cells (NFAT). This was suggested to be responsible for the IL-13 response, because NFAT is 
a transcriptional regulator of cytokines directing Th2 responses (250). This study 
demonstrated how an alteration in the balance of Ca2+ can greatly affect gene expression in T 
cells. However, although the balance of the Th1/Th2 immune response is now known to be 
affected in CF, it is not known what other gene expression pathways are altered. 
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While the above evidence suggests intrinsic defects and alterations in the adaptive immune 
system in people with CF, it is not known to what degree this plays a part in CF disease 
pathology compared with alterations in the innate immune system and in epithelial cells. It is 
possible that the effects of CFTR on the immune system are responsible for significant 
disease pathology because of overall dysfunctional immune response. 
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Table 1. Current knowledge about innate and adaptive immune cell dysfunction in CF. 
 
Cell Type Alteration in CF Reference 
Neutrophils 
Increased pulmonary levels (100) 
Decreased microbicidal activity (96-98) 
Reduced phagocytic capacity (99) 
Increased elastase secretion (251) 
Enhanced chemotaxis (252) 
Reduced apoptosis (253, 254) 
Altered cytokine production (255) 
Macrophages 
Increased pulmonary levels (102) 
Altered cytokine production (256, 257) 
Reduced antigen presentation capacity (258) 
Monocytes 
Reduced phagocytosis (259) 
Increased elastase secretion (90) 
Decreased adhesion (85) 
Altered cytokine production 
Reduced antigen presentation capacity 
(88) 
(260) 
Dendritic cells 
Altered membrane structure (23) 
Delayed differentiation (23, 261) 
Decreased antigen presentation (114) 
Natural killer cells Decreased peripheral blood levels (138-140) 
Myeloid derived suppressor cells Unknown  
T Lymphocytes 
Th2 & Th17 bias  (53, 262) 
Altered Cytokine production (CD4+ and 
CD8+) 
(22, 115, 
263) 
B lymphocytes 
Altered Immunoglobulin production 
 
(145, 146, 
149, 150) 
 
Altered differentiation (144) 
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1.5.1 Hypothesis and Aims 
We hypothesised that innate and adaptive immune dysfunction occurs in CF because of an 
intrinsic defect associated with mutated CFTR in immune cells and that this defect would be 
detectable as altered proportions of innate and adaptive peripheral blood immune cells. We 
aimed to characterise the proportions of CD4+ effector (Th1, Th2 and Th17) and regulatory 
(FOXP3+ Treg, IL-10+ Tr1 and TGF+ Th3) T cell subsets as well as the proportion of naïve 
and memory CD4+ and Treg cells expressing the Th1-, Th2- and Th17-associated homing 
markers CXCR3, CCR4 and CCR6, respectively. In addition to this we aimed to determine 
the proportions of peripheral blood innate immune cells including monocytes, DCs, NK cells 
and MDSC and their subsets. We then aimed to investigate the gene expression of CD4+ T 
cell subset-specific transcriptional regulators, chemokine receptors and inflammatory markers 
in CD4+ T cells. Lastly, we aimed to determine the levels of all of these immune parameters 
in CFTR heterozygotes/carriers, who are clinically normal, to assess the degree to which 
defects are CFTR-mediated rather than infection- and inflammation-mediated. 
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CHAPTER 2 
Methods 
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2.1 Study Participants and Blood Collection 
Peripheral blood samples were obtained from CF patients (Ethics approval numbers H008013 
and H0012530, Tasmanian Health and Medical Human Research Ethics Committee) attending 
the Royal Hobart Hospital. Participants included 22 children (0–17 years) and 20 adults (18–
54 years) who were either attending outpatient clinics or were admitted because of clinical 
exacerbations. Clinical exacerbation was defined according to the Tasmanian Department of 
Health and Human Services’ microbial surveillance and antimicrobial management guidelines 
(264), which define clinical exacerbation as the decline in two or more symptoms and one or 
more objective measures. Symptoms include cough, sputum volume, sputum purulence, self-
reported breathlessness on exercise, fatigue and appetite. Objective measures include a 
reduction in absolute FEV1 of greater than 10% compared with the best achieved in the 
previous one year when stable, weight loss of greater than or equal to 1 kg in the past two 
weeks, increased respiratory rate at rest and new radiological changes on chest X-ray. Overall 
numbers of CF samples were limited by the number of patients in the Hobart region, but to 
obtain sufficient cells to allow full analysis of all patients, repeated samples were obtained 
over four years where possible, as indicated in Table 24-25. Before collection, informed 
consent was obtained either from patients themselves, or for children, from their legal 
guardians. 
Peripheral blood samples for use as controls were obtained from healthy children (6 months–
17 years) and adults (19–61 years) who had no history of chronic illness, no known family 
history of CF and no infectious illness within the previous two weeks. Informed consent was 
obtained from the adult volunteers, or from the legal guardians of the children. 
Peripheral blood samples were also obtained from adult (22–47 years) CF heterozygotes (CF 
carriers), who were primarily the parents of the paediatric CF patients, following informed 
consent. The genotype of their defective CFTR allele was obtained where available. 
Power calculations were performed based on our preliminary data of the immune cells of 
interest in CF and this suggested that, with an  = 0.05 (95% confidence), samples sizes 
ranging from 10-40 would be sufficient. Sufficient participant numbers were achieved for 
each analysis. 
Blood samples were collected in lithium heparin Vacuettes (Life Technologies, Mulgrave, 
VIC, Australia) and processed on the day of collection. 
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A detailed summary of the characteristics of all participants, including age, sex, type of 
infection and antibiotic treatment regime, clinical status, white cell count, C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR) inflammatory markers and lung function (as 
FEV1 % predicted) is given in Appendix 2. 
2.2 Peripheral Blood Mononuclear Cell (PBMC) Isolation and Activation 
Peripheral blood mononuclear cells (PBMC) were isolated using the density gradient medium 
Histopaque-1077 (Sigma Aldrich, Castle Hill, NSW, Australia) according to the 
manufacturer’s instructions, then washed twice in phosphate-buffered saline (PBS) containing 
10% foetal calf serum (FCS, Bovogen, East Keilor, VIC, Australia) at 300  g for 10 min at 
room temperature. PBMC were either used fresh or were cryopreserved for future analysis. 
No difference was found in the cytokine expression of fresh versus cryopreserved cells: an 
example of flow cytometric staining of a control sample when fresh and then again after three 
months of cryopreservation is shown below (Figure 4). PBMC (2  106 cells) were activated 
in 4 mL of complete culture media (CCM) (detailed in Appendix 1a) in a 6-well tissue culture 
dish (Sigma-Aldrich, Castle Hill, NSW, Australia) at 37 C in 5% CO2 in air. Cells were 
activated for 5 h with 50 ng/mL phorbol myristate acetate (PMA) (Sigma Aldrich) and 1 
l/mL ionomycin (Life Technologies, Mulgrave, VIC, Australia). These were used as they 
stimulate the cells in a T cell receptor independent fashion. At the time of activation, 2.67 L 
of BD GolgiStop was added to inhibit cytokine secretion. 
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Fig. 4. Histograms demonstrating staining of the same PBMC sample when fresh (A1–A5) and after three months of cryopreservation 
(B1–B5). 
‘A1’ and ‘B1’ show lymphocytes as a percent of total cells, ‘A2’ and ‘B2’ show single cells as a percent of lymphocytes, ‘A3’ and ‘B3’ show 
CD4 cells as a percent of lymphocytes, ‘A4’ and ‘B4’ show the percent of CD4 cells that are positive for IL-10 and TGF- and ‘A5’ and ‘B5’ 
show the percent of CD4 cells that are positive for FOXP3 and IL-17A. 
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2.3 Cryopreservation of PBMC 
PBMC were stored at 2–4  106 cells/mL in complete culture medium containing 10% 
dimethyl sulfoxide (DMSO) (Sigma Aldrich, Castle Hill, NSW, Australia). Freezing medium 
(CCM containing 10% DMSO) was prepared and cooled on ice. Cells were resuspended in 
ice-cold CCM then the freezing medium was added dropwise to the cells to minimize cell 
damage caused by the DMSO. Cells were transferred to cryovials and placed in a cooler box 
(Life Technologies, Mulgrave, VIC, Australia) at –80 C. Within 3 days, cryovials containing 
cells were transferred into liquid nitrogen for longer-term storage. 
2.4 Resuscitation of PBMC from Cryopreservation 
Cells were removed from liquid nitrogen storage on ice and resuscitated immediately. CCM 
was heated in a water bath to 37 C prior to retrieval of the cells. Cryovials were gently 
agitated in the 37 C water bath until the medium had melted, then were gently transferred to 
a 15 mL tube (ThermoFisher Scientific, Scoresby, VIC, Australia). Two millilitres of warmed 
CCM was added dropwise to the cells, and then tube slowly topped up to 10 mL. Cells were 
then centrifuged at 500  g for 5 min and resuspended in 1 mL of CCM for counting using a 
haemocytometer. 
2.5 Immune cell phenotyping 
Innate and adaptive peripheral blood immune cells were identified by flow cytometric 
analysis using the monoclonal antibodies listed in Table 2. Specific staining procedures for 
each antibody panel can be found in the methodology of chapters 3-5. 
  
Table 2. Antibodies used for identification of innate and adaptive peripheral blood immune cell subsets 
Antibody Marker Fluorochrome Hybridoma Clone Supplier 
anti-CD4 CD4
+ helper T cells Peridinin chlorophyll protein cyanin 5.5 (PerCP-Cy5.5) SK3 BD Biosciences 
anti-IFN Th1 cells Fluorescein isothiocyanate (FITC) B27 BD Biosciences 
anti-IL-4 Th2 cells Allophycocyanin (APC) MP4-25D2 BD Biosciences 
anti-IL-17A Th17 cells Phycoerythrin (PE) N49-653 BD Biosciences 
anti-FOXP3 Treg cells Alexa Fluor 647 (AF647) 259D BD Biosciences 
anti-IL-10 Tr1 cells Allophycocyanin (APC) JES3-19F1 BD Biosciences 
anti-TGF Th3 cells Phycoerythrin (PE) TW4 BD Biosciences 
APC isotype control rat IgG2a kappa Allophycocyanin (APC) R35-95 BD Biosciences 
PE isotype control mouse IgG1 kappa Phycoerythrin (PE) MOPC-21 BD Biosciences 
Live/dead  Dead cells Near infrared (IR)  ThermoFisher Scientific 
anti-CD4 CD4
+ helper T cells V500 RPA-T4 BD Biosciences 
anti-CD25 Treg cells Allophycocyanin (APC) 2A3-9E7 BD Biosciences 
anti-CD127 Treg cells Brilliant violet 421 (BV421) A019D5 BioLegend 
anti-CD45RO Memory/naïve cells BUV395 UCHL1 BD Biosciences 
anti-CXCR3 Th1-associated cells Alexa Fluor 488 (AF488) 1C6 BD Biosciences 
anti-CCR4 Th2-associated cells Phycoerythrin cyanin (PE-Cy7) L291H4 BD Biosciences 
anti-CCR6 Th17-associated cells Phycoerythrin (PE) 11A9 BioLegend  
anti-CD3 T cells Biotin OKT3 Centenary Institute, Newtown, NSW, Aus 
anti-avidin Biotin labelled cells (T and B cells) Pacific orange (PO)  Centenary Institute 
anti-CD19 B cells Biotin HIB19 BD Biosciences 
anti-CD14 Monocytes 
Myeloid derived suppressor cells 
Pacific Blue (PB) M5E2 BD Biosciences 
anti-CX3CR1 Monocytes 
Dendritic Cells 
Fluorescein isothiocyanate (FITC) 2A9-1 BioLegend 
anti-NKP46 Natural killer cells Phycoerythrin (PE) 9E2 BD Biosciences 
anti-CD16 Natural killer cells 
Monocytes 
Myeloid derived suppressor cells 
Peridinin chlorophyll protein cyanin 5.5 (PerCP-Cy5.5) 3G8 BD Biosciences 
anti-CD11b Myeloid derived suppressor cells Phycoerythrin cyanin (PE-Cy7) ICRF44 BD Biosciences 
anti-CD56 Natural killer cells Allophycocyanin (APC) NCAM16.2 BD Biosciences 
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2.6 Spirometry 
Using a spirometer, forced vital capacity (FVC) and forced expiratory volume in 1 second 
(FEV1) values were recorded. FEV1 % predicted values were calculated according to the 
Australian CF Data Registry guidelines (265) to obtain lung function values that accounted 
for body mass, because both children and adults were included in the analyses. 
2.7 Statistical Analysis 
2.7.1 GraphPad Prism 
All flow cytometric and gene expression data were analysed using GraphPad Prism Version 6 
(GraphPad Software, La Jolla, CA). Because many parameters were not normally distributed, 
nonparametric tests (Mann-Whitney U and Kruskal–Wallis) were applied to the data to 
investigate the differences between groups. To determine correlations between clinical 
parameters and subset percentages a Spearman correlation was performed. All P values < 0.05 
were considered significant. 
2.7.2 Multi Experiment Viewer (MeV) 
Raw data from experiments investigating immune cell subsets were imported into 
MultiExperiment Viewer (MeV) Version 4.8 (TM4 Microarray Software Suite, Boston, MA, 
USA) in the format of a .txt file. A heat map was automatically generated to allow 
visualisation of the relative expression of a marker by use of colour, with black indicating no 
change in expression, green indicating a downregulation in expression and red an 
upregulation in expression, all relative to the median of all samples combined. 
Data were normalised across rows and an unsupervised clustering analysis was performed 
(hierarchical clustering). Hierarchical clustering was performed using a nonparametric 
Spearman rank correlation distance metric and average linkage clustering with an associated 
heat map expression image to visualise the grouping of parameters. 
A nonparametric Kruskal–Wallis test was also performed using MeV to determine differences 
in the proportions of each subset between groups, and again a hierarchical clustering was 
performed and a heat map expression image created to visualise results. 
2.7.3 Analyses within the CF Cohort 
The relationships between peripheral immune cell percentages and clinical continuous 
variables such as ‘age’ and ‘FEV1 % predicted’ were assessed using a Spearman correlation. 
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Differences in peripheral immune cell percentages between subgroups of patients were also 
investigated. Patients were stratified by sex, clinically stable or exacerbating, those with or 
without chronic P. aeruginosa infection (defined by sputum culture on two or more occasions 
within a six month period), with or without current S. aureus infection, with or without 
current A. fumigatus infection (both assessed by sputum microbiology), with or without 
current treatment with any antimicrobial and genotype (DF508 homozygous, DF508 
heterozygous, other). Genotypes were classified into these two groups as there were only two 
patients that did not possess a DF508 allele. 
 
 
  P a g e  | 39 
 
CHAPTER 3 
Flow Cytometric Analysis of Peripheral Blood CD4+ T Cell Subset 
Proportions 
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3.1 Introduction 
The development of chronic infection and inflammation of the lungs is characteristic of CF, 
with P. aeruginosa being the most significant pathogen with respect to deterioration of lung 
function and reduced life expectancy. The inflammation present in the lungs is exaggerated, 
damaging, and ineffective for clearance of pathogens (266). A disruption in the balance of T 
cell responses in CF lung has been reported, with many studies observing a skewing towards a 
Th2- and Th17- dominated immune response (17, 22, 216, 248, 262, 263, 267, 268). 
However, whether this imbalance is specific to CF or is characteristic of inflammatory lung 
disease in general is still uncertain, given that similar features have been reported in other 
immunoinflammatory lung diseases such as asthma (269-272) and chronic obstructive 
pulmonary disease (COPD) (273-275). 
Although CFTR encodes a chloride channel, this defective channel affects signalling through 
other ion channels including those specific for Ca2+ (276) and Na+ (277). An initial step in the 
activation of T cells is the influx of Ca2+ across the T cell membrane. The strength of this Ca2+ 
signalling, in part, influences the development of the naïve T cell into its functional subsets 
(e.g., Th1, Th2, Th17). Mueller and colleagues (22) have shown that in CFTR-deficient 
lymphocytes, enhanced intracellular Ca2+ influx leads to abnormal immune responses. While 
there are no studies involving Ca2+ signalling in human CF T cells, this is much evidence to 
show it is altered in other cells types (276) including human macrophages (278). 
We therefore hypothesised that altered ion transport across the T cell membrane during 
stimulation would result in alterations in the relative proportions of peripheral CD4+ T cell 
subsets. Shifts in proportions of cells such as Treg (279) and Th17 (268) have previously been 
reported in CF, as have alterations in peripheral cytokine concentrations (150), but it is not yet 
clear to what extent this is related to the CFTR defect or to the effects of chronic infection.  
The proportions of three effector (Th1, Th2, Th17) and three regulatory (FOXP3+ Treg, IL-
10+ Tr1 and TGF-+ Th3) CD4+ subsets were measured in the peripheral blood of people with 
CF and compared with those in age-matched healthy controls, after stimulation with PMA and 
ionomycin. The use of ionomycin would allow the stimulation of these calcium pathways and 
as a result the detection of the signature intracellular cytokines of interest. The CF group was 
also further analysed to determine any correlations between subset proportions and relevant 
clinical variables. 
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3.2 Materials and Methods 
3.2.1 Th1, Th2 and Th17 Staining of PBMC 
Two million PBMC were activated as detailed in Chapter 2. After activation they were 
washed with FACS buffer and collected by centrifugation, 250  g for 10 min. Cells were 
fixed using 1 mL of BD Cytofix Fixation buffer (BD Biosciences, San Jose, CA) for 15 min 
then washed a further two times with FACS buffer, 250  g for 10 min. Cells were then 
permeabilised for 15 min using 1 mL of BD Perm/Wash buffer (BD Biosciences). The 
antibody combinations used for identification of Th1, Th2 and Th17 cells are listed in Table 
3. Antibodies were incubated with cells for 30 min at room temperature protected from light. 
Cells were then washed twice with FACS buffer at 500  g for 5 min, before being filtered 
through a 50 m filter mesh in FACS buffer, to prevent cell clumping and blockages of flow 
cytometer fluidics, prior to flow cytometric analysis. 
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Table 3. Antibody combinations for identification of Th1, Th2 and Th17 subsets 
Antibody Marker Fluorochrome Hybridoma Clone Supplier 
anti-CD4* CD4+ helper T cells Peridinin chlorophyll protein cyanin 5.5 (PerCP-Cy5.5) SK3 BD Biosciences 
anti-IFN* Th1 cells Fluorescein isothiocyanate (FITC) B27 BD Biosciences 
anti-IL-4* Th2 cells Allophycocyanin (APC) MP4-25D2 BD Biosciences 
anti-IL-17A* Th17 cells Phycoerythrin (PE) N49-653 BD Biosciences 
* These antibodies are components of a commercial cocktail (Human Th1/Th2/Th17 phenotyping cocktail Cat.No.560751)
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3.2.2 Treg, Th17, Tr1 and Th3 Staining of PBMC 
Two million PBMC were activated as detailed in Chapter 2. After activation they were 
centrifuged and washed with FACS buffer, 500  g for 5 min. Cells were then fixed using 2 
mL of a 1:10 dilution of FOXP3 fixation buffer A (BD Biosciences) for 15 min. After 
washing twice with FACS buffer at 500  g for 5 min, cells were permeabilised using 0.5 mL 
of FOXP3 permeabilisation buffer C (BD Biosciences) for 30 min. Cells were again washed 
twice with FACS buffer at 500  g for 5 min. The antibody combinations used for 
identification of Treg, Th17, Tr1 and Th3 subsets are listed in Table 4. Antibodies were 
incubated with cells for 40 min at room temperature protected from light. Cells were then 
washed twice with FACS buffer at 500  g for 5 min, before being filtered through a 50 m 
filter mesh in FACS buffer prior to flow cytometric analysis. 
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Table 4. Antibody combinations for identification of Treg, Th17, Tr1 and Th3 subsets  
* These antibodies are components of a commercial cocktail (Human Treg/Th17 phenotyping cocktail Cat.No.560762) 
 
Antibody Marker Fluorochrome Hybridoma 
Clone 
Supplier 
anti-CD4* CD4+ helper T cells Peridinin chlorophyll protein cyanin 5.5 (PerCP-Cy5.5) SK3 BD Biosciences 
anti-IL-17A* Th17 cells Phycoerythrin (PE) N49-653 BD Biosciences 
anti-FOXP3* Treg cells Alexa Fluor 647 (AF647) 259D BD Biosciences 
anti-CD4 CD4+ helper T cells Peridinin chlorophyll protein cyanin 5.5 (PerCP-Cy5.5) SK3 BD Biosciences 
anti-IL-10 Tr1 cells Allophycocyanin (APC) JES3-19F1 BD Biosciences 
anti-TGF Th3 cells Phycoerythrin (PE) TW4 BD Biosciences 
APC isotype control rat IgG2a kappa Allophycocyanin (APC) R35-95 BD Biosciences 
PE isotype control mouse IgG1 kappa Phycoerythrin (PE) MOPC-21 BD Biosciences 
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3.2.3 Flow Cytometric Data Acquisition and Analysis 
Cells were analysed on a CyAn ADP 9 colour flow cytometer (Beckman Coulter, Lane Cove, 
NSW, Australia) with blue 488 nm, violet 405 nm and red 633 nm lasers allowing 
measurement of nine fluorescence and two scatter parameters using Summit software 
(Beckman Coulter). Data obtained from the flow cytometer were analysed using FlowJo 
software (Treestar, Ashland, OR). Figure 6 demonstrates the hierarchical gating strategy used 
to identify the CD4+ subsets. Unstimulated controls were run for self-designed panels (CD4, 
TGF, IL-10), an example of which is shown in Figure 5, to detect non-specific staining. 
  
 
Fig. 5. Representative histograms from the same healthy individual demonstrating unstimulated cells compared with stimulated cells for 
the same staining procedure to identify non-specific labelling. ‘A1 & A2’ shows lymphocytes as a percent of total cells, ‘B1 & B2’ shows 
single cells as a percent of lymphocytes, ‘C1 & C2’ shows CD4+ cells as a percent of lymphocytes, and ‘D1 & D2’ shows the percent of CD4+ 
cells that are positive for IL-10 and TGF.  
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Fig. 6. Representative histograms from healthy individual demonstrating the gating strategy for flow cytometry analysis of CD4+ T cell 
subsets. ‘A’ shows lymphocytes as a percent of total cells, ‘B’ shows single cells as a percent of these lymphocytes, ‘C’ shows CD4+ cells as a 
percent of these singlet lymphocytes, and ‘D’,’E’ and ‘F’ show the percent of these CD4+ cells that are positive for IL-4, IFN, FOXP3, IL-17A, 
IL-10 and TGF.   
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3.3 Results 
3.3.1 Comparison between CF and Control Groups 
Median age, sex and CD4+ subset percentages of the CF and control groups are detailed in 
Table 5. Subset percentages for healthy controls corresponded with that published within the 
literature (280). No significant differences between the CF and control groups were found for 
median age, sex distribution, or the proportions of CD4+ effector subsets (Th1, Th2, Th17). 
Proportions of all the CD4+ regulatory subsets were found to be elevated in the CF group 
compared with the control group (p values for FOXP3+ Treg% = 0.015, IL-10+ Tr1% = 
0.0001, TGF+ Th3% < 0.0001). 
To explore further the role of infection versus that of an underlying CFTR defect in the 
increases in CD4+ subsets, the groups were subdivided into adults and children for analysis 
(Table 6). All adults had multiple lung infections and all but two children were free of any 
culture-detectable infection. The increases in regulatory subsets were found to be present only 
in the adult CF group, while the levels in CF children did not differ significantly from those in 
control children. 
Because of the many reports of Th2- and Th17-skewed immune responses in CF, the Th1/Th2 
and Treg/Th17 ratios were calculated (Tables 5 and 6). There was no significant difference in 
the Th1/Th2 ratio between the control and CF groups. The Treg/Th17 ratio was much more 
variable in the CF group and was trending towards being higher than in controls (P = 0.066) 
which is consistent with the observed increase in proportion of Tregs in the CF group. 
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Table 5. Comparison of CD4+ T cell subset percentages between control and CF groups 
 Control Cystic Fibrosis P Value 
N  68 42  
Age median (range) 21 (2–61) 16 (0.5–53) 0.15 
Sex male (%) 33 (48%) 20 (47%)  
CD4+%# median (range) 48.8 (29.7–66.0) 47.0 (28.3–66.1) 0.60 
Th1%* median (range) 7.9 (3.0–22.4) 6.27 (1.2–24.6) 0.04 
Th2%* median (range) 2.3 (0.4–9.8) 1.7 (0.35–8.5) 0.09 
Th1/Th2 ratio* median (range) 4.5 (1.3–11.3) 4.8 (0.7–10.4) 0.81 
Th17%* median (range) 0.47 (0.08–2.26) 0.43 (0.01–1.98) 0.37 
Treg%* median (range) 5.8 (1.8–11.2) 7.1 (2.5–12.8) 0.016 
Treg/Th17 ratio* median (range) 11.9 (2–57) 16.2 (3.2–441) 0.066 
IL-10+ Tr1%* median (range) 1.18 (0.35–3.32) 1.63 (0.41–4.16) 0.0001 
TGF+ Th3%* median (range) 0.027 (0.008–0.190) 0.055 (0.017–0.417) < 0.0001 
P values for Mann–Whitney U–test are shown; significant differences are shown in bold. 
* Indicates all values are calculated as a percentage of the parent population. 
# Indicates all values are calculated as a percentage of the parent population. 
 
  
  P a g e  | 50 
 
Table 6. Comparison of CD4+ T cell subset percentages between control and CF in adults and children 
P values (Mann–Whitney U test) of significant differences are shown in bold. 
* Indicates all values are calculated as a percentage of the parent population. 
# Indicates all values are calculated as a percentage of the parent population. 
     ADULTS  
P value 
 CHILDREN  
P value Control Cystic Fibrosis Control Cystic Fibrosis 
N  51 20  17 22  
Age median (range) 22 (18–61) 24 (18–53) 0.13 8 (2–17) 11 (0.5–17) 0.22 
Sex male (%) 24 (47%) 12 (60%)  9 (51%) 8 (36%)    
CD4+%# median (range) 50.40 (29.7–66.0) 48.15 (28.3–66.1) 0.18 42.1 (32.7–52.6) 46.8 (33.2–61) 0.15 
Th1%* median (range) 9.6 (3.0–22.4) 10.45 (3.5–24.6) 0.82 4.6 (3.0–9.6) 5.4 (1.2–10.7) 0.98 
Th2%* median (range) 2.6 (0.7–9.8) 2.3 (0.4–8.5) 0.74 1.4 (0.4–5.0) 1.2 (0.4–8.4) > 0.99 
Th1/Th2 ratio* median (range) 4.6 (1.3–11.3) 5.15.1  5.1 (1.0–10.4) 0.67 3.8 (1.3–8.5) 3.9 (0.7–8.8) 0.91 
Th17%* median (range) 0.49 (0.15–2.26) 0.52 (0.04–1.98) 0.77 0.37 (0.08–1.08) 0.36 (0.03–1.02) 0.79 
Treg%* median (range) 5.5 (1.8–10.5) 6.46 (4.2–11.4) 0.01 7.6 (3.5–11.2) 7.2 (2.5–12.8) 0.77 
Treg/Th17 ratio* median (range) 10.6 (2–37) 14.8 (4–441) 0.32 18.6 (6.9–57) 18.6 (3.2–305) 0.93 
IL-10+ Tr1%* median (range) 1.15 (0.35–2.63) 1.77 (0.41–4.16) 0.0004 1.27 (0.70–3.32) 1.5 (0.66–2.85) 0.29 
TGF+ Th3%* median (range) 0.022 (0.008–0.19) 0.093 (0.018–0.417) < 0.0001 0.044 (0.020–0.143) 0.043 (0.017–0.301) 0.86 
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3.3.2 Comparison within the CF Cohort  
We next investigated any important associations between CD4+ subset percentages and 
clinical parameters within the CF group. Table 7 details all parameters assessed. 
Analysis of the CFTR genotype showed that all but three patients had at least one DF508 
allele, therefore patients were divided into those who were DF508 homozygous (n = 18) and 
those who were DF508 heterozygous or had other genotypes (n = 24). No significant 
correlations were found based on this division of CFTR genotype. 
To examine the effects of clinical status, the CF group was divided into those who were 
clinically stable (n = 35) and those who were exacerbating (n = 7). Exacerbating patients were 
defined according to the Tasmanian Department of Health and Human Services’ microbial 
surveillance and antimicrobial management guidelines (264). No significant correlations were 
found based on clinical status. 
For patients with chronic P. aeruginosa (n = 15) there was a significantly higher TGF+% (P 
= 0.0006) and a trend towards higher Th17% (P = 0.09) than in patients without chronic P. 
aeruginosa infection. The percentages of these cells were also both found to be significantly 
different (TGF-+% P = 0.05; Th17% P = 0.01) in patients on antimicrobial treatment (n = 
21) compared with those not on antimicrobials. No differences were found between patients 
with and without other infections such as S. aureus and A. fumigatus. 
  
 Table 7. Correlations between CD4+ T cell subset percentages and clinical variables in the CF group. 
[P values] (Mann–Whitney U test) indicating significant differences are shown in bold. 
Parameter [no. of patients] CD4+% Th1% Th2% Th17% Treg% Tr1% Th3% Th1/Th2 Treg/Th17 
Age [42] (Spearman r) –0.032 0.56 0.44 0.23 0.06 0.12 0.29 0.16 -0.11 
P value [0.84] [0.002] [0.018] [0.16] [0.73] [0.46] [0.07] [0.43] [0.51] 
FEV1 % pred. [32] (Spearman r) –0.01 –0.45 –0.31 –0.56 –0.42 0.003 0.04 –0.25 –0.12 
P value [0.95] [0.06] [0.19] [0.0008] [0.016] [0.99] [0.82] [0.28] [0.57] 
FEV1 % pred. stable patients only [25] (Spearman r) –0.13 –0.45 –0.31 –0.58 –0.31 0.16 0.16 –0.10 –0.14 
P value [0.52] [0.06] [0.19] [0.00017] [0.12] [0.44] [0.44] [0.68] [0.52] 
FEV1 % pred. P. aeruginosa negative, <18 only [6] (Spearman r) 0.43 0.00 –0.20 –0.83 0.09 –0.54 –0.03 –0.10 0.83 
P value [0.40] [1.00] [0.75] [0.042] [0.87] [0.27] [0.96] [0.87] [0.042] 
Median percent for each subset          
Sex          
Male 46.3 7.8 1.80 0.43 7.1 1.60 0.090 4.8 14.4 
Female 48.2 5.7 1.42 0.40 6.9 1.67 0.055 4.7 17.0 
P value [0.25] [0.38] [0.32] [0.49] [0.96] [0.69] [0.13] [0.84] [0.30] 
Genotype          
DF508 homozygous [18] 47.8 5.7 1.55 0.41 6.7 1.76 0.053 4.9 13.3 
DF508 heterozygous/other [24] 46.8 6.2 1.42 0.43 7.6 1.47 0069 4.8 19.5 
P value [0.74] [0.85] [0.99] [0.69] [0.12] [0.48] [0.66] [1.0] [0.28] 
Stable [35] 47.0 6.2 1.42 0.43 7.0 1.65 0.053 4.7 17.0 
Exacerbating [7] 48.2 13.1 2.35 0.65 7.1 1.56 0.079 5.90 9.9 
P value [0.94] [0.26] [0.32] [0.14] [0.60] [0.99] [0.76] [0.13] [0.18] 
Chronic P. aeruginosa [15] 46.6 9.6 2.32 0.66 6.8 1.44 0.095 5.8 11.2 
No chronic P. aeruginosa [27] 47.8 5.7 1.63 0.36 7.3 1.63 0.041 3.9 18.7 
P value [0.42] [0.17] [0.42] [0.09] [1.0] [0.69] [0.006] [0.04] [0.18] 
Current S. aureus infection [21] 48.1 5.7 2.11 0.42 6.8 1.77 0.044 4.8 16.6 
No S. aureus infection [26] 46.5 6.4 1.42 0.51 7.1 1.63 0.088 4.7 13.8 
P value [0.59] [0.79] [0.50] [0.51] [0.76] [0.53] [0.17] [0.87] [0.34] 
Current A. fumigatus infection [7] 46.3 8.9 1.8 0.43 6.3 1.54 0.091 4.9 18.8 
No A. fumigatus infection [35] 47.5 5.4 1.52 0.43 7.1 1.65 0.048 4.4 15.8 
P value [0.42] [0.06] [0.36] [0.92] [0.48] [0.75] [0.25] [0.56] [0.97] 
Any current antimicrobial [21] 47.6 8.5 2.0 0.71 6.8 1.76 0.092 5.2 9.3 
No current antimicrobial [21] 46.6 5.7 1.69 0.34 7.1 1.54 0.041 3.7 18.8 
P value [0.68] [0.07] [0.35] [0.013] [0.93] [0.42] [0.047] [0.13] [0.02] 
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Analysis of the association between FEV1 % predicted and CD4+ subset percentages was 
performed on a smaller subset of patients for whom lung function tests were available (n = 32, 
17 adults, 14 children). This group had a slightly higher median age (19.5 years), contained no 
children aged under 5 years, and had a higher percentage of males (59%). All other variables 
were similar to the whole CF cohort. In this subgroup, a strong correlation was found between 
FEV1 % predicted and Th17% (r = –0.56, P = 0.0008, Spearman) as well as a significant 
correlation with Treg% (r = –0.42, P = 0.016, Spearman), with increasing levels of these 
subsets both associated with declining lung function (Fig. 7). 
Because lung function testing was not always performed on the same day as blood sampling, 
and because lung function can change quite quickly with infections of the lung and the 
treatment of exacerbations, a more in-depth analysis of the relationship between Th17% and 
Treg% with FEV1 % predicted was performed focusing on clinically stable patients, so as to 
reduce the influence of acute infections. 
Firstly, patients who were exacerbating on the day of blood sampling (n = 5) were excluded. 
When only clinically stable patients were analysed, the relationship between FEV1 % 
predicted and Th17% was still present (r = –0.58, P = 0.0017), but the association with Treg% 
was no longer significant (P = 0.11). 
Secondly, because of reports of P. aeruginosa- and age-related T cell defects in CF, children 
(<18 y) without chronic P. aeruginosa infection (n = 6) were analysed. The relationship 
between FEV 1 % predicted and Th17 precent remained (r = –0.83, P = 0.042) while the 
association with Treg% did not (r = 0.09, P = 0.87). 
Thirdly, the relative timing of blood sampling to lung function testing was considered in the 
analysis. When investigating this timing it was apparent that the correlation was strongest 
when the two tests were performed within a week of each other (Th17% r = –0.86, P = < 
0.0001; Treg% r = –0.62, P = 0.01; n = 16) and was no longer significant when the two tests 
were performed more than two weeks apart. 
The use of antimicrobials and the presence of chronic P. aeruginosa infection were also 
investigated in relation to these associations, however these analyses were compromised 
because patients on antimicrobials and with chronic P. aeruginosa infection were mostly 
adults and those without either were mostly children (median age on antimicrobials 22 years; 
median age without antimicrobials 13 years; median age with chronic P. aeruginosa infection 
22 years; median age without chronic P. aeruginosa infection 11 years). Median lung function 
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was also therefore altered, with those patients not on antimicrobials and those without chronic 
P. aeruginosa infection having a high FEV1 % predicted (97% and 85% respectively) while 
for those on antimicrobials and those with chronic P. aeruginosa infection it was much lower 
(54% and 51% respectively). However, the relationship between FEV1 % predicted and 
Th17% remained significant in the group on antimicrobials (P = 0.03, n = 18) and trended 
towards significance in the group with chronic P. aeruginosa infection (P = 0.056, n = 15). 
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Fig. 7. Correlation of Th17% and Treg% with FEV1 % predicted in the CF group. Analysis was performed using a nonparametric Spearman 
correlation. The solid line indicates the linear regression line and the dotted lines indicate the 95% confidence intervals. Solid closed circles indicate 
those patients for whom blood testing and spirometry were performed within a 2-week period of each other (n = 21). Open circles indicate those 
patients for whom blood testing and spirometry were performed more than 2-weeks apart (n = 11). 
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Table 8. Correlations between Th17% and Treg% with FEV1 % predicted based on time elapsed between blood sampling and lung function 
testing in the CF group. 
 
*P values indicating significant differences are shown in bold. 
Group (no.) Age years median (range) % male Th17% Spearman 
r (P value)* 
Treg% Spearman 
r (P value)* 
All (32) 19.5 (6–53) 59% –0.57 (0.0008) –0.42 (0.016) 
FEV1 % predicted test on same day as blood sampling (10) 22 (10–53) 70% –0.85 (0.003) –0.60 (0.07) 
FEV1 % predicted test within 1 week of blood sampling (16) 22 (10–53) 63% –0.86 (< 0.0001) –0.62 (0.01) 
FEV1 % predicted test within 2 weeks of blood sampling (21) 20 (10–53) 67% –0.72 (0.0003) –0.49 (0.02) 
FEV1 % predicted test more than 2 weeks from blood sampling (11) 11 (6–38) 45% 0.49 (0.12) –0.35 (0.29) 
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3.4 Discussion 
Th17 cells have been implicated in many inflammatory lung diseases, but this is the first 
report of a link between lung function (FEV1 % predicted) and Th17% in the peripheral blood 
of CF patients, rather than that in the lung or bronchoalveolar lavage fluid (BALF). This 
relationship has been reported previously in COPD (275, 281), where the percent Th17 cells 
was also increased. A study by Xu et al. (282) of COPD peripheral blood also demonstrated a 
similar relationship of lung function with IL-17-producing CD8+ (Tc17) cells. 
Many studies have demonstrated the importance of Th17-mediated inflammation in CF lung 
pathology (53, 220, 283). Although there was no significant difference in peripheral blood 
Th17% between CF patients and healthy controls, the strong inverse relationship between 
Th17% and FEV1 % predicted within the CF group is consistent with these reports of the 
damaging effects of Th17 cells in the lungs. It is also quite remarkable that this strong 
negative correlation was observed in peripheral blood, away from the site of infection, rather 
than as previously reported in the lungs (284) and BALF (53). This association only became 
stronger the closer together spirometry and blood tests were performed. In CF adults a trend 
was seen (P = 0.09) towards an association between chronic P. aeruginosa infection and 
Th17%. It has been reported that Th17-dominated immune responses are a risk factor for P. 
aeruginosa infection, possibly because they are ineffective against this pathogen (216) as they 
recruit neutrophils that, in CF, are ineffective or because the antibody response elicited is also 
ineffective (285). This may explain the strong inverse correlation of peripheral blood Th17% 
with FEV1 % predicted, because those with a higher Th17% may be predisposed to this 
highly damaging lung infection. This theory is also consistent with the association seen 
between higher Th17% and treatment with antimicrobial therapy. However, because this was 
a cross-sectional study, causality could not be confirmed. 
An association between FEV1 % predicted and Treg% was also observed for the whole CF 
group. However, when the group was divided into stable and exacerbating patients, this 
association was no longer significant. Treg cells have been shown to have a reduced 
suppressive capacity specifically during P. aeruginosa infection (217), and it may be that 
levels of these cells increase in those who are exacerbating in order to compensate for their 
reduced suppressive capacity. It is also quite curious to see that both Treg% and Th17% were 
negatively correlated with FEV1 % predicted, when these two subsets are often described as 
mutually antagonistic. Because Treg cells are anti-inflammatory and dampen effector immune 
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responses, it would be expected that a high Treg% would be associated with less 
inflammation and thus improved lung function. Other studies have shown a positive 
correlation between FEV1 % predicted and Treg cells and an P. aeruginosa-linked and age-
dependent loss of Treg function, however these studies involved mainly infants and 
adolescents (217, 279). In our study, when lung function was investigated only in those 
children (< 18 years) without P. aeruginosa for whom lung function tests were available (n = 
6), there was no longer a negative correlation between Treg% and FEV1 % predicted. The 
presence of the negative correlation between Treg% and FEV1 % predicted for the entire CF 
group may be the result of the reported reduced suppressive capacity of Treg cells during 
inflammation and P. aeruginosa infection (217) (286). This is further supported by the 
positive association observed between FEV1 % predicted and the Treg/Th17 ratio in the 
children without P. aeruginosa infection. 
When considering the relationship between Th17% and FEV1 % predicted it should be noted 
that there was a negative correlation between FEV1 % predicted and age (Table 7). However, 
because there was no association between Th17% and age, it is likely that the link between 
Th17% and FEV1 % predicted is unrelated to age, although a multivariate analysis in a larger 
group is required to confirm this. The higher Th17% found in peripheral blood of patients 
with poor lung function may reflect a higher level of these cells in the lungs, at the main site 
of infection, which could be associated with lung damage (263). However, while there is no 
published information regarding the homing of Th17 cells in CF, the only two studies (219, 
287) that have investigated Th17 in CF peripheral blood reported reduced levels of these cells. 
Given the many studies indicating high levels of lung Th17 in CF, we can speculate that this 
could be the result of homing of these cells to the lungs. The reason why our study did not 
show reduced levels of Th17 cells in the periphery may be related to our identification 
technique, because some CD4+ populations other than Th17 cells, such as  T cells, are 
capable of producing IL-17. 
It is also possible that as has been reported for high lung Th17% (53), a high peripheral blood 
Th17% may be a predisposing factor to chronic P. aeruginosa acquisition, which in turn is a 
cause of lung damage. 
Lastly, a high Th17% could also be related to an individual’s inherent propensity towards a 
Th17-biased immune response. If this propensity is similar to that for Th2-biased allergic 
responses, which are formed and detected at an early age (288, 289), Th17 cells could 
potentially be a useful prognostic indicator of susceptibility to P. aeruginosa acquisition and 
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therefore lung function decline. However, because the correlation between FEV1 % predicted 
and Th17% was strongest when spirometry and blood sampling were performed close 
together in time, it would appear that the Th17% changes may be synchronised with changes 
in lung function. Additional research would be required to determine any prognostic value for 
lung function decline of Th17% in peripheral blood. 
Previous studies have reported a bias towards increased Th2 and Th17 cells in CF lung and 
peripheral blood (53, 220), but no such bias was found in this study, with no significant 
increase in peripheral blood percentages of either the Th2 or Th17 subsets, and no difference 
between CF and controls in the peripheral blood Th1/Th2 and Treg/Th17 ratios. This 
discrepancy may simply be due to more complex sets of identification markers used in other 
studies. However, there a was an significant decrease in Th1 percent in CF compared with 
healthy controls indicating a Th2 dominated response in CF. 
A significant increase was found in the percentages of three regulatory subsets measured, 
FOXP3+ Treg, IL-10+ Tr1 and TGF+ Th3 cells, in CF adults (>18 years) compared with 
control adults. It was unexpected to see an increase in IL-10-producing cells, because many 
studies have previously reported a decrease of this cytokine in CF peripheral blood (290, 
291). While there is very little information available regarding TGF+ Th3 cells in CF, reports 
of increased TGF in plasma (292), sputum (293) and BALF (294) in CF and in one study of 
peripheral blood CD4+ cells of A. fumigatus-infected CF patients (51) are consistent with this 
finding. 
The increase in FOXP3+ Treg% barely reached significance compared with the highly 
significant differences in IL-10+ Tr1% and TGF+ Th3%. While there have been reports of 
reduced FOXP3+ Tregs in CF (217, 279), other studies have reported increases in regulatory 
cells in response to chronic inflammation (286, 295). This is consistent with our results, 
because we saw increases in regulatory subsets only in the CF adult population, nearly all of 
whom had experienced chronic infection/inflammation, with no increase seen in the CF 
children who had experienced very few respiratory infections. 
It is also possible that the method of Treg identification used in this study may have 
contributed to the increased levels of FOXP3 Tregs that were observed. This study defined 
Tregs as CD4+FOXP3+ cells, but many other studies use additional markers such as CD25 
and/or CD127 (199). Treg levels may also have appeared slightly higher because other more 
recently identified populations, such as CD4+ T follicular regulatory and  T cells, have been 
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shown to have the ability to express FOXP3 (296, 297). This may also explain why the Treg% 
was significantly increased in CF but the Treg/Th17 ratio did not differ significantly between 
CF patients and controls. 
This study has some weaknesses. First, Treg cells were analysed as a single population and 
we did not use additional markers such as CD45RA or CD45RO to identify naïve and 
memory Tregs, respectively, or any homing markers. Therefore, both of these additional 
analyses were performed in a subsequent set of experiments that are discussed in Chapter 4. 
Second, the only function of Treg cells that we analysed was their ability to produce their 
signature cytokines in vitro after polyclonal stimulation. It is therefore possible that while 
they may express the appropriate surface markers/cytokines, they may still differ functionally 
from those in healthy individuals. Indeed, it has been shown that inflammation-induced 
FOXP3+ Tregs are functionally different from nTregs (286). 
It was interesting to note an association of an increased TGF+ Th3% with a trend towards 
increased Th17% in patients with chronic P. aeruginosa infection but an absence of this 
association with any other common infection such as S. aureus or A. fumigatus. This may be 
because of the persistent and highly inflammatory nature of P. aeruginosa infection, but it 
also may be that, as previously suggested by Tiringer et al. (53), that the type of T cell subset 
analysis we performed could generate useful markers to monitor/predict P. aeruginosa 
infection. However, this cannot be determined from the current data. 
One strength of this study is its relatively large numbers and broad age range compared with 
many similar studies. This allowed for a thorough analysis of the relationships between age 
groups and clinical variables with the T cell subsets measured, although a weakness is that 
some subgroups were too small to allow extended analyses of their differences. Other 
weaknesses include that this was a cross-sectional study and therefore none of the parameters 
measured provide any predictive ability or allow determination of causality. Additionally, 
lung function measurements were not available for every patient and not all of the 
measurements were performed on the same day as blood sampling. 
In conclusion, this study shows for the first time that a high peripheral blood Th17% is 
associated with poorer lung function in people with CF and that this could potentially be used 
as an alternative marker of lung function. This could be particularly useful in young children 
(< 6 years) for whom standard lung function testing is not always possible. While several 
infant spirometry tests exist, they are generally invasive and are yet to be recognised as 
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essential for routine clinical care. Most CF children have annual routine blood tests for review 
of their condition, so the development of a blood test reflecting changes in lung function 
could prove to be very useful clinical tool. 
The increase of TGF+ Th3% in relation to P. aeruginosa infection could also prove to be a 
useful clinical tool to predict changes in lung function. However, further studies are required 
to determine the prognostic value of this measurement in predicting the progression of CF-
related lung disease. 
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CHAPTER 4 
Flow Cytometric Analysis of Peripheral Blood CD4+ T Cell Subset Homing 
Markers 
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4.1 Introduction 
Trafficking of T cells to sites of infection and inflammation is vital for their ability to exert 
their functional capacity and produce an immune response. Chemokines are a family of 
cytokines with the ability to induce chemotaxis in cells with responsive receptors. 
Chemokines and their receptors are a major regulatory factor of, and are essential for, this 
migration of immune cells. A cascade of signalling events, relying heavily upon Ca2+ 
signalling, leads to the activation of chemokine receptors and the resulting migration of the 
cells that express them. Calcium signalling has been shown to be affected indirectly by 
defective expression of the CFTR chloride channel (276, 298), and Mueller and colleagues 
(22) have shown that this altered Ca2+ signalling results directly in aberrant cytokine 
signalling in mouse T cells. In addition, while there are no studies that have investigated this 
relationship in human T cells, a study by Assani et al. has shown that Ca2+ signalling is 
affected in human macrophages which affects their phagocytic function. 
The most extensively studied chemokine in CF is the neutrophil-associated IL-8 (CXCL8), 
which acts via the CXCR1 and CXCR2 receptors and has been shown to be dysregulated in 
CF (241-243). Defects in not only chemokines but also chemokine receptors have also shown 
to have negative impacts in CF with reduced functioning of receptors such as CXCL9 leading 
to increased colonisation of pathogens such as P. aeruginosa (299). Many other studies of 
chemokines and their receptors in CF have focused on monocytes and macrophages, which 
also display varying levels of dysregulation (102, 244, 300). There is very little research 
involving chemokines and their receptors, specifically those associated with Th1-, Th2- and 
Th17-directed immune responses, in CF peripheral blood. 
The presence in CF of altered ion signalling and neutrophil and macrophage/monocyte-
associated chemokine signalling led us to hypothesise that this altered signalling would lead 
to alterations in chemokine receptor activation in T cells and thus T cell trafficking in people 
with CF, leading to ineffective immune responses. To investigate this, we stained PBMC from 
adult CF patients and healthy age-matched controls with antibodies for CD4, CD25, and 
CD127 to identify Treg cells, a more precise and newer identification technique for Tregs 
(199) than that described in Chapter 3, as well as for the chemokine receptors CXCR3, CCR4 
and CCR6 to identify cells homing to sites of Th1-, Th2- and Th17-mediated inflammation, 
respectively. In addition to this the CD45RO marker was used to identify CD4 and Treg cells 
that were naïve (CD45RO) and memory (CD45RO+) expressing these markers. The 
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participants with CF were further analysed to determine any correlations between subset 
proportions and relevant clinical variables. 
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4.2 Materials and Methods 
4.2.1 PBMC Staining 
Cryopreserved cells were used for all staining, and were resuscitated and prepared as described in Chapter 2. Specific antibody combinations 
used for staining for the experiments described in this chapter are listed in Table 9. Cells were counted using a Sysmex Cell Counter (Sysmex, 
NSW, Australia). 
 
Table 9. Antibody combinations used to identify naïve and memory CD4+ and Treg cells 
Antibody Marker Fluorochrome Hybridoma 
Clone 
Supplier 
Live/dead  Dead cells Near infrared (IR) - ThermoFisher Scientific 
anti-CD4 CD4+ helper T cells V500 RPA-T4 BD Biosciences 
anti-CD25 Treg cells Allophycocyanin (APC) 2A3 BD Biosciences 
anti-CD127 Treg cells Brilliant violet 421 (BV421) A019D5 BioLegend 
anti-CD45RO Memory/naïve cells BUV395 UCHL1 BD Biosciences 
anti-CXCR3 Th1-associated cells Alexa Fluor 488 (AF488) 1C6 BD Biosciences 
anti-CCR4 Th2-associated cells Phycoerythrin cyanin (PE-Cy7) L291H4 BD Biosciences 
anti-CCR6 Th17-associated cells Phycoerythrin (PE) 11A9 BioLegend 
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4.2.2 Flow Cytometric Data Acquisition and Analysis 
Stained cells were analysed using a 10-colour LSR II flow cytometer (BD Biosciences) with 
blue 488 nm, red 633 nm, violet 405 nm and UV 355 nm lasers to allow the measurement of 
10 fluorescent and two scatter parameters using FACSDiva Software. Five hundred thousand 
events were collected per sample analysed. Data obtained from the flow cytometer was 
analysed using FlowJo software (Treestar). Figure 8 demonstrates the hierarchical gating 
strategy for identification of CD4+ and Treg cells that express the CXCR3, CCR4 and CCR6 
chemokine receptors. 
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Fig. 8. Representative histograms from healthy individual demonstrating the gating 
strategy for flow cytometry analysis of naïve and memory CD4+ and Treg cells 
expressing the chemokine receptors CCR4, CXCR3 and CCR6. ‘A’ shows ungated cells, 
‘B’ and ‘C’ show gating of single cells, ‘D’ shows gating of CD4+ cells, ‘D1’ shows gating of 
naïve and memory CD4+ cells and ‘D2’, ‘D3’ and ‘D4’ show gating of naive and memory 
CD4+ cells expressing CCR4, CXCR3 and CCR6 respectively. ‘E’ shows gating of Treg cells, 
‘E1’ shows gating of naïve and memory Treg cells and ‘E2’, ‘E3’ and ‘E4’ show gating of 
Treg cells expressing CCR4, CXCR3 and CCR6, respectively. 
  
4.3 Results 
4.3.1 Comparison between CF and Control Groups 
No significant differences were found between control and CF groups for median age, sex 
distribution, CD4+%, Treg% or naïve/memory CD4+% and Treg% (see Table 10), although 
there was a trend towards increased naïve Treg% and decreased memory Treg% in CF. It is 
important to note that here, Treg cells were identified as CD4+CD25+CD127lo, in contrast to 
the analysis in Chapter 3 that identified them as CD4+FOXP3+, because since the experiments 
described in Chapter 3 were performed, it has become the standard technique to use these cell 
surface markers only and therefore avoid the cell permeabilisation required for FOXP3 
staining (199). The percentages of memory CD4+ cells expressing CXCR3 and CCR6 were 
significantly decreased in CF patients compared with controls, (P = 0.049 & 0.001 
respectively) while there was no significant difference in the percentages of CCR4+ memory 
CD4+ cells. The percentages of memory Treg cells expressing CXCR3, CCR4 and CCR6 
were all decreased in CF compared with controls (P = 0.025, 0.03 & 0.003 respectively). 
However, there were no significant differences between CF and controls in the percentages of 
any of the CXCR3+, CCR4+ and CCR6+ naïve CD4+ or Treg populations. 
4.3.2 Comparison within the CF Cohort  
We next performed an analysis of associations between the percentages of the measured cell 
populations and patient clinical parameters within the CF group, similar to that described in 
Chapter 2. Investigating those with (n = 3) or without (n = 15) current A. fumigatus infection 
and those with (n = 16) or without (n = 1) current treatment with any antimicrobial was not 
possible because of the small sizes of one of the groups. Tables 11, 12 and 13 detail all 
parameters assessed. 
No significant differences were found in the percentages of any of the T cell subsets measured 
between different CFTR genotypes or between exacerbating and clinically stable patients. 
FEV1 % predicted was first analysed in CF patients for whom spirometry and blood tests 
were performed within two weeks of each other (n = 13). A negative correlation was found 
between FEV1 % predicted and Treg% (r = –0.68, P = 0.010). FEV1 % predicted was then 
analysed in all the clinically stable patients (n = 14) and this relationship was still present (r = 
–0.72, P = 0.019). A trend was seen towards an inverse correlation of the percentages of 
CCR4+ naïve (P = 0.06) and memory (P = 0.09) Treg cells and CCR4+ naïve CD4+ cells (P = 
0.07) with FEV1 % predicted. Lastly, FEV1 % predicted was analysed only in stable patients 
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for whom spirometry and blood tests were performed within one week of each other (n = 5), 
because we had previously shown a time-dependent relationship between lung function and 
changes in peripheral blood T cell subset levels. Although findings from this analysis need to 
be considered cautiously given the small size of the group, we identified that percentages of 
both memory CCR4+ CD4+ (r = –1.00, P = 0.017) and Treg (r = –1.00, P = 0.017) cells were 
negatively correlated with FEV1 % predicted. As was the case for the experiments reported in 
Chapter 3, the relationship between total Treg% and FEV1 % predicted was no longer 
significant (P = 0.08). 
When the CF group was divided based on the presence or absence of chronic P. aeruginosa 
infection, the naïve CXCR3 CD4+% was found to be significantly lower (P = 0.014) in those 
with chronic P. aeruginosa infection, and there was a trend to lower memory CCR4+CD4+% 
(P = 0.06). No differences between the groups were seen for any of the Treg subsets 
measured. 
Dividing the CF group based on S. aureus infection showed no differences in any of the CD4+ 
subsets. The only difference noted in the regulatory subsets was a decrease in CXCR3+Treg% 
in those with S. aureus infection (P = 0.0273).   
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Table 10. Comparison of percentages of CCR4+, CCR6+ and CXCR3+ CD4+ T cells and 
Treg cells in control and CF groups 
P values (Mann–Whitney U test) indicating significant differences are shown in bold. 
* Indicates all values are calculated as a percentage of the parent population. 
 
 Control CF P value 
N 15 17  
Age median (range) 28 (22–50) 25 (19–54) 0.50 
Sex male (%) 5 (33%) 8 (47%)  
CD4+ %* median (range) 34.00 (20.40–54.10) 34.60 (21.30–59.30) 0.94 
CD4+RO+ %* median (range) 40.50 (19.90–58.40) 30.80 (15.00–61.00) 0.13 
CD4+RO– %* median (range) 59.50 (41.60–80.10) 69.20 (39.00–85.00) 0.13 
CD4+CXCR3+RO+ %* median (range) 18.40 (4.13–36.40) 13.20 (6.40–24.50) 0.049 
CD4+CXCR3+RO– %* median (range) 2.54 (1.20–12.20) 2.53 (1.25–7.12) 0.94 
CD4+CCR4+RO+ %* median (range) 23.20 (7.90–38.60) 17.90 (9.69–38.30) 0.06 
CD4+CCR4+RO– %* median (range) 1.53 (0.21–5.90) 1.22 (0.19–4.32) 0.46 
CD4+CCR6+RO+ %* median (range) 17.40 (7.43–34.70) 13.40 (2.94–19.10) 0.001 
CD4+CCR6+RO– %* median (range) 0.33 (0.15–1.01) 0.30 (0.07–0.72) 0.26 
Treg %* median (range) 7.33 (4.00–8.91) 7.85 (5.29–16.30) 0.39 
Treg RO+ %* median (range) 57.10 (40.30–77.60) 51.10 (30.40–91.30) 0.06 
Treg RO– %* median (range) 42.90 (22.40–59.70) 48.90 (8.72–69.60) 0.06 
Treg CXCR3+RO+ %* median (range) 17.20 (2.81–30.10) 11.70 (3.30–21.20) 0.025 
Treg CXCR3+RO– %* median (range) 2.74 (1.00–8.14) 3.96 (0.71–7.22) 0.21 
Treg CCR4+RO+ %* median (range) 50.00 (34.10–72.30) 44.90 (21.20–70.80) 0.033 
Treg CCR4+RO– %* median (range) 1.55 (0.53–7.08) 1.96 (0.46–8.76) 0.60 
Treg CCR6+RO+ %* median (range) 33.70 (14.90–48.50) 21.70 (4.20–35.90) 0.003 
Treg CCR6+RO– %* median (range) 0.87 (0.33–2.67) 0.64 (0.12–3.20) 0.41 
CD4+ CD45RO+ CXCR3/CCR4 ratio median (range) 0.82 (0.18–1.51) 0.67 (0.15–1.59) 0.18 
CD4+ CD45RO– CXCR3/CCR4 ratio median (range) 0.93 (0.39–29.26) 3.03 (0.31–19.35) 0.46 
Treg CD45RO+ CXCR3/CCR4 ratio median (range) 0.32 (0.05–0.62) 0.31 (0.07–0.53) 0.53 
Treg CD45RO– CXCR3/CCR4 ratio median (range) 1.27 (0.32–7.40) 1.15 (0.23–8.67) 0.97 
CD45RO– Treg/CD4+CCR6+ ratio median (range) 2.78 (1.54–8.13)  3.46 (2.17–12.48) 0.11 
CD45RO+ Treg/CD4+CCR6+ ratio median (range) 105.70 (42.48–311.3) 159.70 (55.19–382.9) 0.05 
  
Table 11. Correlations between CCR4+ CCR6+ and CXCR3+ naïve and memory CD4+ T cell percentages and clinical variables in the CF group. 
[P values] (Mann–Whitney U test) indicating significant differences are shown in bold. 
*Indicates values are calculated as a percentage of the parent population,  # Indicates number of weeks between blood and spirometry testing. 
Parameter [no. of patients] CD4+ %* CD4+RO+ 
%* 
CD4+RO–
%* 
CD4+ 
CXCR3+RO+ 
%* 
CD4+ 
CXCR3+RO– 
%* 
CD4+ 
CCR4+RO+ 
%* 
CD4+ 
CCR4+RO– 
%* 
CD4+ 
CCR6+RO+ 
%* 
CD4+ 
CCR6+RO– 
%* 
Age [17] (Spearman r) 0.20 0.11 –0.11  -0.12 0.12 –0.04 0.01 –0.18 –0.14 
P value [0.45] [0.69] [0.69]  [0.64] [0.65] [0.88] [0.96] [0.48] [0.58] 
FEV1 % pred. 2 weeks# all patients [13] (Spearman r) –0.17 –0.14 0.14 0.35 0.34 –0.23 –0.12 0.17 0.29 
P value [0.59] [0.64] [0.64] [0.24] [0.26] [0.45] [0.71] [0.58] [0.34] 
FEV1 % pred. 2 weeks# stable patients only [10] (Spearman r) –0.15 –0.14 0.14 0.39 0.26 –0.49 –0.60 0.06 0.42 
P value [0.68] [0.70] [0.70] [0.26] [0.47] [0.15] [0.07] [0.88] [0.23] 
FEV1 % pred. 1 week# stable patients only [5] (Spearman r) 0.10 –0.70 0.70 –0.10 0.60 –1.00 –0.70 –0.30 0.70 
P value [0.95] [0.23] [0.23] [0.95] [0.35] [0.017] [0.23] [0.68] [0.23] 
Median percent for each subset          
Sex          
Male 30.10 28.85 71.15 13.05 2.12 18.35 2.01 12.85 0.23 
Female 40.30 33.10 66.90 15.40  2.73 16.60 0.52 13.90 0.33 
P value [0.17] [0.11] [0.11] [0.69] [0.81] [0.61] [0.28] [0.33] [0.54] 
Genotype          
DF508 [8] 37.50 32.80 67.20 14.15 2.36 17.70 0.87 13.00 0.30 
DF508 heterozygous/other [9] 34.30 30.00 70.00 13.20 3.24 17.90 1.22 13.90 0.30 
P value [0.54] [0.42] [0.42] [0.59] [0.61]  [0.89] [0.81] [0.56] [0.74] 
Stable [14] 36.20 30.40 69.60 13.05 2.43 18.35 1.28 12.25 0.27 
Exacerbating [7] 31.60 33.10 66.90 15.60 2.53 19.00 2.20 13.80 0.33 
P value [0.80] [0.43] [0.43] [0.35] [0.86] [0.86] [0.86] [0.22] [0.26] 
Chronic P. aeruginosa [10] 34.45 34.30 65.70 13.20 1.94 19.75 1.28 13.30 0.302 
No chronic P. aeruginosa [7] 43.50 30.50 69.50 15.40 3.76 13.30 0.59 13.90 0.303 
P value [0.42] [0.27] [0.27] [0.99] [0.014] [0.06] [0.48] [0.46] [0.81] 
Current S. aureus infection [11] 34.30 30.50 69.50 12.50 2.53 17.30 1.52 12.60 0.30 
No S. aureus infection [6] 35.80 34.30 65.70 16.90 2.46 18.65 0.82 14.55 0.30 
P value [0.99] [0.22] [0.22] [0.10] [0.88] [0.35] [0.66] [0.13] [0.88] 
  
 
Table 12. Correlations between CCR4+ CCR6+ and CXCR3+ naïve and memory Treg cell percentages and clinical variables in the CF group 
 [P values] (Mann–Whitney U test) indicating significant differences are shown in bold. 
*Indicates values are calculated as a percentage of the parent population. #Indicates number of weeks between blood and spirometry testing.
Parameter [no. of patients] Treg 
%* 
Treg RO+ 
%* 
Treg RO– 
%* 
Treg 
CXCR3+RO+ 
%* 
Treg 
CXCR3+RO– 
%* 
Treg 
CCR4+RO+ 
%* 
Treg 
CCR4+RO– 
%* 
Treg 
CCR6+RO+ 
%* 
Treg 
CCR6+RO– 
%* 
Age [17] (Spearman r)  0.17 0.12  –0.12  –0.18 –0.08 0.03 0.06 –0.02 –0.07 
P value [0.52] [0.66] [0.66] [0.48] [0.76] [0.90] [0.82] [0.94] [0.79] 
FEV1% pred. 2 weeks# all patients [13] (Spearman r) –0.68 –0.16  0.16 0.36 0.28 –0.17 –0.19 –0.09 0.07 
P value [0.010] [0.60] [0.60] [0.22] [0.36] [0.58] [0.54] [0.78] [0.83] 
FEV1% pred. 2 weeks# stable patients only [10] (Spearman r) –0.72 –0.47 0.47 0.39 0.52 –0.55 –0.61 –0.25 0.39 
P value [0.019] [0.17] [0.17] [0.26] [0.13] [0.09]  [0.06] [0.49] [0.26] 
FEV1% pred. 1 week# stable patients only [5] (Spearman r) –0.90 –0.90 0.90 0.10 0.80 –1.00 –0.60 –0.30 0.70 
P value [0.08] [0.08] [0.08] [0.95] [0.13] [0.017] [0.35] [0.68] [0.23] 
Median percent for each subset          
Sex          
Male 8.20 52.05 47.95 13.00 3.49 45.45 3.35 23.65 0.89 
Female 7.24 48.10 51.90 11.10 3.96 40.20 1.72 16.90 0.55 
P value [0.09] [0.48] [0.48] [0.42] [0.74] [0.28] [0.24] [0.09] [0.74] 
Genotype          
DF508 homozygous [8] 7.80 49.60 50.40 9.75  3.64 42.55 1.94 16.60 0.53 
DF508 heterozygous/other [9] 8.05 51.20 48.80 12.00  4.21 46.00 2.05 23.00 0.78 
P value [0.27] [0.54] [0.54] [0.61]   [0.89] [0.37] [0.67] [0.11] [0.48] 
Stable [14] 7.86 49.65 50.35  11.85  3.69 44.65 2.01 20.60 0.49 
Exacerbating [7] 7.85 51.10 48.90  11.20  3.96 45.10 4.04 16.90 0.64 
P value [0.68] [0.54] [0.54] [0.99] [0.50] [0.50] [0.80] [0.74] [0.22] 
Chronic P. aeruginosa [10] 8.12 52.00 48.00 11.60 3.27 45.00 2.01 20.60 0.612 
No chronic P. aeruginosa [7] 7.85 48.10 51.90 11.70 4.79 40.20 1.72 23.00 0.640 
P value [0.58] [0.36] [0.36] [0.99] [0.32] [0.32] [0.54] [0.96] [0.67] 
Current S. aureus infection [11] 7.85 43.50 56.50 10.40 3.96 33.10 3.04 18.80 0.67 
No S. aureus infection [6] 7.24 50.90 49.10 16.05 4.06 44.75 1.94 24.05 0.53 
P value [0.87] [0.18] [0.18] [0.027] [0.99] [0.30] [0.66] [0.15] [0.46] 
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4.3.3 CXCR3/CCR4 (Th1/Th2) Ratios within the CF Group 
Because of the many reports of a Th2 bias in CF, we compared the ratios of CXCR3+/CCR4+ 
CD4+ and Treg cells between the CF and control groups (Table 13), but found no significant 
differences. 
The CXCR3/CCR4 ratios were also analysed within the CF cohort using the same parameters 
used for the other subsets (Table 13). No significant associations were found between the 
ratios of CXCR3+/CCR4+ CD4+ and Treg cells and sex, genotype, stable/exacerbating clinical 
status or the presence/absence of S. aureus infection. 
When CF patients were divided based on the presence of chronic P. aeruginosa infection, 
those patients with chronic P. aeruginosa infection had lower naïve CD4+ CXCR3+/CCR4+ 
ratios compared with patients without chronic P. aeruginosa infection (P = 0.025), indicating 
that they had lower levels of Th1-associated and higher levels of Th2-associated naïve CD4+ 
cells. 
When analysing the CXCR3+/CCR4+ ratios in relation to lung function for patients for whom 
spirometry was available within two weeks of blood testing (n = 13), no significant 
associations were found, although there was a trend towards an increase in FEV1 % predicted 
with increased memory CD4+CXCR+/CCR4+ ratio (P = 0.09). When only the clinically stable 
patients were included in this analysis (n = 14), a positive correlation was found between 
chronic P. aeruginosa infection and the memory CD4+ CXCR3+/CCR4+ ratio (r = 0.75, P = 
0.013), while there was a trend towards a positive correlation between FEV1 % predicted and 
the naïve CD4+ CXCR3+/CCR4+ ratio (P = 0.09). Naïve Treg CXCR3+/CCR4+ cells were 
positively correlated with FEV1 % predicted (r = 0.64, P = 0.048) while the memory Treg 
CXCR3+/CCR4+ ratio trended towards being positively correlated with FEV1 % predicted (P 
= 0.054). Analysis of clinically stable patients for whom blood and spirometry tests were 
performed within one week of each other (n = 5) showed no significant differences in 
CXCR3+/CCR4+ ratios; however, there was a trend towards a positive correlation between 
FEV1 % predicted and both naïve and memory Treg and memory CD4+ CXCR3+/CCR4+ 
ratios (all P values = 0.083). 
 
4.3.4 Treg/CD4+CCR6+ (Treg/Th17) Ratios within the CF Group 
As Treg/Th17 imbalances are often reported to cause immune pathology, the 
Treg/CD4+CCR6+ ratio was investigated but there was no significant difference between the CF 
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and control groups (Table 13). The Treg/CD4+CCR6+ ratio was also analysed within the CF 
cohort using the same parameters used for the other subsets (Table 13). However, no 
significant associations were found between the Treg/CD4+CCR6+ ratio and any of the 
clinical variables. 
  
  
 
Table 13. Correlations between ratios of naïve and memory T cells and clinical variables in the CF group 
 [P values] (Mann–Whitney U test) indicating significant differences are shown in bold. 
# Indicates number of weeks between blood and spirometry testing.
Parameter [no. of patients] CD4+RO+ 
CXCR3/CCR4 
ratio 
CD4+RO–
CXCR3/CCR4  
ratio 
Treg RO+ 
CXCR3/CCR4  
ratio 
Treg RO–
CXCR3/CCR4  
ratio 
RO+ Treg/CD4+CCR6+ 
ratio 
RO– 
Treg/CD4+CCR6+ 
ratio 
Age [17] (Spearman r) –0.25 0.05 –0.26   –0.13  0.16 0.13  
P value [0.34] [0.84] [0.31] [0.62] [0.54] [0.62] 
FEV 1% pred. 2 weeks# all patients [13] (Spearman r) 0.49 0.26 0.47 0.28 0.00 –0.07 
P value [0.09] [0.39] [0.12] [0.35] [1.00] [0.83] 
FEV 1% pred. 2 weeks# stable patients only [10] (Spearman r) 0.75 0.55 0.62 0.64 –0.01 –0.27 
P value [0.013] [0.09] [0.054] [0.048] [0.99] [0.45] 
FEV 1% pred. 1 week# stable patients only [5] (Spearman r) 0.90 0.60 0.90 0.90 –0.10 0.10 
P value [0.08] [0.35] [0.08] [0.08] [0.95] [0.95] 
Median percent for each subset       
Sex       
Male 0.79 1.31 0.27 0.88 147.7 3.99 
Female 1.00 6.66 0.35 2.75 198.3 3.24 
P value [0.20] [0.20] [0.42] [0.32] 0.37 0.42 
Genotype       
DF508 homozygous [8] 0.82 4.15 0.33 1.88 187.2 3.35 
DF508 heterozygous/other [9] 0.84 3.03 0.28 1.15 155.5 3.92 
P value [0.96] [0.82] [>0.99] [0.89] 0.28 0.67 
Stable [14] 0.70 2.34 0.24 1.04 138.9 3.41 
Exacerbating [7] 0.84 1.51 0.32 1.02 147.7 3.16 
P value [0.23] [0.97] [0.69] [0.80] 0.74 0.44 
Chronic P. aeruginosa [10] 0.75 1.45 0.28 0.98 151.6 3.30 
No chronic P. aeruginosa [7] 0.91 22.12 0.31 3.30 170.0 3.92 
P value [0.27] [0.025] [0.42] [0.16] 0.81 0.54 
Current S. aureus infection [11] 0.57 3.03 0.28 1.15 162.8 3.64 
No S. aureus infection [6] 0.84 4.15 0.38 1.78 130.7 3.35 
P value [0.40] [0.66] [0.30] [0.99] 0.43 0.96 
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4.4 Discussion 
Balanced T helper responses are essential to prevent immunopathology resulting from an 
immune response to pathogens. Studies have shown that a Th2-mediated immune response 
dominates in CF patients with P. aeruginosa (247, 262, 301) and A. fumigatus (52, 302-304) 
infections, and that this bias impairs efficient clearance of these infections. Our study, which 
investigated chemokine receptors on both memory and naïve CD4+ and Treg cells in the 
peripheral blood of CF patients, demonstrates for the first time that CCR4 (Th2-associated) 
expression on peripheral CD4+ effector and regulatory T cell subsets and the ratio of 
CXCR3+/CCR4+ memory CD4+ cells are correlated with FEV1 % predicted in clinically 
stable CF patients. Because the patients’ clinical condition can change quite rapidly and 
because our previous findings showed that the relationship between peripheral blood Th17% 
and lung function was very time-dependent, no data involving measurements of lung function 
beyond a two-week period around the blood sampling for CD4 subset analysis were included. 
The relationship shown between the CXCR3+/CCR4+ ratio and FEV1 % predicted indicates 
that a Th1-mediated immune response to lung infection may be more beneficial for 
maintaining lung function. Supporting this concept is the negative correlation observed 
between FEV1 % predicted and the percentages of Th2-associated CCR4+CD4+ cells and 
CCR4+Treg cells within the same group of clinically stable patients. We were unable to 
access samples to measure T cell subsets in the patients’ lungs, but it is possible that the high 
levels of Th2-associated and low levels of Th1-associated cells in peripheral blood of patients 
with poor lung function could reflect the levels of these cells in the lungs. The correlation 
between higher Th2-associated cells and poorer lung function would be consistent with the 
results of previous studies showing that a Th2-type response is less effective than a Th1-type 
response (249) in combating CF-related pathogens. 
Alterations in the CXCR3+/CCR4+ ratio were found not only for total CD4+ cells but also for 
Treg cells. A positive association was found between naïve Treg cells and FEV1 % predicted 
(P = 0.048) as well as a trend towards the same association between memory Treg cells and 
FEV1 % predicted (P = 0.054). This could be explained by the fact that Th1-associated 
regulatory cells are required to suppress the Th1 cell-mediated inflammation that can be 
damaging to tissues during prolonged inflammation (305). 
It is important to note that in CF peripheral blood, the proportions of both memory CD4+ and 
memory Treg cells expressing CXCR3 and CCR6 were decreased, while the proportion of 
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CCR4+ cells was decreased only for memory Treg cells not memory CD4+ cells. Therefore, 
the overall levels of CCR4+ regulatory cells were decreased while those of CCR4+ effector 
cells were unchanged. This apparent imbalance of effector and regulatory CCR4+ cells 
suggests that there are fewer Th2-associated regulatory cells to suppress Th2-associated 
effector cells, which could potentially contribute to the Th2 bias observed in CF. This 
imbalance could potentially be a target of therapy to reduce overactive Th2 immune responses 
and improve clearance of respiratory pathogens. 
Lastly, decreased percentages of naïve CXCR3+CD4+ cells were seen in patients with chronic 
P. aeruginosa infection. This could be because CXCR3+ Th1 CD4+ cells, which are known to 
be more effective than Th2 cells at clearing P. aeruginosa, have homed to the lung-draining 
lymph nodes in response to the presentation of P. aeruginosa antigens by APC there. 
However, an alternative explanation suggested by Lazarski and colleague’s study (306), 
which showed that IL-4, a signature Th2 cytokine, limits trafficking of Th1 cells to inflamed 
tissues, is that because of the Th2 dominance observed in the lungs of CF patients with 
chronic P. aeruginosa infection, the Th1-associated cells may not make it into the lungs to 
produce an effective immune response. Yet another potential explanation is that long-term 
Th2 dominance may have an effect on Th1 cell development at the gene expression level. 
Expression of Th2-associated genes is known to suppress Th1 cell development through 
inhibition of key Th1-regulating transcription factors (307). Prolonged inhibition of 
expression of these genes could therefore potentially affect the generation of new Th1 cells. 
However, given that the memory CXCR3+CD4+% appears unaffected in patients with P. 
aeruginosa infection, this may not be important in that context. The reduction of naïve 
CXCR3+CD4+% also has an effect on the CXCR3+/CCR4+ ratio for naïve CD4+ cells, but 
because this ratio showed no relationship with any relevant clinical parameters including lung 
function, this could therefore be considered inconsequential. However, given that low 
percentages of naïve CXCR3+CD4+ cells are specific to patients with P. aeruginosa, it is also 
possible that this could be a marker for monitoring/predicting P. aeruginosa infection, 
although this cannot be determined from the current data. 
The only previous study in CF patients that has assessed CXCR3 and CCR4 expression (247) 
evaluated these chemokine receptors on CD4+ and CD8+ T cells in BALF. The primary 
findings from that study all related to P. aeruginosa infection, and reported elevated levels of 
CCR4+CD4+ cells and of the Th2-related cytokines IL-4 and IL-13, as well as an association 
between these cytokines and P. aeruginosa infection and poorer lung function. Consistent 
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with this, Tiringer and colleagues (53) showed that high levels of Th2 and Th17 cells 
preceded P. aeruginosa infection. The correlations observed between the peripheral memory 
CD4+CXCR3+/CCR4+ ratio and memory CCR4+CD4+% and Treg% and the FEV1 % 
predicted in clinically stable CF patients may therefore be a useful indicator of susceptibility 
to P. aeruginosa acquisition and therefore lung function decline. However, because we 
observed that the association between these T cell subset percentages and FEV1 % predicted 
was only detected within a tight time frame, additional research is required to determine 
whether there is any prognostic value for lung function decline in measuring Th1/Th2 related 
markers in peripheral blood. 
Studies in non-CF patients infected with pathogens such as Mycobacterium tuberculosis, A. 
fumigatus and Leishmania spp (302, 306, 308) have all demonstrated the presence of a Th2-
biased response to infection. A study of patients with idiopathic pulmonary fibrosis has also 
implicated imbalances of CXCR3 and CCR4 expression on BALF cells in disease progression 
(309). These studies suggest that the alterations in Th1/Th2 associated markers observed in 
our study may not be specific to CF. It has been suggested that a high microbial burden in 
infected patients can lead to suppression of the cell-mediated Th1 response and dominance of 
the humoral-mediated Th2 response as a mechanism to prevent excessively damaging cell-
mediated immune responses that can potentially cause more harm than the pathogen (158, 
305). In addition, the generation of Th2 cells producing cytokines such as IL-4, IL-5 and IL-
13 produces a cytokine milieu conducive to the further generation of Th2 cells and inhibition 
of Th1 cells (305), and Lazarski et al. (306) showed that IL-4, a signature Th2 cytokine, not 
only promotes further Th2 cell generation but also limits trafficking of Th1 cells to inflamed 
tissues. Therefore, all of these could be contributing factors to altered peripheral T cell subset 
levels in CF. 
It is notable that although many differences between CF patients and healthy controls were 
observed among the memory CD4+ and Treg cell populations expressing CXCR3 (Th1-
associated), CCR4 (Th2-associated) and CCR6 (Th17-associated), no differences were found 
for any naïve subset. This may indicate that although in CF patients there are normal levels of 
‘inexperienced’ cells able to differentiate into effector and regulatory cells upon antigen 
stimulation, either their ability to differentiate to CXCR3+ and CCR6+ memory cells is 
impaired or the memory cells have homed to sites away from the periphery. It would appear 
most logical that the decrease in these cells is because of their homing to the lungs, where 
there is a high concentration of proinflammatory cytokines and chemokines to combat the 
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chronic infection in the lungs. The reported overactive Th2 response in the lungs may also be 
reflected in the periphery and could explain why, in contrast to those of CXCR3+ and CCR6+ 
memory CD4+ cells, the percentage of CCR4+ memory T cells is not decreased in the 
periphery. This is consistent with a study by Häusler and colleagues (140) that investigated 
memory CD4+ T cells as a whole population, rather than identifying specific subsets, and 
showed a decrease of CD4+ memory cells in CF peripheral blood but an increase of these cells 
in CF lung tissue, suggesting that it is possible that memory CD4+ T cells home from the 
periphery to the lungs in CF. 
It is interesting to note that the percentages of Tregs defined using CD4, CD25 and CD127 
rather than the CD4 and FOXP3 markers used in the previous experiments described in 
Chapter 3, are still negatively correlated with FEV1 % predicted. Although two previous 
studies in CF have shown peripheral blood Tregs to be positively correlated with FEV1 % 
predicted (217, 279), those studies included mainly infants and adolescents who were yet to 
experience prolonged infection, in contrast with our cohort who were all adults (>18 years), 
many with chronic infections. Because it has been reported that Tregs undergo an age- and 
disease progression-dependent impairment of their suppressive ability (217), it is possible that 
in older patients, increasing numbers of Tregs are induced because they become less effective. 
The main strength of this study is the detailed analysis that combines both chemokine receptor 
markers and a naïve/memory marker for both CD4+ effector and regulatory T cells. One 
weakness is that this is a cross-sectional study and therefore none of the parameters measured 
provide any predictive ability or allow determination of causality. A second weakness is that 
the levels of these cells were not measured in the lung or BALF (site of infection) or in the 
lymph nodes (site of antigen presentation) to provide a true picture of where the T cells are 
homing in response to infection. 
In conclusion, we have shown that the level of CD4+ T cells expressing CXCR3 and CCR4 
chemokine receptor in peripheral blood is reflective of lung function in clinically stable CF 
patients. These markers, like peripheral blood Th17%, could potentially be used as relatively 
noninvasive markers of lung function. The decrease in naïve CXCR3+CD4+% in relation to P. 
aeruginosa infection could also have potential as a clinical tool to predict changes in lung 
function. 
Peripheral percentages of CXCR3+, CCR4+ and CCR6+ memory Treg cells were decreased in 
CF compared with healthy controls while only CXCR3+ and CCR6+ memory CD4 cells were 
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decreased, resulting in an imbalance of Th2-associated effector and regulatory cells. 
Correction of this imbalance to dampen overactive Th2 immune responses could potentially 
improve clearance of respiratory pathogens in CF patients. 
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CHAPTER 5 
Flow Cytometric Analysis of Peripheral Blood Monocytes, Natural Killer 
(NK) cells, Dendritic Cells (DC) and Myeloid Derived Suppressor Cells 
(MDSC)
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5.1 Introduction 
Effective communication between the innate and adaptive immune system is essential for 
mounting appropriate immune responses. Destruction of lung tissue, in which the immune 
system is thought to play a major role, is the primary cause of morbidity and mortality in 
CF. In recent years, innate immune cells and their subsequent effects on adaptive immune 
responses have become an area of interest in understanding immune dysregulation in CF and 
its effects on lung damage. While we (310) and others (20, 220, 262, 290) have shown 
dysregulation of adaptive CD4+ T cells in CF, there is far less research investigating how 
innate immune cells other than neutrophils are contributing to this dysregulation. In 
particular, much of the research involving the innate immune response is based primarily at 
the site of infection, in the lungs. 
Cell types such as monocytes/macrophages (311, 312) and DCs (23) are of particular 
interest because they are also known to normally express CFTR and they directly influence 
T cells through antigen presentation. Other cell types that have not been confirmed to 
express CFTR, such as NK cells and MDSCs, are also of interest because of their prominent 
role in controlling infection and inflammation. Therefore, investigating changes in these 
cells away from the lungs and the direct influence of infection and inflammation may 
provide insight about intrinsic defects in these cell types. 
To investigate innate immune cells in CF, we stained PBMC from adult CF patients and 
healthy age-matched controls with antibodies to identify monocytes, NK cells, DCs and 
MDSCs and analysed these populations using flow cytometry. The CF group data were also 
analysed to determine any correlations between subset proportions and relevant clinical 
variables. 
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5.2 Materials and Methods 
5.2.1 PBMC Staining  
Cryopreserved cells were used for all staining, and were resuscitated and prepared as described in Chapter 2. The specific antibody combinations 
used for staining for the experiments described in this chapter are listed in Table 14. Cells were counted using a Sysmex Cell Counter (Sysmex, 
NSW, Australia). 
Table 14. Antibody combinations used for identification of monocytes, natural killer, dendritic and myeloid derived suppressor cells 
Antibody Marker Fluorochrome Hybridoma Clone Supplier 
Live dead  Dead cells Near infrared (IR)  ThermoFisher Scientific 
anti-CD3 T cells Biotin OKT3 Centenary Institute, Newtown, 
NSW, Aus 
anti-avidin Biotin labelled cells (T and B cells) Pacific orange (PO)  Centenary Institute 
anti-CD19 B cells Biotin HIB19 BD Biosciences 
anti-CD14 Monocytes 
Myeloid derived suppressor cells 
Pacific Blue (PB) M5E2 BD Biosciences 
anti-
CX3CR1 
Monocytes 
Dendritic Cells 
Fluorescein isothiocyanate 
(FITC) 
2A9-1 BioLegend 
anti-NKP46 Natural killer cells Phycoerythrin (PE) 9E2 BD Biosciences 
anti-CD16 Natural killer cells 
Monocytes 
Myeloid derived suppressor cells 
Peridinin chlorophyll protein 
cyanin 5.5 (PerCP-Cy5.5) 
3G8 BD Biosciences 
anti-CD11b Myeloid derived suppressor cells Phycoerythrin cyanin (PE-
Cy7) 
ICRF44 BD Biosciences 
anti-CD56 Natural killer cells Allophycocyanin (APC) NCAM16.2 BD Biosciences 
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5.2.2 Flow Cytometric Data Acquisition and Analysis 
Stained PBMCs were analysed using a BD FACSCanto II nine-colour flow cytometer (BD 
Biosciences) with blue 488 nm, red 633 nm and violet 405 nm lasers allowing measurement 
of nine fluorescence and two scatter parameters using FACSDiva software (BD 
Biosciences). Five hundred thousand events were collected per sample analysed. Data 
obtained from the flow cytometer were analysed using FlowJo software (Treestar, Ashland, 
OR). Figure 9 demonstrates the hierarchical gating strategy for identification of cells 
expressing markers of monocytes, NK cells, DCs and MDSC. Monocyte, MDSC, NK and 
DC populations were analysed as percentages of ‘non T and B cells’ or as percentages of 
their parent population where appropriate. Measurement of these cells as a percent of ‘non-T 
non-B cells’ allows identification of the proportions of a particular cell type within the entire 
population of cells of interest while measurement of cells as a percent of the parent 
population allows identification of the changes in proportions of a subpopulation within a 
given cell type. 
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Fig. 9. Representative histograms from healthy individual demonstrating the gating strategy for flow cytometry analysis of monocytes, 
natural killer cells, dendritic cells and myeloid-derived suppressor cells. ‘A’ shows ungated cells, ‘B’ shows gating of single cells, ‘C’ shows 
gating of live cells and ‘D’ shows gating of non-T and B cells. ‘E’ shows gating on a population containing natural killer cells and a population 
containing monocytes, dendritic cells and myeloid-derived suppressor cells. ‘E1’shows gating of natural killer cell subpopulations. ‘E2’ shows 
gating of myeloid-derived suppressor cells and a population containing monocytes and dendritic cells. ‘E2a’ shows gating of myeloid-derived 
suppressor cell subpopulations. ‘E2b’ shows gating of dendritic cells and monocytes and ‘E2b2’ shows gating of monocyte subpopulations.
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5.3 Results 
5.3.1 Comparison between CF and Control Groups 
There was no significant difference in the median age or the sex distribution of the control 
and CF groups. A comparison of the flow cytometry results for the two groups is outlined in 
Table 15. Overall percentages of MDSCs, measured as a percent of non-T non-B cells, did not 
differ significantly between the control and CF groups, so we next focussed on analysis of 
subpopulations. First, MDSCs were divided based on CD14 expression to identify monocytic 
(CD14+) and granulocytic (CD14–) populations. When measured as a percent of the parent 
(MDSC) population, CD14+ MDSCs were increased in CF patients compared with controls (P 
= 0.0115) while CD14– MDSCs were decreased in CF (P = 0.004). However, neither 
population differed significantly between CF and control groups when measured as a percent 
of non-T non-B cells. DCs, which were analysed as a single population, were increased in CF 
patients compared with controls (P = 0.0158). 
The overall monocyte population was significantly increased in CF compared with controls (P 
= 0.0214). Three subpopulations of monocytes were identified based on CD14 and CD16 
expression: CD14hiCD16lo, CD14intCD16int and CD14lo/negCD16hi, and the levels of these were 
calculated as a percent of the parent (monocyte) population as well as a percent of ‘non-T 
non-B’ cells. CD14hiCD16lo ‘classical’ monocytes were increased in CF compared with 
controls when defined as either a percent of the parent population (P = 0.0331) or as a percent 
of ‘non-T non-B’ cells (P = 0.002). CD14intCD16int ‘intermediate’ monocytes were unchanged 
in CF compared with controls. CD14lo/negCD16hi ‘non-classical’ monocytes were decreased 
when measured as a percent of ‘non-T non-B’ cells (P = 0.0412) but were unchanged when 
measured as a percent of the parent population. 
The overall NK cell population, identified by NKP46 expression, was decreased in CF 
compared with controls (P = < 0.0001). When NK cells were further divided into 
subpopulations based on CD16 and CD56 expression, three distinct populations were 
identified, CD16hiCD56int, CD16lo/negCD56hi and CD16lo/negCD56int, as described in section 
1.2.2.5. All of these subsets were measured as a percent of the parent population (NK cells) 
and of ‘non-T non-B’ cells. The CD16hiCD56int cytotoxic NK cells were significantly 
decreased in CF compared with controls when calculated as either a percent of parent 
population (P = <0.0001) or as a percent of ‘non-T non-B’ cells (P = < 0.0001). The 
CD16lo/negCD56hi cytokine-producing subpopulation was significantly increased in CF 
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compared with controls (P = < 0.0001) when calculated as a percent of the parent population, 
but did not differ significantly between the groups when calculated as a percent of ‘non-T 
non-B’ cells. CD16lo/negCD56int cytotoxic NK cells showed a trend towards an increase in CF 
compared with controls (P = 0.0695) when calculated as a percent of the parent population, 
but did not differ significantly when they were calculated as a percent of ‘non-T non-B’ cells. 
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Table 15. Comparison of monocyte, natural killer, myeloid derived suppressor and 
dendritic cell subset percentages between control and CF groups 
P values indicating significant differences are shown in bold. 
  
 Control CF P value 
N 15 17  
Age median (range) 28 (22–50) 25 (19–54) 0.4947 
Sex male (%) 5 (33%) 8 (47%)  
MDSC (% non-T non-B cells) median (range) 0.44 (0.15–1.72) 0.36 (0.03–1.33) 0.1922 
CD14+ MDSC (% non-T non-B cells) median (range) 0.035 (0.006–0.346) 0.047 (0.001–0.389) 0.3310 
CD14+ MDSC (% MDSC) median (range) 8.27 (1.06–25.20) 15.10 (5.56–34.60) 0.0115 
CD14– MDSC (% non-T non-B cells) median (range) 0.40 (0.14–1.52) 0.23 (0.02–0.99) 0.1206 
CD14– MDSC (MDSCs) median (range) 91.00 (74.80–98.80) 83.30 (65.40–92.60) 0.0040 
Dendritic Cells (% non-T non-B cells) median (range) 12.50 (8.66–22.30) 18.90 (6.07–49.80) 0.0158 
Monocytes (% non-T and B cells) median (range) 34.90 (20.00–56.10) 46.00 (24.60–76.70) 0.0214 
CD16hiCD14lo Monocytes (% non-T non-B cells) median (range) 1.68 (0.49–4.80) 4.50 (0.65–8.37) 0.0020 
CD16hiCD14lo Monocytes (% monocytes) median (range) 6.05 (1.24–15.70) 7.65 (1.93–22.90) 0.0331 
CD16intCD14int Monocytes (% non-T non-B cells) median (range) 1.27 (0.51–2.68) 3.04 (1.47–7.04) 0.1203 
CD16intCD14int Monocytes (% monocytes) median (range) 4.40 (1.53–6.25) 1.55 (0.59–4.24) 0.4497 
CD16lo/negCD14hi Monocytes (% non-T non-B cells) median (range) 88.80 (78.40–97.20) 37.20 (20.40–65.00) 0.0412 
CD16lo/negCD14hi Monocytes (% monocytes) median (range) 63.10 (40.20–76.90) 88.70 (70.20–92.70) 0.3647 
Natural Killer Cells (% non-T non-B cells) median (range) 49.50 (26.50–66.50) 23.10 (9.31–41.40) <0.0001 
CD16hiCD56int NK (% non-T non-B cells) median (range) 42.60 (21.70–60.80) 18.20 (1.43–33.70) <0.0001 
CD16hiCD56int NK (% NK cells) median (range) 89.10 (80.20–94.90) 76.70 (15.30–91.00) <0.0001 
CD16lo/negCD56hi NK (% non-T non-B cells) median (range) 3.03 (1.41–3.95) 3.29 (0.68–9.27) 0.3954 
CD16lo/negCD56hi NK (% NK cells) median (range) 5.94 (2.35–11.30) 16.70 (3.01–50.20) <0.0001 
CD16lo/negCD56int NK (% non-T non-B cells) median (range) 2.07 (0.99–7.44) 1.84 (0.38–4.48) 0.3699 
CD16lo/negCD56int NK (% NK cells) median (range) 5.17 (1.90–15.00) 6.64 (3.59–48.10) 0.0695 
 P a g e  | 91 
 
5.3.2 Comparisons within the CF Cohort 
We next investigated any important associations between the measured cell populations and 
clinical parameters within the CF group, as described in Chapter 2. Investigating those with (n 
= 3) or without (n = 15) current A. fumigatus infection and those with (n = 16) or without (n = 
1) current treatment with any antimicrobial was not possible given the small sizes of one of 
the groups. Tables 16, 17 and 18 detail all parameters assessed. 
No significant differences were found for any of the subsets between patients with different 
CFTR genotypes or between exacerbating and clinically stable patients or between patients 
with or without P. aeruginosa or S. aureus infection. 
Sex was correlated with both CD16lo/negCD56int NK cells (as % of NK cells) and dendritic 
cells (as % of CD3 cells), with higher levels of these subsets in women with CF compared 
with men. When NK cells were investigated as a whole rather than as individual 
subpopulations, they were found to be negatively correlated with age (r = 0.51, P = 0.038). 
However, when individual NK subpopulations were considered in relation to age, only 
CD16hiCD56int NK cells, measured as either % of CD3 cells (r = 0.60, P = 0.011) or % of 
NK cells (r = 0.60, P = 0.011), were negatively correlated with age. 
FEV1 % predicted was first analysed in all patients for whom spirometry and blood tests were 
performed within two weeks of each other (n = 13), in whom it was positively correlated with 
CD16hiCD56int NK cells (as % NK cells) (r = 0.65, P = 0.015) and negatively correlated with 
CD16lo/negCD56hi NK cells (as % NK cells) (r = 0.63, P = 0.021). FEV1 % predicted was 
also positively correlated with CD14 MDSCs (as % CD3 cells) (r = 0.60, P = 0.029). Next, 
FEV1 % predicted was analysed in only clinically stable patients for whom spirometry and 
blood tests were performed within two weeks of each other (n = 9). When NK cells were 
considered as a whole population (% CD3 cells) they were positively correlated with FEV1 
% predicted (r = 0.77, P = 0.009). However, when subpopulations of NK cells were 
investigated, varying relationships with lung function were identified. CD16hiCD56int NK 
cells measured as either % CD3 cells (r = 0.78, P = 0.007) or % NK cells (r = 0.76, P = 
0.011), and CD16lo/negCD56int (% CD3 cells) (r = 0.78, P = 0.008) were positively correlated 
with FEV1 % predicted, while CD16lo/negCD56hi NK cells (% NK cells) were negatively 
correlated with FEV1 % predicted (r = 0.78, P = 0.008). When MDSCs were considered as a 
whole population (% CD3 cells), they were positively associated with FEV1 % predicted (r = 
0.81, P = 0.005). When subpopulations of MDSCs were analysed based on CD14 expression, 
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both CD14+ and CD14 MDSCs (% CD3 cells) were positively correlated with FEV1 % 
predicted (r = 0.79, P = 0.006 and r = 0.89, P = 0.001, respectively).  
  
Table 16. Correlations between monocyte subset percentages and clinical variables in CF patients 
 [P values] (Mann–Whitney U test) indicating significant differences are shown in bold.
Parameter [no. of patients] Monocytes  
(% CD3–) 
CD16hiCD14lo 
Monocyte 
(% CD3–) 
CD16hiCD14lo 
Monocyte  
(% monocytes) 
CD16intCD14int 
Monocyte  
(% CD3–) 
CD16intCD14int 
Monocyte  
(% monocytes) 
CD16lo/negCD14hi 
Monocyte  
(% CD3–) 
CD16lo/neg CD14hi 
Monocyte  
(% monocytes) 
Age [17] (Spearman r)  0.34  0.04  –0.24 0.08 –0.16 0.36 0.16 
P value [0.19] [0.88] [0.35] [0.76] [0.53] [0.16] [0.55] 
FEV1 % pred. [13] (Spearman r) –0.20 0.11  0.36 –0.15 –0.03 –0.15 –0.21 
P value [0.51] [0.72] [0.23] [0.63] [0.93] [0.62] [0.49] 
FEV1 % pred., stable patients only [9] 
(Spearman r) 
–0.41 –0.04 0.47 –0.32 –0.08 –0.36 –0.26 
P value [0.24] [0.91] [0.17]  [0.37] [0.83]  [0.31] [0.47] 
Median percent for each subset        
Sex        
Male 57.40 4.80 7.84 1.49 2.62 51.55 89.60 
Female 40.00 4.50 7.65 1.92 3.26 36.30 88.40 
P value [0.15] [0.62] [0.96] [0.31] [0.25] [0.20] [0.72] 
Genotype        
DF508 [8] 42.10 4.97 8.03 1.74 3.04 36.75 86.25 
DF508 heterozygous/other [9] 46.00 4.50 7.65 1.53 3.26 40.80 89.10 
P value [0.91] [0.80] [0.89] [0.56] [0.69] [0.96] [0.66] 
Stable [14] 46.00 4.50 7.96 1.63 3.49 39.00 88.30 
Exacerbating [7] 40.00 5.10 7.58 1.92 3.03 36.30 88.40 
P value [0.76] [0.79] [0.80] [0.81] [0.99] [0.81] [0.73] 
Chronic P. aeruginosa [10] 43.00 4.44 8.69 1.63 3.71 36.25 89.80 
No chronic P. aeruginosa [7] 58.80 5.10 7.65 1.53 3.03 52.40 88.70 
P value [0.72] [0.98] [0.96] [0.98] [0.65] [0.54] [0.69] 
Current S. aureus infection [11] 46.00 5.10 8.26 1.83 3.26 40.80 88.40 
No S. aureus infection [7] 39.40 2.47 6.26 1.39 3.38 36.00 91.10 
P value [0.86] [0.45] [0.30] [0.39] [0.83] [0.96] [0.06] 
  
Table 17. Correlations between natural killer cell subset percentages and clinical variables in CF patients 
 [P values] (Mann–Whitney U–test) indicating significant differences are shown in bold. 
Parameter [no. of patients] Natural 
Killer Cells 
(% CD3–) 
CD16hiCD56int 
Natural Killer Cell 
(%CD3–) 
CD16hiCD56int 
Natural Killer Cell 
(% natural killer) 
CD16lo/negCD56hi 
Natural Killer Cell 
(% CD3–) 
CD16lo/negCD56hi 
Natural Killer Cell 
(% natural killer) 
CD16lo/negCD56int 
Natural Killer Cell 
(% CD3–) 
CD16lo/negCD56int 
Natural Killer Cell 
(% natural killer) 
Age [17] (Spearman r)  –0.51  –0.60  –0.60 0.07 0.46 –0.13 0.23 
P value [0.038] [0.011] [0.011] [0.79] [0.06] [0.63] [0.37] 
FEV1% pred. [13] (Spearman r) 0.13 0.34 0.65  –0.51 –0.63 0.26 0.04 
P value [0.67] [0.26] [0.015] [0.07] [0.021] [0.38] [0.90] 
FEV1% pred. stable patients only [9]  
(Spearman r) 
0.77 0.78 0.76 –0.41 –0.78 0.78 0.21 
P value [0.009] [0.007] [0.011]  [0.24] [0.008]  [0.008] [0.56] 
Median percent for each subset        
Sex        
Male 23.55 19.26 73.75 3.57 21.20 1.50 5.21 
Female 23.10 18.20 78.60 2.56 10.60 2.44 8.68 
P value [0.98] [0.96] [0.61] [0.42] [0.24] [0.08] [0.03] 
Genotype        
DF508 [8] 15.95 12.21 74.90 2.93 16.20 2.14 9.07 
DF508 heterozygous/other [9] 30.10 27.40 77.70 3.81 16.70 1.83 5.25 
P value [0.47] [0.32] [0.54] 0.67 [0.96] [0.37] [0.06] 
Stable [14] 29.45 25.20 76.70 2.56 12.80 1.83 6.07 
Exacerbating [7] 15.20 12.10 79.35 2.36 15.50 1.84 7.29 
P value [0.35] [0.31] [0.54] [0.74] [0.74] [0.86] [0.60] 
Chronic P. aeruginosa [10] 21.40 16.35  74.90 2.94 16.20 1.84 6.97 
No chronic P. aeruginosa [7] 30.10 25.20 77.70 3.29 16.70 2.00 6.00 
P value [0.72] [0.96] [0.99] [0.96] [0.96] [0.54] [0.89] 
Current S. aureus infection [11] 23.10 18.20 80.10 2.36 13.30 1.83 5.25 
No S. aureus infection [7] 25.40 17.50 72.90 4.86 20.85 1.89 7.99 
P value [0.64] [0.96] [0.12] [0.26] [0.59] [0.59] [0.18] 
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 Table 18. Correlations between dendritic and myeloid derived suppressor cell subset percentages and clinical variables in CF patients 
[P values] (Mann–Whitney U test) indicating significant differences are shown in bold.  
Parameter [no. of patients] Dendritic Cells 
(% CD3–) 
MDSC  
(% CD3–) 
CD14+ MDSC  
(% CD3–) 
CD14+ MDSC  
(% MDSC) 
CD14– MDSC  
(% CD3–) 
CD14– MDSC 
(% MDSC) 
Age [17] (Spearman r)  0.04  –0.32  –0.31 –0.10 –0.36 0.06 
P value [0.87] [0.21] [0.23] [0.7] [0.16] [0.98] 
FEV1 % pred. [13] (Spearman r) 0.80 0.51  0.51 –0.03 0.60 0.16 
P value [0.08] [0.08] [0.07] [0.93] [0.029] [0.71] 
FEV1 % pred. stable patients only [9] (Spearman r) 0.20 0.81 0.79 –0.03 0.89 0.33 
P value [0.58] [0.005] [0.006]  [0.93] [0.001]  [0.35] 
Median percent for each subset       
Sex       
Male 16.40 0.16 0.03 16.30 0.14 83.10 
Female 22.10 0.49 0.10 14.40 0.42 83.50 
P value [0.02] [0.14] [0.14] [0.99] [0.17] [0.99] 
Genotype       
DF508 [8] 21.65 0.37 0.04 13.90 0.31 84.95 
DF508 heterozygous/other [9] 17.60 0.36 0.08 15.90 0.23 82.90 
P value [0.24] [0.89] [0.74] [0.54] [0.74] [0.81] 
Stable [14] 26.70 0.45 0.03 12.50 0.32 85.10 
Exacerbating [7] 35.00 0.36 0.06 22.20 0.23 77.50 
P value [0.33] [0.74] [0.09] [0.11] [0.86] [0.23] 
Chronic P. aeruginosa [10] 18.50  0.22 0.03 15.90 0.18 81.85 
No chronic P. aeruginosa [7] 20.30 0.49 0.10 13.30 0.42 86.70 
P value [0.89] [0.32] [0.48] [0.54] [0.19] [0.42] 
Current S. aureus infection [11] 18.90 0.49 0.08 15.90 0.42 77.40 
No S. aureus infection [7] 21.65 0.24 0.03 13.35 0.21 86.65 
P value [0.88] [0.40] [0.40] [0.53] [0.35] [0.26] 
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5.3.3 Multiexperiment Viewer (MeV) Bioinformatic Analysis of Peripheral 
Immune Cell Subsets 
Flow cytometry is a high-throughput technology analysing multiple parameters for millions 
of cells, which produces large volumes of data. To improve the efficiency of analysis, 
bioinformatic analysis techniques using Multiexperiment Viewer (MeV) were employed. 
This allowed for visualisation of common trends/patterns between CF patients and healthy 
controls. Data were analysed using MeV as described in Chapter 2. 
Firstly, all subsets detailed in Table 15 were analysed in all CF patients and controls. 
Although the results were not clear cut, a trend was seen towards separate clustering of CF 
patients and controls (Fig. 10). 
Next, a heat map was generated that included only the subsets that differed significantly 
between controls and CF patients, to allow visualisation of patterns of 
upregulation/downregulation between the CF and control groups. (Fig. 11). This resulted in a 
clearer separation of the CF patients and controls, although, there were still two controls that 
clustered with the CF group and two CF patients that clustered with the control group (Fig. 
12). 
Lastly, all the subsets detailed in Table 15 were again analysed, but this time only including 
clinically stable CF patients compared with controls, in an attempt to identify changes that 
were not related to acute exacerbation of disease. A heat map was again generated including 
only the subsets that differed significantly between CF patients and controls, which showed a 
clear separation between clustering of CF patients and controls (Fig. 12), with only two 
control samples clustering amongst the CF group, and no patients clustering with controls. 
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Fig. 10. Heat map of monocyte, natural killer, dendritic and myeloid derived suppressor cell subset percentages in all CF patients and 
healthy controls. Raw data were imported in txt. file format to MeV. Data were normalised across rows and a nonparametric Kruskal–Wallis 
test was performed to determine differences in the proportions of each subset between groups. An unsupervised clustering analysis (hierarchical 
clustering) was performed using a nonparametric Spearman rank correlation distance metric and average linkage clustering. A heat map 
expression image was created to visualise results. Rows correspond to the immune cell subsets and columns correspond to individual subjects. 
Black squares indicate unchanged relative expression, green squares indicate down regulated relative expression and red squares indicate up 
regulated relative expression of that variable.  
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Fig. 11. Heat map of significantly different monocyte, natural killer, dendritic and myeloid derived suppressor cell subset percentages 
between all CF patients and healthy controls. Raw data were imported in txt. file format to MeV. Data were normalised across rows and a 
nonparametric Kruskal–Wallis test was performed to determine differences in the proportions of each subset between groups. An unsupervised 
clustering analysis (hierarchical clustering) was performed using a nonparametric Spearman rank correlation distance metric and average linkage 
clustering. A heat map expression image was created to visualise results. Rows correspond to the immune cell subsets and columns correspond 
to individual subjects. Black squares indicate unchanged relative expression, green squares indicate down regulated relative expression and red 
squares indicate up regulated relative expression of that variable.  
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Fig. 12. Heat map of monocyte, natural killer, dendritic and myeloid derived suppressor cell subset percentages in clinically stable CF 
patients and healthy controls. Raw data were imported in txt. file format to MeV. Data were normalised across rows and a nonparametric 
Kruskal–Wallis test was performed to determine differences in the proportions of each subset between groups. An unsupervised clustering 
analysis (hierarchical clustering) was performed using a nonparametric Spearman rank correlation distance metric and average linkage 
clustering. A heat map expression image was created to visualise results. Rows correspond to the immune cell subsets and columns correspond 
to individual subjects. Black squares indicate unchanged relative expression, green squares indicate down regulated relative expression and red 
squares indicate up regulated relative expression of that variable. 
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5.4 Discussion 
This study shows for the first time that proportions of monocytes, DCs, NK cells and MDSC 
are all altered in CF peripheral blood compared with healthy controls. We also showed that in 
CF patients, peripheral total and subpopulations of NK and MDSCs were correlated with lung 
function as assessed by FEV1 % predicted. 
Previous studies of NK cells have been undertaken primarily in disease states such as cancer, 
tumours, autoimmunity, viral infections and asthma (313), with changes in not only numbers 
but also function being implicated in disease pathogenesis. There is very little research 
investigating NK cells in CF. The three studies investigating this cell type in CF (138-140) 
have all shown peripheral blood decreases, and one (138) also demonstrated a positive 
correlation between NK cells and FEV1 % predicted. However, all of these studies 
investigated these cells as one heterogeneous population rather than focussing on individual 
NK subsets. 
Our data confirmed that NK cells, measured as a single population based on NKp46 and 
CD56 expression, are decreased in CF peripheral blood compared with that of healthy 
controls. Because this innate population is involved in the initial response to infection, 
particularly viral infection, this may have a negative impact on the ability of CF patients to 
deal with viruses. Unfortunately, as screening for viruses is not included in routine clinical 
tests we do not have data pertaining to viral infections in the CF patients. 
Further analysis of NK subpopulations using CD56 and CD16 expression revealed a shift in 
CF patients from CD56int to CD56hi NKs, with a positive correlation between CD56int NKs 
and FEV1 % predicted and a negative correlation between CD56hi NKs and FEV1 % 
predicted. These subpopulations of NK cells are functionally different: CD56int cells are 
highly cytotoxic while CD56hi cells have a strong propensity for cytokine production. 
Therefore, decreased CD56int (cytotoxic) NK cells could contribute to difficulty in limiting 
the scope of viral infections because of decreased killing of virus-infected cells, while 
increased CD56hi (cytokine producing) cells could increase tissue damage caused by high 
levels of cytokine production. The negative correlation seen between the CD56hi cytokine-
producing NK cells and FEV1 % predicted could be related to the damaging effects on lung 
tissue of the key proinflammatory cytokines that they produce, IFN and TNF, especially 
because CD56hi NK cells are known to be the dominant NK cell subset in tissues such as the 
lung (136). However, previous studies have also shown that CD56hi NK cells are able to 
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produce the Th2-associated cytokines, IL-4, IL-5 and IL-13 when stimulated ex vivo, and that 
this cytokine production is promoted by the presence of IL-4 and inhibited by the presence of 
IL-12 and IL-13 (136, 314-316). Given that there is a known Th2 dominance in CF lungs and 
that Th2-dominated immune responses have been associated with poorer lung function, it 
would be reasonable to suggest that if the CD56hi NK cells were producing the Th2-associated 
cytokines, they too would be negatively associated with lung function. Consistent with this 
hypothesis, NK cells producing Th2-associated cytokines have been implicated in the 
pathogenesis of asthma, another Th2-dominated inflammatory disease (317). The positive 
correlation seen between CD56int cytotoxic NK cells and FEV1 % predicted could be because 
of the ability of these cells to kill virus-infected cells and thus reduce the spread of infection 
and damage to the lungs. 
It is not possible to determine from our data whether the decrease in CF peripheral NK cells is 
because of the homing of these cells to the lungs during lung inflammation and infection, as 
has been reported previously (136, 318-324), or is because of an absolute decrease in their 
numbers, as seen in autoimmune conditions such as systemic lupus erythematosus (SLE) 
(325). However, our findings are similar to those seen in SLE, which also presents with a 
decrease in peripheral NK cells and a switch from CD56int to CD56hi NK cells. Autoreactive T 
cells are also known to mediate NK cell degeneration in autoimmune disease (326). This may 
suggest that there are similar autoimmune mechanisms contributing to CF pathogenesis. This 
is further supported by the results reported by Lachenal et al. (327) who demonstrated a high 
frequency of autoantibodies in CF that were associated with the severity of lung disease and 
prognosis. The mechanism behind autoimmunity in CF is not yet understood with the 
possibility, as suggested by Lachenal et al. (327), that the immune system responds 
nonspecifically because of chronic infection and inflammation, and that autoimmunity could 
be contributing to the hyperinflammation seen in CF and promoting infection and lung 
damage. 
Alternatively, or in addition to this, the effects of P. aeruginosa, the dominant CF pathogen, 
on NK cells could be contributing to their decreased levels. One study showed that P. 
aeruginosa is able to kill NK cells through induction of apoptosis (328), while Broquet et al. 
reported that a systemic depletion of NK cells increased the susceptibility to P. aeruginosa 
infection in a mouse model of P. aeruginosa pneumonia (329). This mouse model also 
presented with an influx of neutrophils that was associated with this reduction in NK cells; a 
similar manifestation is seen in CF. It has also been shown, using a mouse model, that NK 
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cell-depleted mice are more susceptible to pulmonary infection with S. aureus and develop a 
pulmonary expansion of neutrophils and macrophages in response to NK cell reduction, 
which also resembles features of CF. In addition, cytokines such as IL-12 and IL-18, involved 
in the initiation of cell mediated immunity through Th1 cell induction, are also required for 
the generation of NK cells and have been reported to be low in CF lungs and peripheral blood 
(249, 330, 331). 
Another innate immune cell population of interest, given its recent implication in many 
disease pathologies, particularly infection and inflammation, is MDSCs. Because MDSCs are 
a newly described and heterogeneous population of immature myeloid cells, their 
characterisation is ongoing. However, two distinct subsets have been identified, known as 
monocytic MDSCs and granulocytic MDSCs (120). Our flow cytometry antibody panel 
identified monocytic and granulocytic MDSCs based on CD11b, CD16 and CD14 expression. 
There is only one study, by Rieber and colleagues (126), describing MDSCs in CF, which 
focussed on granulocytic MDSCs in CF patients with and without P. aeruginosa infection 
compared with healthy subjects (126), and found that granulocytic MDSCs were positively 
correlated with lung function and were directly able to downregulate several cytokines (IFN, 
IL-13, IL-6, GM-CSF, IL-10) including IL-17. Consistent with this, we also showed a 
positive correlation between the level of granulocytic MDSCs and FEV1 % predicted. 
However, Rieber et al. (126) reported that granulocytic MDSCs were increased in CF patients 
chronically infected with P. aeruginosa compared with healthy controls, which contrasts with 
our finding of decreased granulocytic MDSCs in CF, even in only those positive for P. 
aeruginosa. This discrepancy cannot be explained, but may be accounted for by differences in 
the method of granulocytic MDSC identification, with Rieber and colleagues using a much 
more extensive array of markers such as CD33, CD66b, IL-4R and HLA-DR. Given the 
relationship Rieber and colleagues have shown between granulocytic MDSCs and Th17 cells, 
it would be expected that a decrease in granulocytic MDSCs would result in an increase of 
Th17 levels. As we have previously shown no change in peripheral Th17 levels this may 
suggest that monocytic MDSCs, which Rieber and colleagues did not investigate, may also be 
capable of suppressing Th17 cell proliferation. This is supported by our finding that 
monocytic MDSCs are also positively correlated with FEV1 % predicted in CF. With regard 
to the positive association we saw between MDSCs and FEV1 % predicted, Rieber et al. 
(126) suggested that P. aeruginosa is able to induce MDSCs that are in turn able to 
downregulate Th17 responses, thereby reducing IL-17 production and the associated 
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recruitment of damaging neutrophils. This may explain why we did not observe an increase in 
Th17 levels in peripheral blood, as has been shown in the lungs, because MDSCs measured as 
one heterogeneous population are unchanged in CF and are therefore able to keep Th17 cells 
under control. 
While we saw no difference in the proportion of MDSCs between CF and controls, there is a 
switch from a granulocytic to a monocytic MDSC phenotype in CF. The upregulation of 
CD14 on MDSCs may be because of the presence of chronic bacterial infection in people with 
CF, because CD14 is a coreceptor for detection of bacterial LPS.  
Given their association with FEV1 % predicted, NK cells and MSDC could potentially be 
considered useful therapeutic targets, and as suggested previously for peripheral blood T cells 
(310), act as potential surrogate markers of lung function.  
Other innate immune populations that have a major influence on the adaptive immune 
response are antigen presenting cells such as monocytes and DCs. These cells are of particular 
interest because of their ability to directly influence T cell responses, which are known to be 
dysregulated in CF, and because both monocytes and DCs have been reported to normally 
express CFTR (23, 311). While CF monocytes have been reported to have defects in adhesion 
(85), secretion of IL-8, proteinase and elastase (88-90), and complement-mediated 
phagocytosis of pathogens such as P. aeruginosa (92), these studies have all investigated 
monocytes as one heterogeneous population.  
We have shown an overall increase in peripheral blood monocytes in CF with expansion of 
both the ‘classical’ (CD16lo/negCD14hi) and ‘non-classical’ (CD16hiCD14lo) monocyte 
populations. The levels of these cells we recorded in healthy controls were within the range 
reported in the published literature (74). A contributing factor to this expansion, given that CF 
is characterised by a Th2-dominated immune response, could be the Th2 cytokine IL-4 that is 
increased in CF peripheral blood (301), which is known to drive expansion of monocytes 
during Th2 inflammation (332). Classical and non-classical monocytes are able to migrate to 
sites of infection and inflammation via the chemotactic effects of the chemokines CCL2 and 
CX3CL1, respectively (333). Increases in peripheral blood and sputum CCL2 and normal 
levels of peripheral blood CX3CL1 have been reported in CF patients (244, 334). Therefore, it 
would be expected that increased migration of classical monocytes to the lungs would occur 
in CF because of their high expression of CCR2, and consequently a reduction would be seen 
in the periphery. However, given the chronic nature of lung infection and inflammation in CF, 
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it is possible that over time, a high level of these cells also becomes detectable in the 
periphery. Because this population is considered proinflammatory, with the ability to develop 
into both lung macrophages and DCs during inflammation, persistently increased levels of 
these cells and their subsequent trafficking to the lung could be considered harmful to lung 
tissue. 
Although an increase in non-classical monocytes has been reported during several types of 
bacterial infections (74, 335), their role, positive or negative, during these infections is yet to 
be elucidated. Non-classical monocytes have been shown to be potent stimulators of IL-17 
production by T cells (336) and therefore, in CF, expansion of non-classical monocytes could 
be contributing to disease pathogenesis by increasing Th17 differentiation. Although this was 
not detectable in the periphery because we have shown normal levels of Th17, the high Th17 
reported in the CF lung (53, 263, 283) may be as a result of these increased non-classical 
monocytes that are known to home to inflamed tissues (76). In addition to this, this population 
has been shown to preferentially differentiate into alternatively activated ‘M2’ macrophages 
(337), particularly in response to the Th2-associated cytokines IL-4 and IL-13, which in CF 
have been shown to be associated with poorer lung function (103).  
Only one previous study has investigated subsets of peripheral monocytes in CF (244), which 
characterised only two subpopulations based on CD16 and CD14 expression, rather than the 
now commonly accepted three subsets, because it included the ‘intermediate’ 
(CD16intCD14int) population within the ‘classical’ (CD16lo/negCD14hi) and ‘non-classical’ 
(CD16hi CD14lo) populations. Although that study reported an increase in CCL2, a monocyte 
chemoattractant, in the peripheral blood of CF patients, it did not show any changes in the 
levels of the two monocyte populations. However, the study was performed in a much 
younger cohort than that analysed in our study, which could explain the contrasting results if 
the changes are associated with chronic infection and disease progression. 
Despite this possibility, the changes in classical and non-classical monocyte subsets in 
peripheral blood that we observed were not associated with any clinical variable we analysed, 
including FEV1 % predicted. Understanding the role of individual monocyte subpopulations 
in disease states is an emerging area of research, with controversy still surrounding the 
functional roles of each subset, as discussed in section 2.2.1. While we and others have 
demonstrated an expansion of monocytes in CF peripheral blood, more detailed analyses of 
the function of individual subsets in CF are required to determine their specific role, if any, in 
CF pathogenesis. 
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DCs are particularly important during immune responses because they are uniquely able to 
present antigen to and stimulate naïve T cells. We have shown for the first time that there is 
an increase in peripheral blood DCs in CF patients. Our method of DC identification did not 
allow us to differentiate between specific dendritic cell subsets, because it was based upon the 
lack of expression of lineage-specific markers such as CD3, NKP46, CD56, CD14 and CD16. 
During infection, DCs home towards the lymph nodes to present processed antigen to T cells 
to elicit an immune response against invading pathogens. It would therefore be expected that 
peripheral DC levels would be decreased in CF because of the presence of chronic lung 
infection. However, under inflammatory conditions classical monocytes, which we have also 
shown to be increased, are able to differentiate into DCs, which may explain the observed 
increase in peripheral blood DCs. 
Many of the studies investigating DCs in CF use mouse models, and have demonstrated a 
downregulation of costimulatory molecules CD40, CD80 and CD86, reduced maturation 
capacity and reduced expression of genes associated with membrane structure and lipid 
metabolism in DCs (23, 114-118), particularly in response to specific pathogens such as P. 
aeruginosa (23, 117) and B. cepacia complex (118). However, the role of DCs in CF lung 
disease has not been fully elucidated. In a mouse model of P. aeruginosa infection, DCs were 
found to be involved in the polarisation of T cells towards a Th2 phenotype (330), which may 
suggest that increased levels of DCs could be contributing to the detrimental Th2 bias in CF. 
It has also been shown using a mouse model that after exposure to fungal antigens, DCs 
experience an influx of Ca2+ that allows production of IL-2, which in turn controls Th17 
responses (338). Because defective CFTR is known to affect Ca2+ signalling in CF cells, it 
could be suggested that increased levels of DCs with an altered capacity to control Th17 
differentiation may also be contributing to CF pathogenesis. Further studies investigating 
human DC populations are required to confirm whether similar events are occurring in people 
with CF. However, because, as was seen for monocytes, altered DC proportions did not 
correlate with any clinical parameters analysed including FEV1 % predicted, they may not 
directly influence CF disease pathology. 
Analysis of such a wide range of immune cell subsets produced a large amount of data, 
meaning that bioinformatic techniques were particularly useful to assist the analysis. This 
analysis of these data allowed the identification and visualisation of patterns of changes in the 
immune cells of interest. Firstly, identification of relationships between study participants was 
possible using hierarchical clustering tools, which identified a clear divide between CF 
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patients and healthy controls. This discrete clustering of the CF and healthy control groups 
was most distinct when only clinically stable patients were included in the analysis, 
suggesting a distinct innate immune cell phenotype in CF patients compared with healthy 
controls. Secondly, it allowed the identification of relationships between individual cell 
populations and consequently, whether changes in these populations could be associated. For 
instance, the shifts toward CD14+ MDSCs and CD56hi (cytotoxic) NK cells were linked, 
possibly indicating that these both change in response to infection, given that CD14 is a 
coreceptor for detection of bacterial LPS and CD56hi NKs produce inflammatory cytokines. 
Interestingly, we found that changes in classical monocytes and intermediate monocytes were 
more closely related to each other than to those in non-classical monocytes. This is in contrast 
to the ongoing debate suggesting that intermediate monocytes are more closely linked to non-
classical monocytes (74) than classical monocytes. 
The main strength of this study is that it investigated a wide range of peripheral innate 
immune cells and their subsets within one analysis. While we did not include neutrophils in 
our analyses this population has been extensively studied in CF. Our study also investigated 
only the proportions of these immune cells and did not assess their functions. Understanding 
function in addition to proportion will provide a more detailed picture of CF innate immune 
dysfunction. Also, while investigating these cells in the periphery has its advantages, also 
assessing their levels in the lungs and lymph nodes would provide a more complete picture. 
In conclusion, this study has shown decreased peripheral levels of NK cells with a switch 
from a CD56int to CD56hi phenotype, an increase in classical (CD16lo/negCD14hi) and non-
classical (CD16hi CD14lo) monocytes, an increase in dendritic cells and lastly a switch from 
CD14– granulocytic to CD14+ monocytic MDSCs. A negative correlation was also seen 
between CD56hi NK cells and FEV1 % predicted while a positive correlation was seen 
between CD56int NK, CD14+ MDSCs, CD14– MDSCs and FEV1 % predicted. This provides 
new information about innate immune cells in CF, and the bioinformatic analysis also allowed 
the identification of a broad CF immune cell phenotype. This study demonstrates again that 
peripheral immune cell subsets can reflect lung pathology in CF. However, further research is 
required to determine any prognostic value of these measurements in predicting the 
progression of CF-related lung disease. NK and MDSC subsets, given their relationship with 
FEV1 % predicted, may also prove to be useful therapeutic targets, although further studies 
are required to confirm this. Given the widespread dysregulation of the innate immune 
response in CF, correction of this could, in addition to the traditional lung-based outcomes 
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such as increased lung function, reduced exacerbation and infection, also be an important 
marker of the efficacy of new CF therapeutics. 
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CHAPTER 6 
RT–qPCR Analysis of Peripheral Blood CD4+ T Cell Subset Related Markers 
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6.1 Introduction 
Cystic fibrosis is characterized primarily by chronic infection and inflammation of the lungs 
but the role of the immune system, particularly the adaptive immune response, is yet to be 
fully elucidated. Dysfunctional CFTR has been shown to directly lead to aberrant T cell 
responses in CF (22) via increased nuclear localization of the transcription factor NFAT, 
which leads to increased production of Th2-assoiciated cytokines. Because NFAT activation 
has been shown to be altered as a result of dysfunctional CFTR and because NFAT is 
associated with other T cell subset transcriptional regulators (339), the possibility arises that 
transcriptional regulation of T cell function may be affected at many points. The CF immune 
response is also known to be hyperinflammatory, but the contribution of CD4+ T cells to this 
state is as yet unclear. 
Investigation of transcription factors at a cellular level is problematic because the proteins are 
generally expressed at very low levels. The most practical approach for assessing their role in 
CD4+ T cell dysregulation is through analysis of gene expression, which provides much 
greater sensitivity and allows for detection of a large range of markers. While differentiation 
of CD4+ T cells into specific subsets is controlled by many transcriptional regulators, many 
subsets have a primary regulator (see Figure 1). In order to investigate transcriptional 
regulation of CD4+ T cell subsets we used RT–qPCR to analyse the level of expression of the 
transcription factors T-BET, GATA3, c-REL, FOXP3, STAT3, c-MAF and AHR in isolated 
CD4+ T cells. This allowed identification of transcription factors involved in differentiation of 
Th1, Th2, Th17, nTreg, iTreg, IL-10+ Tr1, and TGF+ Th3 cells, respectively. 
To investigate the role of CD4+ T cells in the hyperinflammatory response we also 
investigated gene expression of inflammatory and anti-inflammatory markers such as TNF, 
IL-6 and peroxisome proliferator activated receptor (PPAR). TNF and IL-6 are 
proinflammatory cytokines while PPAR is an anti-inflammatory transcription factor. 
Paraoxonase 2 (PON2), an enzyme that can degrade a key P. aeruginosa signalling molecule 
and expression of which is known to be correlated with that of PPAR in BAL cells of CF 
patients (340), was also investigated. 
Lastly, we have previously shown alterations in the levels of the homing markers, CXCR3, 
CCR4 and CCR6, on CD4+ and Treg cells using flow cytometry. We therefore also assessed 
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the level of gene expression of these markers to further clarify whether dysregulation of these 
markers is present at the mRNA level. 
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6.2 Materials and Methods 
6.2.1 Isolation of CD4+ T Cells from PBMC 
Fresh and frozen PBMC were used for isolation of CD4+ T cells. CD4+ cells were isolated 
using the EasySep Human CD4+ T Cell Isolation Kit (Stemcell Technologies, Tullamarine, 
VIC, Australia) according to the manufacturer’s instructions. Briefly, cells were suspended in 
a 12  15 mm polystyrene tube at a concentration of 5  107 cells/mL in cell sorting medium 
containing PBS, 2% FCS and 1mM EDTA. Cells were then treated with 100 g/mL DNase 
(Stemcell Technologies) for 15 min at room temperature. EasySep Human CD4+ T cell 
enrichment cocktail was added at 50 L/mL for 10 min at room temperature followed by 
EasySep D Magnetic Particles at 100 g/mL for 5 min at room temperature. The cell 
suspension volume was increased to 2.5 mL with cell sorting medium, mixed well, and then 
placed in an EasySep Magnet for 5 min at room temperature. The negatively selected CD4+ 
cells were then decanted ready for use. The purity of the CD4+ cells ranged between 93–97%, 
and a representative example of the results is shown in Figure 13. 
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Fig. 13. Histograms illustrating CD4+ cell purity obtained using the CD4+ isolation 
technique. ‘A1’ and ‘B1’ shows gating of the main cell populations of unsorted and CD4+ 
sorted PBMC respectively. ‘A2’ and ‘B2’ histograms show percent of CD4 positive and 
negative cells in unsorted and CD4+ sorted cells respectively. Original data. 
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6.2.2 RNA Extraction and DNase Treatment 
RNA was extracted using the ReliaPrep RNA Cell Miniprep System (Promega, Alexandria, 
NSW, Australia) according to the manufacturer’s instructions. Briefly, 5  105 – 2  106 cells 
were washed with 1 PBS at 300  g for 5 min. To the cell pellet 250 L BL + TG buffer (as 
detailed in appendix 1.4) was added, the tube vortexed and left for 3 min. Then, 85 L of 
isopropanol was added, tube vortexed, and the sample was transferred to a ReliaPrep Mini 
Column. The column was centrifuged at maximum speed (20,800  g) for 1 min at room 
temperature and supernatant discarded. Bound RNA was washed with 500 L RNA Wash 
Solution, column centrifuged at maximum speed for 1 min at room temperature and the wash 
solution discarded, after which 30 L DNAse I mixture was added directly to the membrane 
and column incubated for 15 min at room temperature. Column was then washed successively 
with 200 L Column Wash Solution, 500 L RNA Wash Solution, 500 L RNA Wash 
Solution. RNA was eluted in water by centrifuging at maximum speed at room temperature. 
The eluted RNA was transferred onto the membrane and column re-centrifuged to increase 
the concentration of RNA released from the column. 
6.2.3 cDNA Synthesis 
cDNA was synthesised using the Transcriptor First Strand cDNA Synthesis Kit (Roche 
Diagnostics, Castle Hill, NSW, Australia) according to the manufacturer’s instructions. 
Briefly, a 10 L reaction was prepared containing 1 L of anchored-oligo(dT)18, primer (50 
pmol/L), water and DNase treated RNA (172.8 ng). The template–primer mixture was 
denatured by heating in a thermal block cycler with a heated lid at 65 C for 10 min. The 
reaction was made up to 20 L by the addition of 4 L of Transcriptor Reverse Transcriptase 
Reaction Buffer (5 concentrate), 0.5 L of Protector RNase Inhibitor (40 U/L), 2 L of 
deoxynucleotide mix (10 mM each) and 0.5 L of Transcriptor Reverse Transcriptase (20 
U/L). The 20 L reaction was incubated in a thermal block cycler with heated lid at 50 C 
for 60 min and the Transcriptor Reverse Transcriptase subsequently inactivated by heating at 
85 C for 5 min. The reaction was cooled to 4 C and samples were stored at –80 C. 
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6.2.4 Primer Design 
All primers, except for those used to amplify AHR, were either designed using Primer 4 based 
on available sequences (http://www.ncbi.nlm.nih.gov) or were previously published and were 
synthesised by Geneworks (Thebarton, SA, Australia). The primers targeting AHR were 
designed and synthesised by Qiagen (Melbourne, VIC, Australia). Primers used in this study 
are detailed in Table 19. Primer specificity was confirmed via melt curve analysis and 
products run on agarose gels to ensure correct band size. 
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Table 19. Primer sequences for RT–qPCR analysis. 
Target Role Forward Primer Reverse Primer Source 
RPL19 Reference gene GCGGATTCTCATGGAACACA GGTCAGCCAGGAGCTTCTTG Jubb et al. (341) 
T-BET Major transcriptional regulator of Th1 lineage GATGCGCCAGGAAGTTTCAT GCACAATCATCTGGGTCACATT Vale-Pereira et al. (342) 
GATA3 Major transcriptional regulator of Th2 lineage TCCTGTGCGAACTGTCA TCTGGTCTGGATGCCTT Refaat et al. (343) 
c-MAF Major transcriptional regulator of Tr1 lineage 
Involved in IL-4 production 
CCGCATCATCAGCCA GCGCGTAGCCATCGA Li et al. (344) 
c-REL Major transcriptional regulator of nTreg lineage 
Involved in IL-2, IL-3, IFN and GM-CSF production by T 
cells 
ATCATGCCTCAATGG TTGTATTGCCTGAGC This study 
AHR Major transcriptional regulator of Tr1 lineage and iTreg 
Involved in Treg/Th17 balance 
Sequence unknown Sequence unknown Qiagen 
FOXP3 Provides cells with suppressive function 
Marker of T regulatory cells 
GAAACAGCACATTCC ATGGCCCAGCGGATG Burgler et al. (345) 
STAT3 Major transcriptional regulator of Th17 lineage GACGTGTCTGGTTGAGCTCAGG CACAGAAACTCTGATCAGCTGAGG This study 
PPARg Anti-inflammatory transcription factor AGCTGAACCACCCTGAGTCC TCATGTCTGTCTCCGTCTTCTTG Griffin et al. (340) 
PON2 Degrades a key P. aeruginosa signalling molecule GCCAACAATGGGTCTGTTCTCC CAGCTTCCCATCATACACTGAGGC Griffin et al. (340) 
TNF Inflammation GGTGCCATCAGAGGG GGGCAGCCTTGGCCC This study 
IL-6 Inflammation AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC This study 
CXCR3 Chemokine receptor preferentially expressed on Th1 cells CTCCACCTAGCTGTAGCAGA AGGAAGATGAAGTCTGGGAG This study 
CCR4 Chemokine receptor preferentially expressed on Th2 cells GAAGAAGAACAAGGCGGTGAAGAT ATGGTGGACTGCGTGTAAGATGAG This study 
CCR6 Chemokine receptor preferentially expressed on Th17 cells GCCATCCGTGTAATCATAGCTGTG CGTTATCTGCGGTCTCACTGGTC This study 
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6.2.5 RT–qPCR Data Acquisition 
RT–qPCR data acquisition was performed using a Light Cycler 480 (Roche Diagnostics, Castle Hill, NSW, Australia). The conditions used for 
the Light Cycler 480 analysis are listed in Table 20.  
 
Table 20. Roche Light Cycler 480 run conditions for RT–qPCR analysis. 
 
 
Program Cycles Analysis Mode Target (C) Acquisition mode Hold Ramp Rate Acquisition 
Denature 1 None 95 – 5 min 4.8 – 
        
PCR 40 Quantification 95 – 10 s 4.8 – 
   60 – 10 s 2.5 – 
   72 Single 30 s 4.8 – 
        
Melt 1 Melting Curves 95 – 10 s 4.8 – 
   58 – 1 s 2.5 – 
   95 Continuous – 0.11 5 
        
Cool 1 None 40 – 5 min 2.5 – 
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6.2.6 Data Analysis 
Data analysis was performed on the LightCycler480 using the second derivative maximum 
method. From the extracted data, mRNA expression was calculated relative to the reference 
gene RPL19 which is commonly used for gene expression analysis in CD4 T cells (346, 347). 
Relative mRNA was calculated using the following formula developed by Livak and 
Schmittgen (348): 
PCR efficiency of target gene (CT control sample – CT patient sample) 
            ----------------------------------------------------------------------------------------- 
PCR efficiency of reference gene (CT control sample – CT patient sample) 
 
All data were analysed using GraphPad Prism Version 6 (GraphPad Software). 
Nonparametric tests (Mann–Whitney U and Kruskal–Wallis) were applied to the data to 
investigate the differences between groups. To determine correlations between clinical 
parameters and subset percentages a nonparametric Spearman correlation was performed. All 
P values < 0.05 were considered significant. 
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6.3 Results 
6.3.1 Comparison between CF and Control Groups 
There was no significant difference in median age or sex distribution between the control and 
CF groups. The comparison of the expression of mRNA for T cell subset and inflammation 
related markers relative to the reference gene RPL19 is shown in Table 21. TNF expression 
was increased (P = 0.023) while c-REL (required for nTreg differentiation) and T-BET 
(required for Th1 differentiation) expression were decreased (P = 0.006 and 0.017 
respectively) in CF patients compared with healthy controls. There were no differences 
between CF patients and healthy controls in the expression of PPAR, PON2, CCR4, CCR6, 
IL-6, FOXP3, GATA3, STAT3 or AHR although CXCR3 (Th1-associated homing marker) and 
c-MAF (required for Tr1 differentiation) were trending towards being decreased in CF 
compared with healthy controls (P = 0.08 and 0.06, respectively). 
6.3.2 Comparisons within the CF Cohort 
We next investigated any important associations between the expression of the measured 
genes and clinical parameters within the CF group, as described in Chapter 2. Investigating 
those with (n = 3) or without (n = 15) current A. fumigatus infection and those with (n = 16) 
or without (n = 1) current treatment with any antimicrobial was not possible given the small 
sizes of one of the groups. No associations were found between the expression of any of the 
measured genes and any clinical parameters. However, expression of many of the genes 
investigated were found to be correlated with each other, as indicated in Table 22, with the 
exception of c-REL (required for nTreg differentiation) and c-MAF (required for Tr1 
differentiation), which appeared to be quite independent. 
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Table 21. Comparison of the relative mRNA expression of immune-related markers in 
CD4+ cells in control and CF groups 
P values indicating significant differences are shown in bold. 
 Control CF P value 
N 16 10  
Age median (range) 28 (23–54) 25.5 (19–55) 0.32 
Sex male (%) 6 (37.5%) 5 (50%)  
Relative mRNA Expression    
TNF median (range) 1.6050 (0.7819–6.3420) 3.0770 (0.9395–11.2000) 0.023 
PPAR median (range) 0.0321 (0.0094–0.1012) 0.0611 (0.0030–0.2449) 0.33 
PON2 median (range) 0.1024 (0.0439–0.2432) 0.1253 (0.0127–0.5783) 0.48 
CCR4 median (range) 0.0369 (0.0077–0.1523) 0.0507 (0.0031–0.1941) 0.59 
IL-6 median (range) 0.0130 (0.0069–0.04000) 0.0127 (0.0035–0.0271) 0.65 
c-REL median (range) 0.0611 (0.0301–0.1107) 0.0412 (0.02936–0.0554) 0.006 
FOXP3 median (range) 0.0034 (0.0015–0.0082) 0.0027 (0.0008–0.0048) 0.15 
T-BET median (range) 0.0064 (0.0016–0.0157) 0.0029 (0.0002–0.0078) 0.017 
GATA3 median (range) 0.0057 (0.0039–0.0093) 0.0061 (0.0033–0.0178) 0.91 
STAT3 median (range) 0.0299 (0.0131–0.1026) 0.0244 (0.0035–0.0474) 0.56 
CXCR3 median (range) 0.0063 (0.0029–0.0137) 0.0044 (0.0019–0.0073) 0.08 
c-MAF median (range) 0.0003 (0.0001–0.0009) 0.0002 (0.00002–0.0007) 0.06 
AHR median (range) 0.0047 (0.0015–0.0167) 0.0060 (0.0033–0.01365) 0.59 
CCR6 median (range) 0.0367 (0.0066–0.1539) 0.0387 (0.0013–0.1044) 0.99 
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Table 22. Relationship between expression CD4+ subset transcriptional regulators, chemokine receptors and inflammatory markers in 
CD4+ T cells 
 
All figures displayed are P values indicating the significance of the relationship between genes. P values indicating significant differences are 
shown in bold 
 TNF PPAR PON2 CCR4 IL-6 c-REL FOXP3 T-BET GATA3 STAT3 CXCR3 c-MAF AHR CCR6 
TNF – 0.02 0.007 0.02 0.23 0.39 0.01 0.13 0.003 0.20 0.21 0.98 0.009 0.28 
PPAR 0.02 – 5.5x10-6 4.9x10-5 0.004 0.07 0.001 0.03 2.1x10-4 0.006 0.04 0.41 0.03 0.02 
PON2 0.007 5.5x10-6 – 1.1x10-4 0.01 0.09 3.4x10-4 0.03 3.5x10-4 0.02 0.03 0.41 0.02 0.03 
CCR4 0.02 4.9 x10-4 1.1x10-4 – 0.001 0.04 0.002 0.04 0.001 0.001 0.01 0.36 0.04 0.003 
IL-6 0.23 0.004 0.01 0.001 – 0.02 0.02 0.12 0.02 4.9x10-5 0.07 0.29 0.23 0.001 
c-REL 0.39 0.07 0.09 0.04 0.02 – 0.08 0.79 0.08 0.06 0.08 0.31 0.89 0.14 
FOXP3 0.01 0.001 3.4x10-4 0.002 0.02 0.08 – 0.03 2.1x10-4 0.04 0.09 0.55 0.04 0.11 
T-BET 0.13 0.03 0.03 0.04 0.12 0.79 0.03 – 0.08 0.09 0.52 0.25 0.08 0.11 
GATA3 0.003 2.1x10-4 3.5x10-4 0.001 0.02 0.08 2.1x10-4 0.08 – 0.03 0.08 0.89 0.01 0.07 
STAT3 0.20 0.006 0.02 0.001 4.9x10-5 0.06 0.04 0.09 0.03 – 0.04 0.34 0.17 2.1x10-5 
CXCR3 0.21 0.04 0.03 0.01 0.07 0.08 0.09 0.52 0.08 0.04 – 0.42 0.11 0.02 
c-MAF 0.98 0.41 0.41 0.36 0.29 0.31 0.55 0.25 0.89 0.34 0.42 – 0.78 0.29 
AHR 0.009 0.03 0.02 0.04 0.23 0.89 0.04 0.08 0.01 0.17 0.11 0.78 – 0.14 
CCR6 0.28 0.02 0.03 0.003 0.001 0.14 0.11 0.11 0.07 2.1x10-5 0.02 0.29 0.14 – 
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6.4 Discussion 
We have shown for the first time that c-REL (required for nTreg differentiation) and T-BET 
(required for Th1 differentiation) gene expression is decreased while TNF gene expression is 
increased in peripheral blood CD4+ T cells in CF. While a Th2 and Th17 bias in CF has been 
widely reported, few studies have investigated expression of the key transcriptional regulators 
of CD4+ T cell subsets, and many studies involving immune cells and their markers have 
focussed on the lungs rather than the periphery. 
The transcription factor c-REL is known to control the differentiation of natural Tregs (nTreg) 
but is not essential for the development of iTregs (189). Therefore, decreased c-REL 
expression could suggest that nTregs are decreased in CF, but because we did not see reduced 
Treg levels in our previous flow cytometric analyses where nTregs and iTreg were measured 
as one population, a compensatory effect could be occurring whereby there are increases in 
peripherally induced iTregs. Secondly, c-REL is also known to be essential for the generation 
of IL-2, IL-3, IFN and GMCSF by T cells (349). Production of both IFN and GMCSF has 
been shown to be decreased in CF lungs and peripheral blood (262, 301) and to be correlated 
with worse outcomes in response to common CF pathogens such as P. aeruginosa. Reduced 
c-REL expression by CD4+ T cells could therefore be an underlying factor in the Th2 bias 
seen in CF (51, 53). Indeed, a previous study has shown that c-REL promotes Th1 and Th17 
responses during infection with the pathogen Leishmania major (350). 
In addition to a decrease in c-REL expression, we also saw a decrease in expression of T-BET, 
the primary transcriptional regulator of the Th1 lineage, and a trend towards decreased 
expression of CXCR3, a Th1 specific marker. These decreases again could be contributing 
factors in the Th2 dominated immune response identified in CF, as seen in the lung (216, 262, 
267) and periphery by us. 
Interestingly, we saw increased levels of TNF expression in CD4+ cells from CF patients. 
Increases in the levels of TNF protein, an inflammatory cytokine, in CF have been reported 
extensively, particularly in the lung and plasma (256, 351-355). However, there have been no 
studies investigating the contribution of CD4+ T cells to TNF production. However, Mueller 
and colleagues have shown that TNF expression is increased in CF lymphocytes as a result of 
the increased nuclear localisation of NFAT caused by mutated CFTR (22), which is consistent 
with our findings. Increased TNF expression may contribute to the hyperinflammatory 
environment characteristic of CF. 
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When considering the relationships between the various immune cell markers it is apparent 
that there is an overarching regulation, because expression of many of the markers is 
correlated. Regulation of only c-MAF (required for Tr1 differentiation) and c-REL (required 
for nTreg differentiation) appears independent of the other markers measured. The strong 
relationships between CD4+ transcriptional regulators and inflammatory markers highlights 
the extent to which changes in the differentiation of one CD4+ subset can affect others. It also 
demonstrates that any action to correct individual dysregulated subsets could have many off-
target effects and suggests that correction of CFTR function may correct much of the immune 
dysfunction seen in people with CF. 
One strength of this study is the investigation of these markers in immune cells in the 
periphery, reducing direct bias caused by chronic infection in the lungs. However, while we 
have investigated the primary transcriptional regulators of CD4+ subsets, there are many 
others that play a role in subset differentiation. Also, given the relatively small numbers in the 
CF group, analysis of the relationships between clinical variables and expression of markers 
resulted in quite small subgroups in which some relationships may not have been detectable. 
In summary, we have shown decreases in expression of the transcription factors c-REL 
(required for nTreg differentiation) and T-BET (required for Th1 differentiation) in CD4+ T 
cells in CF, both of which are involved in the generation of Th1 cells or Th1-related 
cytokines. Peripheral CD4+ T cells were also shown to express increased levels of mRNA for 
the inflammatory cytokine TNF. These changes in gene expression could be contributing 
factors in the dysregulation of the immune response in CF. 
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CHAPTER 7 
Flow Cytometric and RT-qPCR Analysis of Peripheral Blood Immune Cells 
in Carriers of a Mutated Cystic Fibrosis Transmembrane Conductance 
Regulator Gene 
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7.1 Introduction 
Lung damage is the primary cause of morbidity and mortality in CF with inappropriate 
immune responses believed to play a contributing role. We have previously shown changes in 
both innate and adaptive immune cells such as CD4+ T cells, monocytes, DCs, NK cells and 
MDSCs in the peripheral blood of people with CF. However, the role of CFTR in this 
immune dysfunction has yet to be fully elucidated. 
There is limited research, particularly in primary human cells, investigating the direct effects 
of dysfunctional CFTR on the immune response. The presence of inflammation prior to any 
detectable infection has been shown in children with CF (30), with current evidence 
suggesting that CFTR plays a role in neutrophil, macrophage and T cell function. Studies in 
human neutrophils have indicated that CFTR affects microbicidal activity in these cells by 
way of reduced chloride anions that in turn reduces the ability of the phagosome to produce 
hypochlorous acid, a critical component in bacterial killing (96-98), while studies in mice 
have shown a CFTR-mediated activation of NF-B that promotes secretion of 
proinflammatory cytokines (356, 357). Dysfunctional CFTR in human macrophages has also 
been reported to result in reduced microbicidal activity (259) while studies in mouse models 
have indicated that dysfunctional CFTR results directly in increased production of 
proinflammatory cytokines (257, 358, 359). Only one study, using a mouse model, has 
investigated the role of dysfunctional CFTR in T cells. This study demonstrated that CFTR 
directly affects T cell responses, resulting in aberrant cytokine production (22). 
To clarify whether the changes that we have seen in the peripheral immune cells in people 
with CF are mediated by infection and inflammation or by an inherent defect associated with 
CFTR mutations, we investigated these cells in CFTR heterozygotes. CFTR heterozygotes, or 
CF carriers, are those with one normal and one defective CFTR allele, and appear clinically 
normal, although there is evidence to suggest that CFTR carriers are more prone to 
bronchiectasis (360), inflammatory illnesses such as asthma (361) and chronic rhinosinusitis 
(362) and to other conditions including idiopathic chronic pancreatitis (363) and congenital 
bilateral absence of the vas deferens (364). These studies provide further evidence to suggest 
that the immune abnormalities seen in CF patients may, at least in part, be mediated by CFTR 
mutations rather than by chronic infection and inflammation. 
To evaluate the role of CFTR-mediated immune dysfunction in CF we firstly investigated the 
proportions of CD4+ effector and regulatory T cell subsets, monocytes, DCs, NK cells and 
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MDSCs in CFTR carrier PBMC and the expression of the Th1-, Th2- and Th17-associated 
chemokine receptors CXCR3, CCR4 and CCR6 using flow cytometry. Secondly, using RT–
qPCR, we examined the relative mRNA expression of CD4+ subset transcriptional regulators, 
chemokine receptors and inflammatory markers in CD4+ T cells. The results for all these 
parameters in CFTR carrier PBMC were compared with those obtained for healthy controls 
and people with CF. 
7.2 Materials and Methods 
The same analyses described in Chapters 3–5 for CF patients and controls were undertaken 
using PBMC from CFTR carriers. Peripheral blood samples were obtained and PBMC 
isolated as described in Chapter 2. PBMC were analysed to determine proportions of CD4+ 
effector (Th1, Th2, Th17) and regulatory (Treg, Tr1 and Th3) subsets and the expression of 
CXCR3, CCR4 and CCR6 chemokine receptors, as described in Chapters 3 and 4, 
respectively. PBMC were then analysed to determine proportions of monocytes, dendritic 
cells, natural killer cells and myeloid derived suppressor cells, as described in Chapter 5. 
Lastly CD4+ T cells were isolated and analysed for relative mRNA expression of CD4 
transcriptional regulators, chemokine receptors and inflammatory markers, as described in 
Chapter 6. 
These analyses included only adult CF carriers (22–47 years, n = 9–13), adult controls (22–50 
years, n = 15–51) and adult CF patients (19–54 years, n = 10–19). Participant characteristics 
are detailed in appendices 2.1 and 2.2. Of note, 48% of the carrier population carried a DF508 
CFTR mutation.  
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7.3 Results 
7.3.0 Comparison of CF Carriers with Healthy Control and CF Groups 
Flow cytometric and gene expression analyses of CF carrier PBMC revealed that in many 
cases this group appeared similar to CF patients or intermediate between CF patients and 
controls, rather than to healthy controls. Only data for the subsets of interest that differ 
between the three groups are described below, but all subset data from flow cytometric 
analyses of CF carrier PBMC are detailed in Appendix 3. Of note, there were no significant 
differences between the median age and sex distributions of the control, CF carrier and CF 
groups. 
7.3.1 CD4 Effector and Regulatory Subset Analysis 
Analysis of CD4+% and CD4+ effector (Th1, Th2, Th17) and regulatory (FOXP3+ Treg, IL-
10+ Tr1, TGF+ Th3) populations revealed that CF carriers had a higher CD4+% compared 
with people with CF (P = 0.04) (Fig. 14) and a trend toward higher CD4+% compared with 
healthy controls (P = 0.051) (Fig. 14). Proportions of CD4+ effector subsets were unchanged 
in CF carriers compared with both CF and healthy controls (Fig. 14). Proportions of the 
regulatory FOXP3+ Tregs and IL-10+ Tr1 cells were both increased in CF carriers compared 
with healthy controls (P = 0.0004 and P = 0.001 respectively) but only FOXP3+ Tregs were 
increased compared with CF (P = 0.03) (Fig. 15), although IL-10+ Tr1 cells were trending 
toward being higher in CF carriers compared with CF. No difference was seen in the 
proportion of TGF+ Th3 cells between CF carriers and healthy controls although there was a 
trend towards a decrease in CF carriers compared with CF patients (P = 0.08) (Fig. 15). 
However, it must be noted that in this analysis of CD4 effector and regulatory subsets, the 
median age of the CF carriers was significantly greater than that of either CF patients or 
healthy controls (P = 0.018 and P = 0.002 respectively). 
7.3.2 CD4+ and Treg Homing Marker Analysis 
Analysis of memory CD4+ cells expressing the Th1-, Th2- and Th17-associated homing 
markers CXCR3, CCR4 and CCR6 respectively, revealed no changes in the levels of CD4+, 
memory CD4+, CXCR3+CD4+ or CCR4+CD4+ cells in CF carriers compared with either CF 
patients or healthy controls (Fig. 16). However, a significant decrease in CCR6+CD4+ cells (P 
= 0.026) was seen in CF carriers compared with healthy controls (Fig. 16). 
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Examination of Treg cells and their expression of these homing markers revealed a normal 
overall level of Treg cells in CF carriers compared with healthy controls but a decrease in 
memory Tregs (P = 0.026) (Fig. 17). CF carriers also had lower levels of CCR4+Tregs (Th2-
associated, P = 0.039) but normal levels of CXCR3+ Tregs compared with healthy controls 
(Fig. 17). Interestingly, while memory CCR6+Tregs were decreased in CF carriers compared 
with healthy controls (P = 0.023), naïve CCR6+ Tregs were increased compared with the CF 
group (P = 0.036) (Fig. 18). 
7.3.3 Innate Immune Cell Analysis 
All innate immune cell subsets that were measured in CF patients and healthy controls 
(described in Table 15) were assessed in CF carriers but those that did not differ between any 
of the three groups are not discussed below and are detailed in Appendix 3.3. CD14+ and 
CD14– MDSCs were similar in CF carriers compared with both healthy controls and CF 
patients (Fig. 19). DCs showed a trend towards being higher in carriers than in healthy 
controls (P = 0.07) but did not differ significantly from the CF group (Fig. 20). Monocytes 
analysed as a single heterogeneous population were increased in CF carriers compared with 
controls (P = 0.04) but again did not differ from the CF group (Fig. 21). For the individual 
monocyte subsets categorised based on CD14 and CD16 expression, ‘classical’ monocytes 
trended towards being higher in CF carriers compared with healthy controls (P = 0.06) while 
‘non-classical’ monocytes were unchanged; neither population differed significantly from the 
CF group (Fig. 21). Lastly, NK cells assessed as one heterogeneous population based on 
NKP46 and CD16 expression were lower in CF carriers than in healthy controls (P = 0.001) 
but did not differ from the CF group (Fig. 22). When NK cells were divided into 
subpopulations based on CD16 and CD56 expression, CD16hiCD56int (cytotoxic) NKs were 
lower (P = 0.049) while CD16lo/negCD56hi (cytokine-producing) NKs were higher (P = 0.008) 
in CF carriers compared with healthy controls but neither population differed between CF 
carriers and CF patients (Fig. 22). 
7.3.4 Multiexperiment Viewer (MeV) Bioinformatic Analysis of Peripheral 
Innate Immune Cell Subsets 
Multiexperiment Viewer (MeV) was used in order to visualise common trends/patterns 
between the immune profiles of CF patients, carriers and healthy controls. Firstly, all immune 
cell subsets detailed in Fig.19-22 were analysed in all CF patients, carriers and healthy 
controls. A heat map was generated that included only the subsets that differed significantly 
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between controls and CF patients, to allow visualisation of patterns of 
upregulation/downregulation, comparative to the median, between the participant groups. 
(Fig.23). As previously shown (see section 5.3.3) there was a trend towards separate 
clustering of CF patients and controls while the CF carriers showed no distinct clustering 
pattern and were scattered amongst both the CF and control groups. 
Next, in order to further elucidate how the immune cell profile of CF carriers was related to 
healthy controls, a heat map was generated to visualise the significantly different subsets 
(Fig.24). CF carriers tended to cluster separately from healthy controls with a few exceptions. 
A heat map of the significant differences between CF carriers and CF patients was unable to 
be generated as there were no significant differences in innate immune cell subsets between 
these two groups. 
7.3.5 CD4+ T Cell Gene Expression Analysis 
Gene expression analysis of CD4 transcriptional regulators (Table 23) revealed that CF 
carriers differed from healthy controls by having lower expression of c-REL (required for 
nTreg differentiation) and c-MAF (required for Tr1 differentiation) and higher expression of 
AHR (required for Tr1 differentiation). CF carriers also differed from CF patients, with higher 
expression of T-BET (required for Th1 differentiation) and AHR (required for Tr1 
differentiation). No differences were seen between any group for the expression of FOXP3 
and STAT3 or the chemokine receptors CXCR3, CCR4 and CCR6. 
Investigation of expression of the inflammatory cytokines IL-6 and TNF in CF carriers 
showed that IL-6 was lower and TNF expression was higher than in healthy controls but 
neither differed from that in CF patients. 
Expression of PPAR and PON2, which have previously been shown to be correlated in CF 
BAL cells, were found not to differ significantly between any of the groups. 
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Fig. 14. CD4+ effector T cell subset percentages in CF carriers compared with healthy control and CF group. Proportions of CD4+, 
Th1, Th2 and Th17 cells are shown. CD4+ cells were measured as a percent of total cells while Th1 (CD4+IFN+), Th2 (CD4+IL-4+) and 
Th17 (CD4+IL-17+) cells were measured as a percent of CD4+ cells. The significance of differences between populations was assessed using a 
Mann-Whitney U test. Horizontal bars indicate the median.  
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Fig. 15. CD4+ regulatory T cell subset percentages in CF carriers compared with healthy control and CF group. Proportions of FOXP3+ 
Treg (CD4+FoxP3+), IL-10+ Tr1 (CD4+IL-10+), and TGF+ Th3 (CD4+ TGF+) cells are shown. All populations are measured as a percent of 
CD4+ cells. The significance of differences between populations was assessed using a Mann-Whitney U test. Horizontal bars indicate the 
median.  
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Fig. 16. Percentages of CD4+ (total and memory), CCR4+, CCR6+ and CXCR3+ CD4+ T cells in CF carriers compared with healthy control and 
CF group. Proportions of CD4+, CD45RO+CD4+, CXCR3+CD45RO+CD4+, CCR4+CD45RO+CD4+ and CCR6+CD45RO+CD4+ cells are shown. CD4+ 
cells were measured as a percent of total live cells while CD45RO+CD4+, CXCR3+CD45RO+CD4+, CCR4+CD45RO+CD4+ and CCR6+CD45RO+CD4+ 
cells were all measured as a percent of CD4+ cells. The significance of differences between populations was assessed using a Mann-Whitney U test. 
Horizontal bars indicate the median. 
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Fig. 17. Percentages of Tregs (total and memory), CXCR3+ and CCR4+ memory Treg cells in CF carriers compared with healthy 
controls and the CF group. Proportions of Treg, CD45RO+Treg, CXCR3+CD45RO+Treg and CCR4+CD45RO+Treg cells are shown. Treg cells 
were measured as a percent of CD4+ cells while CD45RO+Treg, CXCR3+CD45RO+Treg and CCR4+CD45RO+Treg cells were all measured as a 
percent of Treg cells. Tregs are defined as CD4+CD25+CD127lo. The significance of differences between populations was assessed using a Mann-
Whitney U test. Horizontal bars indicate the median. 
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Fig. 18. Percentages of CCR6+ memory and naïve Treg cells in CF carriers compared with healthy control and CF group. Proportions 
of CCR6+CD45RO+Treg and CCR6+CD45RO–Treg cells are shown. All populations were measured as a percent of Treg cells. Tregs are 
defined as CD4+CD25+CD127lo. The significance of differences between populations was assessed using a Mann-Whitney U test. Horizontal 
bars indicate the median.  
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Fig. 19. Percentages of CD14+/– myeloid derived suppressor cells in CF carriers compared with healthy control and CF group. All 
populations are measured as a percent of total MDSCs (CD3–CD56–NKP46–CX3CR1–CD16+CD11b+). The significance of differences 
between populations was assessed using a Mann-Whitney U test. Horizontal bars indicate the median. 
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Fig. 20. Percentages of dendritic cells in CF carriers compared with healthy control and 
CF group. DC populations (CD3–CD56–NKP46–CD14–CD16–) were measured as a percent of 
CD3– cells. The significance of differences between populations was assessed using a Mann-
Whitney U test. Horizontal bars indicate the median.  
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Fig. 21. Percentages of monocytes and monocyte subsets in CF carriers compared 
with healthy control and CF group. Proportions of monocytes (CD3–CD56–NKP46–
CX3CR1+CD14lo/hiCD16–/+) and of ‘classical’ CD16lo/negCD14hi and ‘non-classical’ 
CD16hiCD14lo monocyte subsets are shown. Monocytes were measured as a percent of 
CD3– cells while ‘classical’ CD16lo/negCD14hi and ‘non-classical’ CD16hiCD14lo monocyte 
subsets were measured as a percent of total monocytes. The significance of differences 
between populations was assessed using a Mann-Whitney U test. Horizontal bars indicate 
the median. 
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Fig. 22. Percentages of natural killer and natural killer cell subsets in CF carriers 
compared with healthy control and CF group. Proportions of NK cells (CD3–
CD56+NKP46+ CD16–/+) and of CD16hiCD56int and CD16lo/negCD56hi NK cell subsets are 
shown. NK cells were measured as a percent of CD3– cells while CD16hiCD56int and 
CD16lo/negCD56hi NK cell subsets were measured as a percent of total NK cells. The 
significance of differences between populations was assessed using a Mann-Whitney U 
test. Horizontal bars indicate the median.  
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Fig. 23. Heat map of significantly different monocyte, natural killer, dendritic and myeloid derived suppressor cell subset percentages 
in CF patients, CF carriers and healthy controls. Raw data were imported in txt. file format to MeV. Data were normalised across rows 
and a nonparametric Kruskal–Wallis test was performed to determine differences in the proportions of each subset between groups. An 
unsupervised clustering analysis (hierarchical clustering) was performed using a nonparametric Spearman rank correlation distance metric and 
average linkage clustering. A heat map expression image was created to visualise results. Rows correspond to the immune cell subsets and 
columns correspond to individual subjects. Black squares indicate unchanged relative expression, green squares indicate down regulated 
relative expression and red squares indicate up regulated relative expression of that variable. 
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Fig. 24. Heat map of significantly different monocyte, natural killer, dendritic and myeloid derived suppressor cell subset percentages 
in CF carriers and healthy controls. Raw data were imported in txt. file format to MeV. Data were normalised across rows and a 
nonparametric Kruskal–Wallis test was performed to determine differences in the proportions of each subset between groups. An 
unsupervised clustering analysis (hierarchical clustering) was performed using a nonparametric Spearman rank correlation distance metric and 
average linkage clustering. A heat map expression image was created to visualise results. Rows correspond to the immune cell subsets and 
columns correspond to individual subjects. Black squares indicate unchanged relative expression, green squares indicate down regulated 
relative expression and red squares indicate up regulated relative expression of that variable. 
  
 
 
 
Table 23. Relative mRNA expression of immune-related markers in CD4+ cells in CF carriers compared with control and CF groups 
P values indicating significant differences are shown in bold
 Control CF Carrier Carrier vs Control 
P value 
Carrier vs CF 
P value 
N 16 10    
Age median (range) 28 (23–54) 25.5 (19–55) 32 (24–48) 0.41 0.23 
Sex male (%) 6 (37.5%) 5 (50%) 4 (36%)   
Relative mRNA Expression      
TNF median (range) 1.6050 (0.7819–6.3420) 3.0770 (0.9395–11.2000) 3.4343 (1.2968–5.7757) 0.001 0.77 
PPAR median (range) 0.0321 (0.0094–0.1012) 0.0611 (0.0030–0.2449) 0.0425 (0.0161–0.1593) 0.47 0.61 
PON2 median (range) 0.1024 (0.0439–0.2432) 0.1253 (0.0127–0.5783) 0.0994 (0.0421–0.3855) 0.72 0.43 
CCR4 median (range) 0.0369 (0.0077–0.1523) 0.0507 (0.0031–0.1941) 0.0637 (0.0245–0.1975) 0.22 0.68 
IL-6 median (range) 0.0130 (0.0069–0.04000) 0.0127 (0.0035–0.0271) 0.0109 (0.0032–0.0145) 0.019 0.13 
c-REL median (range) 0.0611 (0.0301–0.1107) 0.0412 (0.02936–0.0554) 0.0369 (0.0294–0.0537) 0.002 0.23 
FOXP3 median (range) 0.0034 (0.0015–0.0082) 0.0027 (0.0008–0.0048) 0.0032 (0.0018–0.0062) 0.73 0.31 
T-BET median (range) 0.0064 (0.0016–0.0157) 0.0029 (0.0002–0.0078) 0.0071 (0.0048–0.0125) 0.31 0.0005 
GATA3 median (range) 0.0057 (0.0039–0.0093) 0.0061 (0.0033–0.0178) 0.0075 (0.0049–0.0187) 0.06 0.15 
STAT3 median (range) 0.0299 (0.0131–0.1026) 0.0244 (0.0035–0.0474) 0.0301 (0.0108–0.0524) 0.58 0.92 
CXCR3 median (range) 0.0063 (0.0029–0.0137) 0.0044 (0.0019–0.0073) 0.0046 (0.0024–0.0117) 0.39 0.64 
c-MAF median (range) 0.0003 (0.0001–0.0009) 0.0002 (0.00002–0.0007) 0.0001 (0.00002–0.0008) 0.014 0.73 
AHR median (range) 0.0047 (0.0015–0.0167) 0.0060 (0.0033–0.01365) 0.0117 (0.0068–0.0154) 0.003 0.005 
CCR6 median (range) 0.0367 (0.0066–0.1539) 0.0387 (0.0013–0.1044) 0.0387 (0.0092–0.0828) 0.90 0.76 
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7.4 Discussion 
This study is the first to analyse the proportions of peripheral CD4+ effector (Th1, Th2, Th17) 
and regulatory (FOXP3+ Treg, IL-10+ Tr1, TGF-+ Th3) subsets, innate immune populations 
such as monocytes, DCs, NKs and MDSCs, and the gene expression of CD4 transcriptional 
regulators, homing and inflammatory markers in human CFTR heterozygotes (CF carriers). It 
demonstrates for the first time that many peripheral immune cell abnormalities in CF are 
likely to be related to an inherent defect associated with CFTR mutations rather than to 
pulmonary infection and inflammation, because CF heterozygotes/carriers present with an 
immune phenotype that appears, in many aspects, similar to that of CF patients or with an 
intermediate phenotype between that of CF patients and healthy controls, indicating a 
potential CFTR ‘dose effect’. 
While Th1, Th2 and Th17 proportions did not differ significantly between controls, carriers 
and CF, the proportions of FOXP3+ Tregs and IL-10+ Tr1 cells were significantly higher in 
CF carriers compared with those in healthy controls. FOXP3+ Tregs were also significantly 
higher in CF carriers compared with CF patients, while IL-10+ Tr1 cells showed a trend 
towards an increase. This may suggest that while these regulatory cells are increased as a 
result of CFTR mutations, the presence of chronic infection in CF patients (70% chronic P. 
aeruginosa) causes a superimposed reduction of these cells although levels in CF patients are 
still higher than in healthy controls. This is consistent with studies that have shown decreases 
in Tregs in association with CF-related infections such as P. aeruginosa and RSV (217, 365). 
Increases in regulatory cells in CF carriers may also be a contributing factor to the reduced 
severity of influenza infection that has been associated with CFTR heterozygosity (366), 
because Tregs are essential for efficient clearance of this infection (367). Interestingly, TGF-
+ Th3 cells displayed a differing pattern to that of the other regulatory cells, in that this 
population appeared very similar in CF carriers and controls, but was trending towards being 
lower in both than in the CF group. This may suggest that the changes seen in this population 
in CF are indeed related to infection and inflammation rather than specifically to the CFTR 
mutation. 
It must be noted that the median age of the CF carrier group for this analysis was significantly 
higher than that of the CF and control groups. However, studies have shown Tregs decrease 
rather than increase with age (368, 369), suggesting that the difference in age is unlikely to be 
responsible for the observed increases in regulatory populations. 
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With regard to memory CD4+ and Treg cells, CF carriers presented with either a similar 
phenotype to that seen in CF patients or a phenotype intermediate between CF patients and 
controls. Although we saw no significant difference in CXCR3+ (Th1-associated) CD4+ or 
Treg cells in CF carriers compared with either healthy controls or CF patients, the median 
level in carriers was intermediate between those in the other two groups, indicating a potential 
role of CFTR ‘dose’ in changes of this population. 
Interestingly, we saw a significant decrease in both CCR6+ (Th17-associated) CD4+ and Treg 
cells in CF carriers compared with healthy controls, a similar trend to that observed in CF 
patients. This could suggest that either these cells are inherently reduced in the periphery as a 
result of CFTR mutation or potentially that carriers have increased production of Th17-
associated chemoattractants, such as the CCL20 that is produced by human airway epithelial 
cells, as has been shown in CF patients (370), which influences the homing of CCR6+ cells to 
the lungs. Intriguingly, we saw an increase in naïve CCR6+ Treg cells in the blood of CF 
carriers compared with that of CF patients. Potentially, the CFTR mutation leads to an 
increase in the proportion of these Th17-associated naive cells but the chronic infection 
associated with CF may result in their differentiation into effector cells that then home to the 
lungs, where increased levels have been reported in CF (283). 
As seen in CF patients, we see a normal level of CCR4+ CD4+ (Th2-associated) cells in CF 
carriers but a decrease in CCR4+ Treg cells, indicating the potential for a Th2 bias in CF 
carriers because there are fewer Th2-associated regulatory cells able to suppress a normal 
level of Th2-associated effector cells. This may contribute to the increased incidence of 
asthma that has been reported to be associated with CF heterozygosity (361), because asthma 
is a known Th2-associated disease. 
Innate immune cells, like CD4+ cells, also appear to be affected by defective CFTR to varying 
degrees. NK cells in CF carriers, both when measured as one heterogeneous population based 
on NKp46 and CD56 expression and when divided into subpopulations based on CD16 and 
CD56 expression, displayed a very similar phenotype to that in CF patients. NKp46 NK cells 
were decreased and there was a shift from CD56int (cytotoxic) to CD56hi (cytokine-producing) 
NKs compared with healthy controls. NK cells are known to influence adaptive immune 
responses through interaction with antigen presenting cells such as DCs, activation of T cells 
through production of cytokines and chemokines, and by killing T cells (371). A reduction in 
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these cells could therefore have a significant impact on the shape of both the innate and 
adaptive immune response in CF carriers and could be a contributing factor to the increased 
frequency of inflammatory illnesses such as asthma and chronic rhinosinusitis that has been 
associated with CFTR heterozygosity (361, 362). 
Neither CD14+ (monocytic) nor CD14– (granulocytic) MDSCs, highly suppressive innate 
populations, differed significantly in their proportions in CF carriers compared with those in 
healthy controls or CF patients, but showed an intermediate phenotype. However, the median 
percentage for these cell types more closely resembled those of the healthy controls, 
suggesting that infection and inflammation may also contribute to their altered levels in CF 
patients, as suggested by Rieber et al. (126). 
DCs, which are known to express CFTR normally (23) and which are increased in CF, show a 
trend towards being increased in CF carriers compared with healthy controls. DCs are 
professional antigen presenting cells and therefore have great influence over the shape of the 
adaptive immune response. Dysregulation of the adaptive immune response, like the Th2 
Th17 biases seen in CF patients, could be a contributing factor toward the increased incidence 
of illnesses such as bronchiectasis in CF carriers. 
Monocytes, which also act as antigen presenting cells and therefore can have considerable 
influence over the shape of the adaptive immune response, were found to be significantly 
increased in CF carriers compared with healthy controls, and similar to levels in CF patients. 
When individual monocyte populations were analysed, ‘classical’ proinflammatory 
CD16lo/negCD14hi monocytes trended towards being higher in CF carriers compared with 
healthy controls while ‘non-classical’ (more responsive to viral than bacterial infection) 
CD16hiCD14lo monocytes did not differ significantly from either the control or CF groups, 
presenting with an intermediate phenotype. While neither subset was significantly increased, 
an overall increase in these proinflammatory cells could play an important role in 
dysregulation of both the innate and adaptive immune responses in CF carriers. 
Interestingly, when a heat map of the significantly differing innate immune cell subsets 
between CF patients, carriers and healthy controls was generated, there was a lack of distinct 
clustering of the CF carriers. While no clear patterns were present it is clear from the scattered 
clustering that the featurs of some CF carriers resemble those of CF patients while others are 
more like healthy controls. It must also be noted that given the 1 in 25 carrier frequency rate, 
there may be CF carriers within the control population. However, we were unable to identify 
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any factors to explain this observation. When CF carriers were compared individually to 
healthy controls and CF patients, using hierarchical clustering and associated heat map, CF 
carriers’ immune phenotype appeared more like that of CF patients than healthy controls. In 
particular, many of the significantly different subsets identified between CF carriers and 
healthy controls were NK cells. This may indicate that, of the peripheral immune cells, NK 
cells are most greatly affected by defective CFTR. The survival of NK cells is promoted by 
the secretion of IL-15 by bronchial epithelial cells (372) and, given that this cell type is 
known to normally express CFTR, it may be that dysregulation of the production of this 
cytokine by dysfunctioning epithelial cells in CF carriers and CF patients is contributing to a 
reduction of NK cells. Additionally, NK cells can be suppressed by other cells such as 
alveolar macrophages (136), and given that we have shown dysregulation of monocytes in CF 
carriers and patients, this may also be a contributing factor to the reduction in NK cells we see 
in these two groups. 
Interestingly, gene expression of the proinflammatory cytokines TNF and IL-6 in CD4 cells 
of CF carriers was found to be upregulated and downregulated, respectively, compared with 
controls. Consistent with this, TNF production by T cells has been shown to be increased 
because of increased nuclear localisation of NFAT as a consequence of CFTR mutation (22). 
Although IL-6 expression is known to be increased in CF, it is possible that this is due to the 
presence of chronic infection and inflammation and that the effect of CFTR mutation is a 
decreased expression as seen in carriers. IL-6 is also known to downregulate regulatory T 
cells (373), therefore a decrease in IL-6 and subsequently less suppression of Tregs fits with 
the flow cytometric data showing increased Tregs in CF carriers. 
Expression of c-REL, a transcription factor involved in the differentiation of nTregs, was 
found to be decreased in CF carriers compared with healthy controls, and similar to that seen 
in CF patients, while expression of AHR, a transcription factor involved in the differentiation 
of iTreg and IL-10+ Tr1 cells, was upregulated. Therefore, while differentiation of nTregs 
may be decreased, transcriptional regulation of iTregs and IL-10+ Tr1 cells is upregulated, as 
confirmed by the presence of increased iTregs and Tr1 cells analysed by flow cytometry. 
Lastly, while T-BET, a transcription factor involved in the differentiation of Th1 cells, was 
significantly decreased in CF patients, it appeared to be expressed at normal levels in CF 
carriers. This may indicate that the Th2 bias reported in CF is in part related to chronic 
infection and inflammation. 
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A major strength of this study is its novelty: it is the first study to analyse immune cell subsets 
in CF carriers. Another strength is the diverse range of markers investigated in the CF carrier 
population at both cellular and genetic levels. However, functional testing of these subsets 
would provide a more complete picture of the CF carrier immune response. While we have 
shown alterations in the proportions of several immune cell populations in CF carriers, we 
have not investigated the level or function of CFTR in these cells. However, a study by Sorio 
et al. (311) investigating primary monocytes from CF carriers has shown that they have 
decreased CFTR function compared with those of healthy controls; it is likely that similar 
effects would be seen in other immune cells, particularly those also known to normally 
express CFTR such as DCs and lymphocytes. Lastly, we did not genotype our healthy control 
population and therefore the possibility exists that some CF carriers may be present within the 
control population, although given the carrier rate of 1 in 25, this would likely be limited to a 
maximum of one or two individuals. 
In summary, these results suggest that CF carriers experience adaptive and innate immune 
dysfunction that in many cases is similar to that of CF patients or intermediate between CF 
patients and healthy controls. This may suggest that CFTR heterozygosity may cause subtle 
changes that are detectable in individual immune subsets, potentially influencing the 
susceptibility of carriers to development of a number of disorders that research is only just 
beginning to identify. Further research involving CF carriers is required to determine the full 
extent of the clinical consequences of CFTR heterozygosity. Given that 1 in 25 people in 
Australia are CF carriers, this could have widespread impact. 
This study also demonstrates that defective CFTR may play a much larger role in CF immune 
pathogenesis than research has previously indicated. In particular, NK cells appear the most 
greatly affected by defective CFTR. Further investigation into the functional capacity of these 
immune cells may also lead to the identification of potential therapeutic targets for CF. 
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CHAPTER 8 
General Discussion  
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Lung infection is the primary cause of morbidity and mortality in CF. There is an ongoing 
debate as to whether infection or inflammation occurs first in the lungs of people with CF as 
opposed to inflammation being strictly a consequence of infection. The conventional theory 
(Fig. 25) proposes that defective CFTR results in an accumulation of mucus that promotes 
infection and then consequently inflammation that is damaging to the lungs. However studies 
are emerging that have shown increased levels of neutrophils in BALF from young CF 
patients without detectable infection (30, 31) as well as increased macrophages in CF foetal 
lungs, although there is also evidence to suggest that neutrophil levels are normal in BALF 
from ‘infection-naïve’ CF children (41). However, the evidence (256, 257, 356, 374-376) to 
support an inherently proinflammatory immune state in CF is strong, suggesting that defective 
CFTR results directly in both an increase of lung-damaging proinflammatory immune cells 
and in an accumulation of mucus, and that infection simply exacerbates these (Fig. 25). Our 
research also supports this concept as we have shown alterations in levels of both innate and 
adaptive immune cells in CF carriers who do not experience any serious infection such as 
those seen in people with CF disease. This demonstrates the important role CFTR plays in 
maintaining appropriate immune cell levels, but leaves open the question of how their 
function may also be altered. Current knowledge about innate and adaptive immune cells in 
CF patients and carriers is summarised in Table 24. 
  
 Table 24. A summary of the known alterations in innate and adaptive immune cells in CF carriers and patients.
Cell Type Alteration in CF Carriers Reference Alteration in CF Reference 
Neutrophils 
Reduced apoptosis (377) Increased pulmonary levels (100) 
  Decreased microbicidal activity (96-98) 
  Reduced phagocytic capacity (99) 
  Increased elastase secretion (251) 
  Enhanced chemotaxis (252) 
  Reduced apoptosis (253, 254) 
  Altered cytokine production (255) 
Macrophages 
Increased pulmonary levels (366) Increased pulmonary levels (102) 
  Altered cytokine production (102, 257) 
  Reduced antigen presentation capacity (258) 
Monocytes 
Altered cytokine secretion  (88) Increased ‘classical’ CD14hiCD16lo/neg and ‘non-classical’ 
CD14loCD16hi monocytes 
This study 
Increased peripheral blood levels of monocytes (measured as one heterogeneous 
population) 
This study Reduced phagocytosis (259) 
Trend towards increased ‘classical’ CD14hiCD16lo/neg monocytes This study Increased elastase secretion (90) 
Peripheral blood ‘non-classical’ CD14loCD16hi level intermediary to CF and healthy 
controls 
This study Decreased adhesion (85) 
  Altered cytokine production 
Reduced antigen presentation capacity 
(88) 
(260) 
Dendritic cells 
Trend toward increased levels This study Increased peripheral blood levels This study  
Peripheral blood level intermediary to CF and healthy controls This study Altered membrane structure (23) 
  Delayed differentiation (23, 261) 
  Decreased antigen presentation (114) 
Natural killer cells 
Increased peripheral blood levels of NKs (measured as one heterogeneous 
population) 
This study Decreased peripheral blood levels (138-140), 
This study 
Switch from CD56int to CD56hi NK peripheral blood phenotype  
This study 
Switch from CD56int to CD56hi NK peripheral blood phenotype  This study 
Myeloid derived 
suppressor cells 
Peripheral blood levels of CD14– and CD14+ MDSCs intermediary to CF and healthy 
controls 
This study Switch from CD14– to CD14+ peripheral blood phenotype This study 
T Lymphocytes  
Increased regulatory (FOXP3+ Treg & IL-10+Tr1) cells This study Th2 & Th17 bias  (53, 262), 
This study 
Decreased peripheral blood levels of memory Tregs This study Altered cytokine production (CD4 & CD8) (22, 115, 263) 
Decreased peripheral blood levels of memory Th17 (CCR6) associated CD4+ cells This study Increased peripheral blood levels of regulatory (FOXP3+ Treg, IL-
10+ Tr1, TGF+ Th3) cells  
This study 
Peripheral blood levels of memory Th1 (CXCR3) associated CD4+ & Tregs 
intermediary to CF and healthy controls 
This study Decreased peripheral blood levels of memory Th1 (CXCR3) and 
Th17 (CCR6) associated CD4+ cells 
This study 
Decreased memory Th2 (CCR4) associated Tregs This study Decreased peripheral blood levels of memory Th1 (CXCR3), Th2 
(CCR4), Th17 (CCR6) associated Treg cells 
This study 
B Lymphocytes 
  Altered Immunoglobulin production 
 
(145, 146, 
149, 150) 
 
  Altered differentiation (144) 
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Fig. 25. Traditional versus modern view of CF lung lung disease pathology. ‘A’ represents the traditional view of mucus-mediated lung 
pathology while ‘B’ represents the modern inflammatory cell-mediated view. Figure taken from Rao and Grigg. 
 
A
B
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CFTR has been shown to be expressed by innate immune cell populations such as neutrophils 
(96), monocytes, macrophages (311) and DCs (23) and adaptive immune cells such as 
lymphocytes (22). We investigated a diverse range of innate and adaptive immune cell 
populations in the peripheral blood of people with CF, away from the main site of infection in 
the lungs, to reduce the bias in populations resulting from chronic and acute infections. Our 
analyses have demonstrated that immune dysregulation in CF is widespread, affecting both 
the innate and adaptive immune responses. By including in the analyses CF carriers and 
children with CF, we have also provided evidence to suggest that many of the immune 
abnormalities observed in CF are a result of defective CFTR rather than simply the presence 
of infection. This therefore supports the emerging theory that lung damage in CF is a 
consequence of both CFTR immune dysfunction and of infection rather than being purely 
infection-related. In support of this, we have shown a negative correlation between Th17% in 
peripheral blood and FEV1 % predicted, not only in CF adults but also in paediatric CF 
patients who presented with no detectable infection. This therefore indicates that even prior to 
any infection these cells are inherently damaging to the lungs. In support of this a study by 
Bratcher et al. (378) has also shown that treatment of CFTR monocytes with a CFTR 
corrector results in improved functioning. In addition, Virella-Lowe et al. (379) have shown, 
using CF bronchial epithelial cell lines, that defective CFTR results in altered expression of 
up to 843 genes, indicating an extensive role for CFTR in cellular processes additional to its 
activity as a chloride ion channel. We have also shown that the global immune phenotype of 
CF carriers is closer to that of CF patients than to that of healthy controls, with some features 
indicating an intermediate phenotype possibly related to gene dosage. This intermediate 
phenotype was identified when the median level of an immune cell subset in CF carriers did 
not differ significantly from that of CF patients or healthy controls while controls and CF 
patients differed significantly from each other. This may indicate that, in these intermediate 
cases, possessing just one functional CFTR allele is adequate to result in sufficient immune 
cell levels/function and may suggest why CF carriers do not display the severe clinical 
consequences seen in those with two dysfunctional copies of CFTR. The immune alterations 
we see in the CF carrier population likely provide the basis for the reported increased 
incidences of immune related illnesses such as asthma in this group. However, further studies 
are required to determine the full extent of the effects of immune-related changes on disease 
development in CF carriers and if intervention is required or would be beneficial.  
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We have shown that while there are subtle changes in the adaptive immune responses of 
people with CF, including increased proportions of FOXP3+ Tregs, IL-10+ Tr1 and TGF-+ 
Th3 regulatory cells and decreased proportions of CXCR3+ (Th1-associated), CCR4+ (Th2-
associated) and CCR6+ (Th17-associated) CD4+ and Treg cells, the changes in innate immune 
cells are much more striking. While MeV analyses were performed on adaptive T cell data 
and heat maps generated (data not shown), clear differences like those seen in the innate 
immune cell MeV analyses were not identified, supporting the subtler nature of these changes 
in the adaptive immune cells. Aberrations were seen in all innate immune populations 
measured, including monocytes, DCs, NKs and MDSCs, with the greatest effect being seen in 
NK cells. These innate immune cell types are the first line of defence against pathogens and 
can influence the adaptive response primarily through antigen presentation and secretion of 
cytokines and chemokines. DCs and monocytes/macrophages in particular can have great 
influence over the shape of the adaptive response though antigen presentation. Therefore, the 
changes seen in adaptive CD4+ cell populations may be the result of innate immune cell 
dysfunction, possibly as a direct consequence of CFTR dysfunction, and not only the result of 
mutated CFTR in the T cells themselves. While there are no studies in CF specifically 
investigating the effect of innate immune cell function on adaptive immune responses, there is 
evidence demonstrating inherent CFTR-associated defects in cell types such as macrophages 
(256, 257, 259), monocytes (92) and DCs (23), all of which have considerable influence over 
the shape of the adaptive immune response. In particular, Del Fresno et al. (260) have 
demonstrated impaired antigen presentation capacity in CF monocytes, which could be a 
contributing factor behind the altered levels of adaptive immune cells we recorded. 
However, ours is the first study to indicate such global alterations in CF immune cells. We 
have investigated many of the key cell types in CF, with the exception of neutrophils, 
macrophages, B cells and CD8+ T cells, although evidence suggests that these populations are 
also inherently affected by dysfunctional CTFR. This suggests that, because of the highly 
interrelated nature of the immune system, immune responses in CF are inherently altered all 
the way from the initial innate immune response through to the complex adaptive responses. 
Given the nature of this proposed CFTR-dependent immune dysfunction in CF, even a partial 
correction of CFTR function may decrease inflammation and therefore lung damage in 
patients, irrespective of any reduction in infection. Neutrophils and macrophages were not 
included in our analyses as many studies have previously characterised their role in CF. We 
also did not investigate B cells and CD8+ T cells as the primary focus of our study was the 
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CD4+ T cells and innate immune cells which subsequently influence the CD8+ T cell and B 
cell responses through antigen presentation and T cell-dependent activation (142). However, 
given the minimal research involving B cell responses as well as the dysregulation of T cells 
and innate immune cells that we have shown, this could prove to be an interesting population 
to investigate in the future. In addition, while we have investigated many of the known T cell 
subsets, other minor and more recently described T cell populations such as T follicular 
helper/regulatory cells, NKT cells,  T cells and Th9 cells could be additionally contributing 
to the pathogenesis of CF, as new research has begun to suggest (380-382). For instance, 
while NKT cells have been shown to reduce autoimmune responses in CF they have also been 
shown to contribute to the inflammatory response via production of IL-17, which attracts 
neutrophils and macrophages whose products are damaging to the lungs (382). Th9 cells have 
also been implicated in lung inflammation through exacerbation of allergic inflammation via 
production of IL-9 that promotes mast cell cytokine secretion (381). 
When considering adaptive immune responses in people with CF, a Th2 bias has been 
reported, particularly in response to pathogens such as P. aeruginosa and A. fumigatus (52, 
262). We have identified many immune abnormalities that could be contributing to this 
phenomenon, regardless of infection status. Decreases in CD4+IFN+ (Th1 cells), memory 
CXCR3+ CD4+ (Th1-associated) and Treg cells together with decreases in gene expression of 
T-BET (required for Th1 differentiation) and c-REL (involved in IFN production by T cells), 
all of which are associated with Th1 cells, were recorded. In addition, CCR4+ memory Tregs 
(Th2-associated) were decreased but CCR4+ memory CD4+ cells were not. A previous study 
has also shown that in the presence of high levels of IL-10 (which we found to be increased in 
CF CD4+ cells), DCs tend to prime naïve CD4+ T cells to secrete IL-4, a Th2-associated 
cytokine (383). This Th2 bias is significant because research has shown that Th1-mediated 
immune responses are better for clearance of many pathogens, particularly P. aeruginosa, and 
improved lung function (262). This is also supported by our data that revealed a negative 
correlation between CCR4+ (Th2-associated) memory CD4+ and Treg cells and lung function 
as well as a positive correlation between the CD4+ CXCR3(Th1)/CCR4(Th2) ratio and lung 
function. Therefore, enhancement of Th1-mediated immune responses, which has yet to be 
attempted in CF, could be very advantageous for reducing morbidity and maintaining lung 
function.  
We have also shown that the proportions of both adaptive and innate immune cells including 
Th17, NK cells and MDSCs are correlated with FEV1 % predicted, indicating that both innate 
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and adaptive immune responses play a significant role in CF pathogenesis. This is also the 
first demonstration that peripheral immune cell subsets can reflect lung pathology in CF and 
therefore could be useful surrogate markers of lung function decline. They could also be used 
as a marker of efficacy during therapeutic intervention trials, especially with the emerging 
trend towards the development of targeted CFTR correctors, such as Ivacaftor and Orkambi, 
although these have yet to be validated in relation to correcting, or at least not exacerbating, 
immune function deficits. Our data have demonstrated that NK cells appear most affected by 
CFTR dysfunction, being reduced in both CF patients and carriers, which may indicate that 
therapies focussed on increasing NK cells may be beneficial. While there are studies that have 
aimed to therapeutically increase NK cells for treatment of diseases such as cancer, this is 
logistically difficult because of the low abundance of NK cells. However, researchers have 
been able to expand NK cells ex vivo by stimulation with cytokines and stimulatory cells, and 
then transfuse these back into the body where they can further proliferate in vivo (384). 
Emerging therapies such as this, although designed for other conditions, may be beneficial for 
those with CF. 
It must be noted that nearly all of our adult CF patients are administered antibiotics, mostly 
including the potent anti-inflammatory azithromycin. Corticosteroids are also potent anti-
inflammatories, although very few of our patients are treated with these. However, although 
no correlation was found between any antibiotic/steroid treatment and changes in any immune 
population, it must be considered that the immune phenotype identified in CF patients may be 
affected to some degree by administration of these drugs. In particular, azithromycin has 
previously been shown to affect the expression of NFB (385), which is involved in the 
regulation of many immune processes, particularly in T cells (386). It was therefore important 
to explore all immune markers in CF children and carriers who are rarely if ever treated with 
such drugs. In addition to this, given the extent of immune dysfunction apparent in CF, the 
nature of treatment with immunosuppressants following lung transplantation in CF must be 
reflected upon. It has been shown that CF patients receiving lung transplantation, especially 
those with reduced lung function, have only a 50% survival rate two years post-transplant 
(387) compared with non-CF individuals who have an 87% and 68% survival rate one and 
three years, respectively, post-transplant (388). It is possible that greater understanding of the 
underlying CF immune dysfunction could result in improved treatment regimens following 
lung transplantation being tailored to CF patients. 
 P a g e  | 164 
 
Additionally, it must also be considered that immune dysfunction may be playing a role in 
many common manifestations of CF that have not traditionally been associated with the 
immune response, for instance pancreatitis and diabetes. Pancreatitis has recently been shown 
to be associated with increases in NFAT (389), which is a transcription factor revealed to be 
increased in CF (22). Diabetes is also known to be associated with alterations in immune cell 
chemotaxis, phagocytosis and cytokine production (390) which have all been recognized to be 
affected in CF. However, further investigation would be required to determine the 
involvement, if any, of the immune system dysfunction in these CF-associated manifestations. 
Interestingly, we saw increases in peripheral blood Tregs defined by CD4+FOXP3+ staining 
but no change in CD4+CD25+CD127+ Tregs in CF adults compared with healthy controls. 
This highlights the possibility that, because we did not include the additional CD25 marker in 
the first analysis, other CD4+ populations such as T follicular regulatory and  T cells that 
can express FOXP3 (296, 297) may have been included in our initial analysis. This indicates 
that there are likely to be changes in other minor regulatory populations in CF, which should 
be further investigated. It also indicates that, as suggested by Fazekas de st Groth et al. (199), 
the more detailed subset analysis described in Chapter 4 may be superior to that described in 
Chapter 3 for identifying a homogeneous population of Tregs, especially as it does not require 
permeabilisation of the cells.  
While we have shown abnormalities in the proportions of many immune cell populations we 
have not assessed their function, other than the ability of CD4+ cells to produce their signature 
cytokines after nonspecific stimulation. While initial studies examining the function of some 
cell types such as Tregs (217), monocytes (92), macrophages (259), DCs (114) and 
neutrophils (96-98) have been undertaken in CF patients, there has been no investigation into 
the functionality of more specific subsets within these populations. Given the small numbers 
of some of these subsets and therefore the difficulty of isolating sufficient numbers for 
detailed analysis, assessment of the functionality of these subsets would most likely need to 
be undertaken by identifying functionality-related markers using flow cytometry or through 
high-sensitivity techniques such as RNAseq. However, a disadvantage of this latter technique 
is that gene expression does not always correlate with protein expression (391), as we have 
shown with our data. For example, while the proportion of cells expressing FOXP3 protein 
was increased in CD4+ cells, FOXP3 gene expression was unchanged. 
While the intention of this study was to identify inherent immune defects in people with CF 
and therefore was focused on cells in peripheral blood away from the main site of infection, 
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investigation of the same cells in the lungs at the site of infection and in the lymph nodes at 
the site of antigen presentation may, when combined with functional studies, provide a greater 
overall understanding of immune dysfunction in CF. However, procurement of these types of 
samples is quite difficult and they usually only become available in end-stage disease, which 
would not necessarily be reflective of the whole CF population. Investigation of plasma 
cytokine levels may also be informative, because we have only investigated the specific cell 
types that produce particular cytokines. Measurement of plasma cytokine levels would allow 
us to detect signature cytokines produced by all cell types, including ones we did not 
investigate. 
In conclusion, we have defined, in the greatest detail to date, the immune phenotype of people 
with CF and that of CF carriers. While the dysfunctional immune response is rarely 
acknowledged when the primary manifestations of CF are discussed, this study provides 
evidence that greater importance should be placed on this aspect of CF, particularly as the 
immune response is systemic. Fig. 26 provides an overview of the primary manifestations of 
CF updated to include the findings of this study. The findings of our research suggest that 
many immune abnormalities in CF are indeed associated with CFTR mutation rather than 
being simply the result of the presence of infection and inflammation. The implication of this 
finding could be a move towards a greater focus on treating immune defects in CF in addition 
to targeting infection. It is possible that the wave of therapeutic CFTR correctors currently 
entering the market for treatment of CF could also correct the CF immune response, 
ultimately preserving lung function irrespective of infection status and leading to greater 
quality of life and life expectancy. These findings could therefore be useful as a means of 
long-term monitoring and management of patients that are currently on correctors. 
Furthermore, with the estimated 1 in 25 carrier rate of CF (392), up to one million of the 23+ 
million people in Australia could potentially be affected by a subtle as yet unrecognised 
immune dysfunction, the consequences of which are only just beginning to be uncovered. 
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Fig. 26. The primary manifestations associated with CF. Figure modified from Willacy et 
al. (393). 
 
Immune System
Innate:
- Increased and dysfunctional neutrophils, macrophages and 
monocytes
- Altered MDSC subset proportions
- Decreased NK cells with altered subset proportions
Adaptive:
- Increased dendritic cells
- Increased regulatory T cells
- Biased T cell responses
- Altered homing of T cells
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Future Prospects 
While we have now demonstrated extensive alterations in the immune system of CF carriers, 
it would be valuable to investigate the level and function of CFTR in CF carriers. While a 
small study involving chloride-sweat testing of four CF carriers has shown that they on 
average have 50% functionality of CFTR compared with that of healthy controls (394), it 
would be prudent to confirm this with a greater participant pool involving all CFTR mutation 
classes and using more specific tests for protein channel functionality such as that described 
by Sorio et al. (311) in which immune cells were treated with CFTR stimulants and inhibitors 
whilst membrane potential was measured. In addition, it would be important to determine the 
effect of CFTR correction on the immune system. Normalisation of the immune system would 
confirm a direct role of CFTR dysfunction in dysregulation of the CF immune response. This 
could be undertaken through studying the effects of CFTR correctors, such as Ivacaftor and 
Orkambi, on CF and CF carrier immune cells (in vitro and in vivo) or in cftr knockout mice to 
determine any modulations that occur in the level and function of immune cells. It would also 
be particularly interesting to undertake longitudinal studies not only of CF patients to see how 
these immune populations change over time with progression of the disease, but also of CF 
carriers to see how the levels/function of these cells change not only over time but also in 
relation to the development of any clinical conditions that may not necessarily been associated 
previously with reduced function of CFTR. 
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APPENDICES 
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1. Buffers and Media  
1.1 Complete Culture Media 
RPMI media 
5% Foetal Calf Serum 
1% PenicillinStreptomycin 
1% L-glutamine 
 
1.2 FACS Buffer 
1.5 L 1 Phosphate Buffered Saline 
1.5 g Bovine Serum Albumin 
3 ml 10% Sodium Azide 
 
1.3 Cell Sorting Media 
1 Phosphate Buffered Saline 
2% Foetal Calf Serum 
1mM EDTA 
 
1.4 BL + TG buffer 
Per sample: 
500 L BL buffer 
5L 1 thioglycerol
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2.1 Patient Characteristics: 
2.1.1 CF Adults 
Table 25. Clinical characteristics of adult CF patients  
ABPA: allergic bronchopulmonary aspergillosis; (x): indicates the number of times a patient has provided a sample (i.e AP7(2) indicates that 
this is the second sample provided by AP7) 
 Age Sex Genotype 
(no. of DF508 alleles) 
Infection Chronic P. 
aeruginosa 
infection 
S. aureus 
infection 
A. fumigatus 
infection 
Other 
infection 
Past A. 
fumigatus 
culture 
ABPA 
AP 3(3) 25 N 2 N N N N N N N 
AP 7(2) 23 N 1 Y N Y N Y Y N 
AP 14(2) 21 N 0 Y Y Y N N Y N 
AP 16 31 N 2 Y Y N N N N N 
AP 16(2) 31 N 2 Y Y N N N N N 
AP 17(2) 19 Y 1 Y Y Y N N Y N 
AP 18 38 N 2 Y Y N N N N N 
AP 22 30 N 2 Y N Y N Y N N 
AP 23 24 Y 1 Y N Y Y Y Y N 
AP 9(2) 23 Y 1 Y Y Y N N Y N 
AP 11(3) 54 Y 2 Y Y N N N Y N 
AP 11(4) 55 Y 2 Y Y N Y Y Y N 
AP 18(2) 39 N 2 Y Y Y N Y N N 
AP 20 38 N 2 Y N Y N Y N N 
AP 21(2) 27 Y 1 Y N Y N Y N N 
AP 24 22 Y 0 Y Y N N N N N 
AP 25 27 Y 2 Y Y unknown Y unknown Y Y 
AP 26 52 Y 1 Y N Y N N Y Y 
AP 27 24 N 0 Y Y N N N N N 
AP 28 24 N 2 Y Y Y N unknown N N 
AP 28 (2) 24 N 2 Y Y Y N unknown N N 
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Table 26. Clinical characteristics of adult CF patients  
 
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FEV1: forced expiratory volume in 1 second; (x): 
indicates the number of times a patient has provided a sample (i.e AP7(2) indicates that this is the second sample provided by AP7) 
 
  
 Antibiotics Azithromycin Tobramycin Other 
antibiotics 
Steroids Exacerbating/
Stable 
Total serum 
IgE (kU/L) 
WCC 
(/nL) 
CRP 
(mg/L) 
ESR 
(mm) 
FEV1 % 
predicted 
AP 3(3) N N N N Y Stable – 5.0 0.05 10.0 87.00 
AP 7(2) Y N N Y N Stable 25 15.7 2.50 – 81.98 
AP 14(2) Y Y N Y N Stable – – – – 57.71 
AP 16 Y Y N Y N Exacerbating 74 12.7 – – 54.92 
AP 16(2) Y N N Y N Stable – 7.7 16.60 37.0 – 
AP 17(2) Y Y Y N N Stable – 5.4 2.20 11.0 – 
AP 18 Y N Y Y N Exacerbating 22 6.4 27.10 – 28.15 
AP 22 Y N Y Y N Exacerbating – 7.6 6.20 37.0 42.43 
AP 23 Y Y N Y N Stable 237 3.7 7.30 15.0 63.60 
AP 9(2) Y Y N Y N Stable – 6.1 1.40 5.0 – 
AP 11(3) Y Y Y Y N Stable – 9.0 35.20 59.0 22.99 
AP 11(4) Y Y Y Y N Exacerbating – 5.0 – – – 
AP 18(2) Y Y N N N Stable 30 8.0 19.90 – 57.19 
AP 20 Y N N Y Y Exacerbating – 6.0 23.40 – – 
AP 21(2) Y N N Y N Exacerbating – 8.4 3.40 – 78.43 
AP 24 Y Y Y N N Stable – 5.4 7.00 3.9 – 
AP 25 Y Y N N N Stable 1535 5.3 3.70 6.0 51.92 
AP 26 Y N N Y N Stable – 8.8 1.20 6.0 31.58 
AP 27 Y N N Y N Stable – 5.8 15.90 34.0 38.95 
AP 28 Y Y Y N N Exacerbating – 13.2 8.30 – 54.94 
AP 28 (2) Y Y Y N N Stable – 5.1 1.20 – 57.44 
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2.1.2 CF Children 
 
Table 27. Clinical characteristics of paediatric CF patients  
ABPA: allergic bronchopulmonary aspergillosis  
 Age Sex Genotype 
(no. of DF508 alleles) 
Infection Chronic P. 
aeruginosa 
infection 
S. aureus 
infection 
A. fumigatus 
infection 
Other 
infection 
ABPA 
Ch.P 1 11.0 M 1 Y N N N Y N 
Ch.P 2 5.0 F 0 Y N Y N N N 
Ch.P 3 15.0 F 1 Y N N Y Y N 
Ch.P 4 11.0 F 1 N Y N N N N 
Ch.P 5 12.0 M 2 Y N Y Y N N 
Ch.P 6 14.0 F 1 Y Y N N N N 
Ch.P 7 1.0 F 2 Y N N N Y N 
Ch.P 8 4.0 F 0 N N N N N N 
Ch.P 9 15.0 M 2 Y N Y N Y N 
Ch.P 10 10.0 M 1 Y N N Y Y Y 
Ch.P 11 3.0 F 2 Y N Y N Y N 
Ch.P 12 4.0 F 1 Y N N N Y N 
Ch.P 13 17.0 F 1 Y Y N N Y N 
Ch.P 14 15.0 M 1 N N N N N N 
Ch.P 15 6.0 F 2 Y N Y N N N 
Ch.P 16 11.0 M 2 N N N N N Y 
Ch.P 17 6.0 F 0 Y N Y N Y N 
Ch.P 18 13.0 F 1 Y N N Y Y Y 
Ch.P 19 11.0 F 2 Y N Y N N N 
Ch.P 20 15.0 M 2 N N N N N N 
Ch.P 21 14.0 M 2 Y N N Y Y Y 
Ch.P 22 0.5 F 2 N N N N N N 
Ch.P 23 3.0 F 1 N N N N N N 
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Table 28. Clinical characteristics of paediatric CF patients 
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FEV1: forced expiratory volume in 1 second
 Antibiotics Azithromycin Tobramycin Other 
antibiotics 
Steroids Exacerbating/
Stable 
Total serum 
IgE (kU/L) 
WCC 
(/nL) 
CRP 
(mg/L) 
FEV1 % 
predicted 
Ch.P 1 N N N N N Stable – 5.0 0.0 – 
Ch.P 2 N N N N N Stable – 10.3 0.3 – 
Ch.P 3 N N N N N Stable – – 2.4 – 
Ch.P 4 N N N N N Stable – 5.1 – – 
Ch.P 5 Y N N Y N Stable – 7.0 1.5 97.68 
Ch.P 6 Y Y Y Y N Stable – 15.2 1.6 51.07 
Ch.P 7 N N N N N Stable – 8.0 – – 
Ch.P 8 N N N N N Stable – 8.9 – – 
Ch.P 9 N N N N N Stable – 11.4 – – 
Ch.P 10 Y N N Y Y Stable – 8.4 0.2 65.74 
Ch.P 11 N N N N N Stable – 13.5 2.3 – 
Ch.P 12 N N N N N Stable – 8.6 0.4 – 
Ch.P 13 Y Y Y N N Stable – 9.3 10.6 36.35 
Ch.P 14 N N N N N Stable – 6.3 0.2 103.64 
Ch.P 15 N N N N N Stable – 12.5 0.2 – 
Ch.P 16 N N N N N Stable 2.86 7.1 0.2 – 
Ch.P 17 N N N N N Stable – 8.7 – – 
Ch.P 18 N N N N N Stable 13 8.7 0.2 106.21 
Ch.P 19 N N N N N Stable – – – – 
Ch.P 20 N N N N N Stable – – – 117.56 
Ch.P 21 N N N N Y Stable 17.6 – – 77.69 
Ch.P 22 N N N N N Stable – – – – 
Ch.P 23 N N N N N Stable – – – – 
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2.2 Adult CF Carrier Characteristics: 
 
Table 29. Clinical characteristics of adult CF carriers 
 Age Sex Genotype 
A.Car 1 37 F unknown 
A.Car 2 28 F deltaF508 
A.Car 3 43 M deltaF508 
A.Car 4 41 F unknown 
A.Car 5 44 M deltaF508 
A.Car 6 45 F unknown 
A.Car 7 43 F unknown 
A.Car 8  38 F W1282 
A.Car 9 25 M unknown 
A.Car 10 24 F unknown 
A.Car 11 39 F deltaF508 
A.Car 12 45 F unknown 
A.Car 13 32 M deltaF508 
A.Car 14 31 F deltaF508 
A.Car 15 46 M unknown 
A.Car 16 40 F deltaF508 
A.Car 17 29 F unknown 
A.Car 18 46 F deltaF508 
A.Car 19 48 M deltaF508 
  
3. All flow cytometric data comparing healthy controls, CF carriers and CF patients: 
3.1 CD4+ effector (Th1, Th2, Th17) and regulatory (FOXP3+ Treg, IL-10+ Tr1, TGF-+ Th3) T cell subsets 
Table 30. CD4+ T cell subset percentages in CF carriers compared with control and CF groups 
P values indicating significant differences are shown in bold
d Control Cystic Fibrosis Carrier Carrier vs Control 
P Value 
Carrier vs CF 
P Value 
N  51 20 13   
Age median (range) 22 (18–61) 24 (18–53) 39 (24–45) 0.002 0.018 
Sex male (%) 24 (47%) 12 (60%) 3 (23%)   
CD4+% median (range) 50.40 (29.7–66.0) 48.15 (28.3–66.1) 55.2 (37.6–75.7) 0.051 0.04 
Th1% median (range) 9.6 (3.0–22.4) 10.45 (3.5–24.6) 11.1 (5.25–29.2) 0.45 0.34 
Th2% median (range) 2.6 (0.7–9.8) 2.3 (0.4–8.5) 1.9 (1.19–4.61) 0.60 0.91 
Th1/Th2 ratio median (range) 4.6 (1.3–11.3) 5.15.1  5.1 (1.0–10.4) 4.66 (1.89–20.56) 0.50 0.41 
Th17% median (range) 0.49 (0.15–2.26) 0.52 (0.04–1.98) 0.73 (0.13–1.19) 0.76 0.88 
Treg% median (range) 5.5 (1.8–10.5) 6.46 (4.2–11.4) 8.8 (4.67–14.3) 0.0004 0.03 
Treg/Th17 ratio median (range) 10.6 (2–37) 14.8 (4–441) 12.14 (5.46–102.3) 0.89 0.71 
IL-10+ Tr1% median (range) 1.15 (0.35–2.63) 1.77 (0.41–4.16) 2.74 (0.28–7.97) 0.001 0.08 
TGF- Th3% median (range) 0.022 (0.008–0.19) 0.093 (0.018–0.417) 0.03 (0.005–0.40) 0.3 0.08 
  
3.2 CCR4-, CCR6- and CXCR3-expressing CD4+ T cells and Treg cells 
Table 31. Percentages of CCR4-, CCR6- and CXCR3-expressing CD4+ T cells and Treg cells in CF carriers compared with control and CF  
P values indicating significant differences are shown in bold
 Control CF Carrier Carrier vs Control 
P value 
Carrier vs CF 
P value 
N 15 17 10   
Age median (range) 28 (22–50) 25 (19–54) 34 (22–47) 0.27 0.14 
Sex male (%) 5 (33%) 8 (47%) 3 (30%)   
CD4+ %* median (range) 34.00 (20.40–54.10) 34.60 (21.30–59.30) 40.85 (26.10–56.10) 0.23 0.23 
CD4+RO+ %* median (range) 40.50 (19.90–58.40) 30.80 (15.00–61.00) 32.70 (17.00–55.10) 0.49 0.93 
CD4+RO– %* median (range) 59.50 (41.60–80.10) 69.20 (39.00–85.00) 67.30 (44.90–83.00) 0.49 0.93 
CD4+CXCR3+RO+ %* median (range) 18.40 (4.13–36.40) 13.20 (6.40–24.50) 14.85 (6.25–23.80) 0.10 0.85 
CD4+CXCR3+RO– %* median (range) 2.54 (1.20–12.20) 2.53 (1.25–7.12) 3.14 (0.70–7.06) 0.29 0.44 
CD4+CCR4+RO+ %* median (range) 23.20 (7.90–38.60) 17.90 (9.69–38.30) 18.75 (11.20–39.30) 0.46 0.53 
CD4+CCR4+RO– %* median (range) 1.53 (0.21–5.90) 1.22 (0.19–4.32) 2.34 (0.17–7.77) 0.50 0.29 
CD4+CCR6+RO+ %* median (range) 17.40 (7.43–34.70) 13.40 (2.94–19.10) 10.25 (4.28–26.90) 0.026 0.48 
CD4+CCR6+RO– %* median (range) 0.33 (0.15–1.01) 0.30 (0.07–0.72) 0.44 (0.09–1.33) 0.61 0.13 
Treg %* median (range) 7.33 (4.00–8.91) 7.85 (5.29–16.30) 7.43 (4.83–9.71) 0.95 0.30 
Treg RO+ %* median (range) 57.10 (40.30–77.60) 51.10 (30.40–91.30) 42.80 (35.80–80.00) 0.026 0.54 
Treg RO– %* median (range) 42.90 (22.40–59.70) 48.90 (8.72–69.60) 57.20 (20.00–64.20) 0.026 0.54 
Treg CXCR3+RO+ %* median (range) 17.20 (2.81–30.10) 11.70 (3.30–21.20) 12.25 (4.27–26.40) 0.19 0.90 
Treg CXCR3+RO– %* median (range) 2.74 (1.00–8.14) 3.96 (0.71–7.22) 3.70 (1.40–7.38) 0.26 0.90 
Treg CCR4+RO+ %* median (range) 50.00 (34.10–72.30) 44.90 (21.20–70.80) 40.70 (33.60–77.30) 0.039 0.93 
Treg CCR4+RO– %* median (range) 1.55 (0.53–7.08) 1.96 (0.46–8.76) 3.63 (0.38–12.20) 0.20 0.36 
Treg CCR6+RO+ %* median (range) 33.70 (14.90–48.50) 21.70 (4.20–35.90) 16.15 (7.71–54.90) 0.023 0.64 
Treg CCR6+RO– %* median (range) 0.87 (0.33–2.67) 0.64 (0.12–3.20) 1.36 (0.29–2.48) 0.37 0.036 
CD4+ CD45RO+ CXCR3/CCR4 ratio median (range) 0.82 (0.18–1.51) 0.67 (0.15–1.59) 0.58 (0.34–1.3) 0.18 0.98 
CD4+ CD45RO–  CXCR3/CCR4 ratio median (range) 0.93 (0.39–29.26) 3.03 (0.31–19.35) 1.83 (0.36–40.2) 0.64 0.47 
Treg CD45RO+  CXCR3/CCR4 ratio median (range) 0.32 (0.05–0.62) 0.31 (0.07–0.53) 0.32 (0.12–0.41) 0.53 0.60 
Treg CD45RO–  CXCR3/CCR4 ratio median (range) 1.27 (0.32–7.40) 1.15 (0.23–8.67) 0.92 (0.22–9.2) 0.46 0.57 
CD45RO– Treg/CD4+CCR6+ ratio median (range) 105.70 (42.48–311.3) 159.70 (55.19–382.9) 105.7 (42.5–311.3) 0.09 0.44 
CD45RO+ Treg/CD4+CCR6+ ratio median (range) 2.78 (1.54–8.13) 3.46 (2.17–12.48) 2.78 (1.54–8.13) 0.09 0.60 
  
3.3 Monocyte, natural killer, myeloid derived suppressor and dendritic cell subsets 
Table 32. Monocyte, natural killer, myeloid derived suppressor and dendritic cell subset percentages in CF carriers compared to control and CF 
groups 
P values indicating significant differences are shown in bold 
 Control CF Carrier Carrier vs Control 
P value 
Carrier vs CF 
P value 
N 15 17 10   
Age median (range) 28 (22–50) 25 (19–54) 34 (22–47) 0.27 0.14 
Sex male (%) 5 (33%) 8 (47%) 3 (30%)   
MDSC (% non T and B cells) median (range) 0.44 (0.15–1.72) 0.36 (0.03–1.33) 0.54 (0.07–2.50) 0.72 0.51 
CD14+ MDSC (% non T and B cells) median (range) 0.035 (0.006–0.346) 0.047 (0.001–0.389) 0.05 (0.01–0.25) 0.50 0.98 
CD14+ MDSC (% MDSC) median (range) 8.27 (1.06–25.20) 15.10 (5.56–34.60) 9.68 (4.21–36.30) 0.31 0.19 
CD14– MDSC (% non T and B cells)  median (range) 0.40 (0.14–1.52) 0.23 (0.02–0.99) 0.38 (0.04–2.25) 0.71 0.41 
CD14– MDSC (MDSCs) median (range) 91.00 (74.80–98.80) 83.30 (65.40–92.60) 90.10 (63.70–95.80) 0.30 0.17 
Dendritic Cells (% non T and B cells) median (range) 12.50 (8.66–22.30) 18.90 (6.07–49.80) 14.60 (11.20–31.80) 0.07 0.31 
Monocytes (% non T and B cells) median (range) 34.90 (20.00–56.10) 46.00 (24.60–76.70) 45.80 (29.2–62.7) 0.04 0.63 
CD16hiCD14lo Monocytes (% non T and B cells) median (range) 1.68 (0.49–4.80) 4.50 (0.65–8.37) 2.68 (0.32–4.92) 0.34 0.06 
CD16hiCD14lo Monocytes (% monocytes) median (range) 6.05 (1.24–15.70) 7.65 (1.93–22.90) 6.23 (0.59–13.50) 0.77 0.21 
CD16intCD14int Monocytes (% non T and B cells) median (range) 1.27 (0.51–2.68) 3.04 (1.47–7.04) 1.22 (0.71–3.40) 0.95 0.44 
CD16intCD14int Monocytes (% monocytes) median (range) 4.40 (1.53–6.25) 1.55 (0.59–4.24) 3.20 (1.67–5.42) 0.29 0.60 
CD16lo/negCD14hi Monocytes (% non T and B cells) median 
(range) 
88.80 (78.40–97.20) 37.20 (20.40–65.00) 40.90 (25.30–54.30) 0.06 0.72 
CD16lo/negCD14hi Monocytes (% monocytes)  median (range) 63.10 (40.20–76.90) 88.70 (70.20–92.70) 91.70 (81.50–96.20) 0.99 0.11 
Natural Killer Cells (% non T and B cells) median (range) 49.50 (26.50–66.50) 23.10 (9.31–41.40) 35.70 (13.10–47.00) 0.01 0.09 
CD16hiCD56int NK (% non T and B cells) median (range) 42.60 (21.70–60.80) 18.20 (1.43–33.70) 31.30 (7.86–37.30) 0.008 0.046 
CD16hiCD56int  NK (natural killer cells) median (range) 89.10 (80.20–94.90) 76.70 (15.30–91.00) 81.80 (50.60–93.60) 0.049 0.29 
CD16lo/negCD56hi  NK (% non T and B cells) median (range) 3.03 (1.41–3.95) 3.29 (0.68–9.27) 2.91 (1.11–8.01) 0.56 0.96 
CD16lo/negCD56hi  NK (natural killer cells) median (range) 5.94 (2.35–11.30) 16.70 (3.01–50.20) 9.33 (2.79–35.3) 0.008 0.17 
CD16lo/negCD56int  NK (% non T and B cells) median (range) 2.07 (0.99–7.44) 1.84 (0.38–4.48) 2.59 (1.30–3.78) 0.72 0.27 
CD16lo/negCD56int  NK (natural killer cells) median (range) 5.17 (1.90–15.00) 6.64 (3.59–48.10) 6.02 (3.32–24.1) 0.20 0.75 
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